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Abstract 
Interleukin-2 is one of the lymphokines secreted by T helper type 1 cells upon 
activation mediated by T-cell receptor (TCR) and accessory molecules. The ability to 
express IL-2 is correlated with T-lineage commitment and is regulated during T cell 
development and differentiation. Understanding the molecular mechanism of how IL-2 
gene inducibility is controlled at each transition and each differentiation process ofT-cell 
development is to understand one aspect ofT-cell development. In the present study, we 
first attempted to elucidate the molecular basis for the developmental changes of IL-2 gene 
inducibility. We showed that IL-2 gene inducibility is acquired early in immature CD4-
CD8-TCR- thymocytes prior to TCR gene rearrangement. Similar to mature T cells, a 
complete set of transcription factors can be induced at this early stage to activate IL-2 gene 
expression. The progression of these cells to cortical CD4+CD8+TCRlo cells is 
accompanied by the loss of IL-2 gene inducibility. We demonstrated that DNA binding 
activities of two transcription factors AP-1 and NF-AT are reduced in cells at this stage. 
Further, the loss of factor binding, especially AP-1, is attributable to the reduced ability to 
activate expression of three potential components of AP-1 and NF-AT, including c-Fos, 
FosB, and Fra-2. We next examined the interaction of transcription factors and the IL-2 
promoter in vivo by using the EL4 T cell line and two non-T cell lines. We showed an all-
or-none phenomenon regarding the factor-DNA interaction, i.e., in activated T cells, the 
IL-2 promoter is occupied by sequence-specific transcription factors when all the 
transcription factors are available; in resting T cells or non-T cells, no specific protein-DNA 
interaction is observed when only a subset of factors are present in the nuclei. 
Purposefully reducing a particular set of factor binding activities in stimulated T cells using 
pharmacological agents cyclosporin A or forskolin also abolished all interactions. The 
results suggest that a combinatorial and coordinated protein-DNA interaction is required for 
IL-2 gene activation. 
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The thymocyte experiments clearly illustrated that multiple transcription factors are 
regulated during intrathymic T-cell development, and this regulation in tum controls the 
inducibility of the lineage-specific IL-2 gene. The in vivo study of protein-DNA interaction 
stressed the combinatorial action of transcription factors to stably occupy the IL-2 promoter 
and to initiate its transcription, and provided a molecular mechanism for changes in IL-2 
gene inducibility in T cells undergoing integration of multiple environmental signals. 
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Tissue specification during development is characterized by the expression of a 
battery of tissue specific genes. The control of tissue-specific gene expression can be 
achieved by selectively turning on or off tissue specific genes in response to 
developmental cues. Selective gene activation is considered the dominant mechanism in 
higher organisms during cellular differentiation based on the thought that it is more 
efficient to tum on the appropriate cell type-specific genes in limited cells than to repress 
them in all other cells. Unlike many prokaryotic genes, many eukaryotic genes are not 
expressed, or are expressed in vivo at relatively low levels, unless enhanced by the 
sequence-specific trans-acting factors which interact with cis-elements in the enhancer 
region and directly or indirectly with the basic transcriptional machinery to stimulate the 
initiation or completion of pre-initiation complex assembly (Ptashne, 1988; Ptashne & 
Gann, 1990; Johnson & McKnight 1989; Mitchell & Tjian 1989; Hahn 1993). As one of 
the pre-requisites, cells capable of expressing a particular gene would possess necessary 
trans-activators, which include both ubiquitous trans-acting factors and tissue-specific 
activators. Accompanying this gene activation process is the repression of inappropriate 
genes. Instead of being economic, progenitor or precursor cells are adapted for the 
evolutionary flexibility with pluri-potentialities. Therefore, negative regulation of gene 
expression can be equally important as positive regulation in development. For instance, 
activation of the 13-globin locus control region as represented by the presence of 
erythrocyte-specific DNase I sites is seen in both lymphomyeloid stem cells and myeloid 
stem cells preceding their commitment to the erythroid lineage. Selective repression of 
the locus control region is then seen whenever multipotential stem cells differentiate to 
cells other than erythroid lineage (Jimenez et al., 1992). In accord with this result is the 
finding that the transcription factor GATA-1 which is responsible for erythroid 
development and expression of erythroid-specific genes, is actively transcribed in cycling 
erythroid-myeloid precursors. Differentiation to the erythroid lineage is accompanied by 
increased GATA-1 expression; differentiation to the granulocyte-macrophage pathway 
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abruptly shuts off the expression (Sposi et al., 1992). This result suggests a two-step 
control for the expression of transcription factor expression: cell cycle-dependent 
initiation and lineage-dependent maintenance or repression. The development of T 
lymphocytes in mouse or human may apply the same mechanism. In the development of 
T helper type 1 cells (Th1), for example, a hematopoietic stem cell proliferates and 
differentiates into lymphoid lineage and non-lymphoid lineage; lymphoid cells then 
decide to become T or B lymphoid lineage; T lineage cells still have to decide to become 
CD4 T helper cells or CD8 T killer cells; CD4 T helper cells finally make their 
determination to become Th1 or Th2 cells (Fig. 1). During this whole process, each 
differentiated cell turns on or maintains the ability to activate some genes and switches 
off the potentiality to turn on some other genes which are characteristic of the other 
lineage(s) derived from the same precursor cell. Thus, understanding tissue or cell-
specific gene regulation is to understand cell fate control. My thesis work is focused on 
the regulation of a Th1 cell-specific gene-interleukin-2 (IL-2) during T cell receptor a.p 
lineage T cell development. As described above, clarification of the mechanisms 
determining the regulation of IL-2 gene expression would shed light on the 
developmental control of the Thl cell differentiation process. 
Interleukin-2 is not merely a simple marker for type 1 T helper cells; it is one of 
the most important lymphokines secreted by activated Th1 cells. As in the discovery of 
most growth factors, IL-2 was first found by its T-cell mitogenic activity in T-cell 
cultures in the presence of plant lectins, or specific antigens, and in conditioned medium 
from allogeneic mixed leukocyte cultures. Subsequent studies further demonstrated that 
the way that antigens or plant lectins stimulate T cells to proliferate is that they induce 
IL-2 and IL-2 receptor expression in T cells. It was the interaction of the IL-2 with the 
IL-2R that drives T cells into the cell cycle (Leonard et al., 1982; and Smith et al., 1983). 
This finding not only negated the notion that T lymphocytes are terminally differentiated 
hematopoietic cells unable to proliferate, but it also provided new insights for the 
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regulation of immune responses. IL-2 is an essential regulator for helping to mount an 
immune response. It exerts its effect through interacting with the IL-2 receptor expressed 
on a variety of cells. The activities associated with IL-2 include not only proliferation of 
T cells, but also induction of high affinity IL-2 receptor expression on T cells and B cells 
(Depper et al., 1985; Smith & Cantrell, 1985), activation of cytotoxicity by CTL, growth 
and differentiation of activated B cells into antibody-secreting cells (Watson & 
Mochizuki, 1980), and growth of natural killer cells and monocytes (O'Garra et al., 
1988). In this study we have not focused on its function, but use its expression as a 
molecular indicator of T -cell development. Most of my work is based on the recent 
progress on the biochemical studies of IL-2 gene transcription regulation. It is necessary 
to give a general but brief overview of these results. 
Recent development in IL-2 gene regulation 
The cloning of both human and mouse IL-2 genes and resolving of the IL-2 
crystal structure have been accomplished (Taniguchi et al. 1983; Fujita et al. 1983; Fuse . 
et al., 1986; Holbrook et al., 1984a; Macky, 1992; Zurawski et al, 1993). The 
interleukin-2 gene is a single-copy gene with four exons separated by one short and two 
long introns, which is similar to the genomic organization of other cytokines, including 
IL-4 and GM-CSF. The coding regions of the mouse and human IL-2 genes are 62% 
identical at the amino acid level, which may explain why both the human and mouse IL-2 
are functional across species. Sequence analysis and gene transfer experiments 
confirmed that the 5' flanking region immediately upstream of the start site shares a high 
degree of homology (86% identity up to -580bp) between human and mouse and contains 
enhancer activity (Fujita et al., 1986; Fuse et al, 1984; Holbrook et al., 1984b; Novak et 
al., 1990; Durand et al., 1988; Williams et al., 1988). These data suggest the functional 
and regulatory conservation of the IL-2 gene. 
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Further detailed analysis of the cis-acting elements in the proximal IL-2 enhancer 
region and the definition of their cognate trans-acting factors have been the focus of 
study for the past six years. The attempt to connect the proximal T-cell activation 
signalling apparatus and the distal triggering of transcription factor activity also provides 
a system to understand signal transduction events in T cells (Crabtree, 1989). 
Regulatory elements of the IL-2 gene. In addition to its cell-specificity and 
activation-dependence, IL-2 also has a transient expression pattern, with IL-2 mRNA 
appearing at 40 min, peaking at about 6 to 8 hours, and disappearing 24 hours after 
stimulation under certain conditions. Compared to some constitutively expressed house-
keeping genes, activated T cells make only a moderate levels of IL-2 mRNA per cell (200 
to 800 molecules/cell) (McGuire & Rothenberg. 1987; McGuire et al. 1988). Although 
four DNase I hypersensitive sites (upstream of the promoter, -300, -100, and rrrst intron) 
have been identified in the human IL-2 gene locus in stimulated T cells (Siebenlist et al., 
1986), gene transfer studies indicate that the 321 bp sequence immediately upstream of 
the start site is sufficient to confer all the known regulatory characteristics of the 
endogenous IL-2 gene (Durand et al., 1988), which is also true for the highly homologous 
murine IL-2 gene (Novak et al., 1990). Detailed analysis of the cis-acting elements in the 
321 bp regulatory sequence and of the putative trans-acting factors which could interact 
with this region not only revealed the identity of many of the factors but also provided 
valuable information on how signals were transmitted intracellularly. As diagrammed in 
figure 2, the transcription factors which may contact the IL-2 300 bp promoter/enhancer 
region and regulate IL-2 gene activation can be divided into three classes. They are: 1) 
T-cell specific inducible factors (NF-AT, CD28RE); 2) general inducible factors 
(NF-lCB/Rel, AP-I, TGGGC factor); and 3) general constitutively expressed factors 
(Octamers, Spl-like). I will give a general overview of these factors in relation to IL-2 
gene activation. 
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NF-AT. The nuclear factor of activated T cells (NF-AT) was the name given to 
the factor which binds to the -290/-260 and -145/-120 regions of the IL-2 enhancer. The 
distal binding site was first named NF-IL2E or purine-box binding site and was identified 
by in vitro DNase I footprinting studies (Durand et al., 1988; Shaw et al., 1988; Serfling 
et al., 1989). A distal sequence, containing AAAGAGGAAA, can also be found in the 
promoters of multiple genes, including the human IL-4, the human yiFN, and the murine 
GM-CSF, in the HIV-LTR, and in enhancer regions of SV40 and lymphotropic 
papovavirus (Fiegel et al., 1992; Pettersson, M. & W. Schaffner, 1987). The inducible 
binding activity to NF-AT sites is reported to be T-cell specific and is completely 
inhibited by the immunosuppressants cyclosporin A and FK-506 (Flanagan et al., 1991; 
Banerji et al. 1991). The factor which binds to this site is a multi-protein complex which 
contains AP-1 and an immunosuppressant-sensitive cytoplasmic component. The former 
is regulated by the activation of protein kinase C and requires protein synthesis, while the 
latter is present in the cytoplasm and is transported to nucleus by Ca2+ mobilization 
(Flanagan et al., 1991; Jain et al., 1992). Since cyclosporin A and FK-506 block the Ca2+ 
branch of signal transduction pathway by inhibiting the calcium/calmodulin-dependent 
phosphatase calcineurin, it is known that the nuclear localization of the cytoplasmic 
component is a downstream consequence of calcineurin activation (Liu et al. 1991; 
Clipstone et al., 1992). A number of proteins have been reported to able to bind the 
NF-AT site. An ubiquitously expressed 60kD protein was cloned which binds to the 
NF-AT site in the HIV LTR (Li et al., 1992). A recent report indicated that a 110-140 
kDa phosphoprotein might be the actual cytoplasmic NF-AT component (McCaffrey et 
al., 1993). However, since Ets family proteins bind the same site as NF-AT (Wang et al., 
1992), and Ets family genes are expressed predominantly in thymus (Bhat, N. K. 1987 
and 1989), it has been suspected that an Ets gene product is the cytoplasmic component 
of NF-AT. In particular, Elf, an Ets family member, was shown to be able to bind the 
NF-AT site in the IL-2 regulatory region (Thompson et al., 1992). Although Ets-1 was 
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also shown to be able to cooperate with AP-I for activation of transcription (Wasylyk et 
al., I990; Wu et al., I994), the phosphoprotein identified by McCaffrey et al. is now 
generally considered to be the most likely candidate for the actual cytoplasmic 
component of NF-AT. The nuclear component of NF-AT is known to be AP-I; however, 
different combinations of AP-I family members were reported for NF-AT binding 
depending on the cell types tested. This will be discussed further below (Boise et al., 
I993; Jain et al., I992). 
CD28RE. CD28 is aT-cell surface marker (Hansen et al. I980). It is a 44 kD 
homodimeric glycoprotein and belongs to the Ig supergene family. Its ligand B7 (also for 
CTLA4), a 44-to 54--kD glycoprotein, is found on dendritic cells, on monocytes, and on 
activated B cells (Clark et al. 1986, Linsley et al. 199I). Signalling toT cells via anti-
CD28 antibodies synergizes strongly with TCR signals for IL-2 production (Thompson et 
al. 1989, June et al. 1989) and is insensitive to a cyclosporin A block (June, et al. 1987). 
Upon stimulation of human Jurkat T cells in the presence of anti-CD28 antibody, a factor 
is induced which binds to the "CD28 response element" (CD28RE) (-164/-154) 
immediately upsteam of the proximal AP-1 site (Fraser et al., 1991 and see figure 2). 
Closely related cis-elements are also found in the 5' flanking regions of several other 
cytokine genes, including GM-CSF, IL-3, G-CSF and IFN-r, which are also subject to 
CD28 signal modulation (Fraser et al., 1992). The identity of the protein bound to this 
site has not been determined. Although a number of proteins with a molecular weight 
from 30 to 44 kD have been implicated in the binding, it is not clear whether any of them 
could be a general inducible factor like members of the AP-I family (Fraser et al., 1992). 
There is some evidence indicating that this binding activity can be induced in the absence 
of anti-CD28 antibody (Civil et al., I992). Our experiments with thymocyte extracts also 
showed inducible binding for this site without utilizing the anti-CD28 antibody (see 
chapter 4). Further characterization of both the proximal signalling events and factor 
binding to the CD28RE sequence need to be done. In addition, it has also been found that 
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signals transduced by CD28 can regulate IL-2 gene activation post-transcriptionally by 
increasing stability of the message, indicating that the CD28 signal could regulate the 
IL-2 gene at more than one level (Lindsten et al., 1989; Umlauf et al., 1993). 
NF- KB/Rel. NF-KB was initially identified as a B-cell specific trans-acting factor 
which regulated Ig 1e light chain expression (Sen and Baltimore, 1986). It was later found 
that this transcription factors can be induced in multiple types of cells by a number of 
stimuli (see Rev. by Grilli et al., 1993). The cis-acting element is found in a number of 
genes other than the Ig K light chain, including IL-2, IL-2Ra, MHC, and genes encoding 
other cytokines (Grilli et al., 1993). Protein purification and cloning work have resolved 
a family of NF-KB proteins whose DNA binding domains are related to the rel oncogene 
and the Drosophila morphogen, dorsal (Ghosh et al., 1990; Kieran et al., 1990). The 
NF-KB/Rel family contains p50/p105 (KBF-1), p50B/p97 (p49), p52 (NFKB2), v-rel, 
c-rel, RelA (p65), Re1B, and the dorsal. These proteins remain in the precursor form, or 
else form heteromers with a negative regulator protein called l1eB and remain in the 
cytoplasm (Baeuerle and Baltimore, 1988; Baeuerle et al., 1988). The activation of 
NF-KB in association with l1eB is regulated through modification of the IKB molecules. 
Once IKB is phosphorylated by protein kinases, it releases NF-KB!Rel proteins, which 
then translocate to the nucleus and bind DNA as homo or heterodimers by dimerizing 
through the rel-like domain (Shirakawa and Mizel, 1989; Ghosh and Baltimore, 1990). A 
number of proteins with IKB function have been purified or cloned, including l1eB a (37 
kD, MAD-3, pp40), IKB ~ (43 kD), l1eB y (70 kD, C-terminal portion of p105), bcl3 (46-
56 kD), L\bcl 3 (37 kD), and cactus. 
NF-KB is also shown to be important for IL-2 gene activation. A non-canonical 
1eB site is found in the IL-2 promoter ( -206/-195), which can form complexes with 
NF-KB (p65/p50) and KBF (p50/p50) in activated T cells. Mutation of this site results in 
a significant reduction in transcription (Hoyos et al., 1989). Inhibition of protein 
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synthesis does not affect NF-x:B activation, but it does affect IL-2 gene expression, 
suggesting that NF-x:B is necessary but not sufficient for IL-2 gene activation. 
NF-x:B/Rel regulation in B cell development seems to indicate that not only does 
the synthesis of the specific NF-x:B/Rel members change, but the Ix:B molecules also vary 
with B cell maturation, and the combination of both determines the nuclear components 
of the NF-x:B/Rel family. Such variations of the nuclear NF-x:B/Rel may influence the 
transcription of developmentally and functionally regulated genes including the Ig x: gene. 
How are these activators regulated in the context of T -cell development? How do 
different dimerizations affect IL-2 transcription activity? How do signals activating or 
inhibiting NF-x:B/Rel activation influence IL-2 gene activation? Those are some 
questions I attempted to answer in my work. 
AP-1. There are two putative AP-I sites in the 300 base pair enhancer sequence. 
In vitro DNase I footprinting did not reveal any occupancy of the distal AP-1 site 
(-185/-179) in human leukemia T cell line Jurkat (Brunvand et al., 1988). But IL-l and 
PHA stimulated murine T lymphoma LBRM cells showed inducible binding activity to 
this site (Muegge et al., 1989). The proximal site (-151/-145) is footprinted by DNase I 
footprinting analyses, and is gel shifted with nuclear extracts from activated T cells 
(Serfling et al., 1989). AP-I proteins also form the nuclear component of the two NF-AT 
binding complexes and compose QAp40 , which cooperates with octamer proteins to 
form a protein-DNA complex at the octamer site (Ullman et al., 1991; Ullman et al, 
1992). The multiple engagements of AP-I in the limited enhancer region indicate that it 
may play a very important role in IL-2 gene regulation (see fig. 2). Furthermore, the 
AP-1 factor involves either a Jun-Jun dimer or a Jun-Fos dimer. These jun and fos family 
members are each regulated by multiple signals and at multiple levels. Different 
combinations of AP-1 and different signal transduction events may well result in 
differences in IL-2 gene activation. By utilizing specific AP-1 antibodies in gel shift 
analysis or by transfecting particular jun or fos eDNA toT cells, several reports from a 
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number of laboratories suggested that different combinations of AP-1 can participate in 
the AP-1 or NF-AT complexes (Hentsch et al., 1992; Jain et al., 1992). However, 
because different T cell lines or T cell clones were tested and different stimuli were used 
in each experiment, there has not been a consensus in the results on this issue. In my 
work, I focused on two questions concerning AP-1 regulation in T cells: (1) how AP-1 
binding activity is controlled in developing T cells, and (2) how signals which synergize 
or antagonize with the TCR transduced signals affect AP-1 activation. One aspect of 
AP-1 regulation which has not yet been under study in T cells is the status of kinases 
which potentially mediate the DNA binding or trans-acting activity of AP-1 in resting or 
activated T cells. Understanding this will provide more evidence as to which members of 
the AP-1 family are actually the players in IL-2 activation. 
OAp40JOct. The octamer motif ATGCAAAT was first reported as a conserved 
sequence motif in the promoters of Ig genes and was later found in enhancers of other 
genes such as the histone genes, small nuclear RNA genes and viral genes (Fletcher et al., 
1987; Gerster & Roeder, 1988). The trans-acting activity of Oct-1 is induced by 
phosphorylation (Segil et al., 1991). Its association with the viral protein VP16 can 
activate viral promoters (Gerster & Roeder, 1988). The cis-acting element at -90/-60 
(NFIL-2A) contains noncanonical AP-1 (OAJ>40) and octamer binding sites. It was 
discovered that both c-Jun and JunD are associated with this region in conjunction with 
Oct-1 protein in activated human Jurkat cells, so either or both may provide OAJ>40 
function (Ullman et al., 1991; Ullman et al, 1992). Although Oct-1, Oct-2A, and Oct-2B 
can interact with the Oct site in gel shift studies, it is likely that Oct-1 alone can mediate 
binding and activation, since in human Jurkat cells, human peripheral T cells and IL-2 
producing murine thymocytes, only Oct-1 is found to form complexes with the element 
(Granelli-Pipemo & Nolan, 1991; Ullman et al., 1991; and see chapter 4). In EL4 cells 
Oct-1, Oct-2A and Oct-2B can all interact with this site (Hentsch et al. , 1992; see chapter 
2 & 3). Cotransfection of the NFIL-2A containing enhancer construct with either Oct-1, 
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Oct~2A, c-Jun, JunD, and c-Fos, but not JunB, can increase enhancer activity (Bielinska 
et al., 1990; Rentsch et al., 1992). Both deletion and mutation analyses also indicate that 
this region plays a positive role for IL-2 gene activation (Durand et al., 1988; William et 
al., 1988; Bielinska et al., 1990). Furthermore, this element is the target of the inhibitory 
effects of CsA, TGF~, and retinoic acid (RA) (Ullman et al., 1992; Barbletz et al., 1993; 
Felli et al., 1991). In those situations, the in vitro DNA binding activity of octamer 
proteins is not affected by the addition of TGF~ and RA, and the binding activities of 
both octamer proteins and OAJ>40 are unaffected by CsA, but the transactivation activity 
of the concatamerized octamer site is significantly reduced. These results suggest that the 
inhibition is directed at the level of the transactivation activity, which is dependent on 
Ca2+ influx (Ullman et al., 1992). 
Novel cis-elements and their corresponding factors. In analyzing the factor 
binding activities in thymocytes, we identified a novel site upstream of the distal NF-AT 
site. The in vivo footprinting analysis confirmed the presence of the distal CACCC site 
along with the discovery of a proximal CACCC site, a TGGGC site, and a ATGG site 
which were not reported in previous in vitro DNAase I footprinting studies. The identity 
of the factors bound to these elements is not known. Gel mobility shift assays indicated 
that the factor bound to the TGGGC site is induction dependent and protein kinase A 
sensitive. The binding cannot be competed individually with oligos containing NF-lCB, 
AP-2, AP-3, or Sp-1 sequences. Two GC rich elements (CACCC) in the IL-2 promoter 
region might belong to one of the two elements present in a very large number of 
eukaryotic promoters and appear to be generally important for promoter function 
(Mitchell et al., 1989). Although Sp-1 has been suggested to be the factor bound to the 
site, studies have shown that there are a number of zinc-finger proteins which can interact 
with this element (Kingsley & Winoto, 1992). Interestingly, aT-cell specific zinc-finger 
factor called lkaros binds to a GC-rich sequence (TGGGGGT) in the CD3-8 enhancer, 
and it is exclusively expressed in the fetal liver and the thymus (Georgopoulos et al., 
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1992 & 1990). Therefore, Ikaros may be one of the proteins interacting with CACCC 
sites in IL-2 promoter, and may also contribute to the T-cell specificity of the IL-2 gene. 
The different transcription factors have been described individually. In general, 
these factors do not act individually, since mutation of any particular site or decreasing 
availability of one or two factors will decrease the transcriptional efficiency. The 
activation-dependent nature of IL-2 gene expression indicates that in T cells all the 
necessary factors required for IL-2 activation are present. It is necessary to clarify the 
mechanism of how these factors function coordinately to initiate transcription in response 
to activation signals . 
Acquisition of IL-2 gene inducibility during T cell development 
Maturation ofT cells occurs in the thymus. T precursor cells from fetal liver and 
bone marrow migrate to the thymus, where they become immunocompetent mature T 
cells and emigrate to the secondary lymphoid organs (spleen and lymph nodes, etc). T 
cells are categorized according to the type of TCR expressed, i.e., TCRyo or TCRaj3 T 
cells. The latter accounts for the majority of T cells. Certain T cells bearing specific 
TCR yo chains are produced early in ontogeny and home to certain locations in the body. 
For example, Vy3Vo1 and Vy4V01 cells are only produced in late fetal life and home to 
the skin and reproductive tract respectively. Other yo cells as well as aj3 cells are 
generated both late in fetal and adult thymus and home to the spleen (Vy4 and aj3), the 
intestine (Vy5) or to lymph nodes (aj3). During intrathymic development, the aj3lineage T 
cells can be further defined by the expression of a number of other surface markers, like 
CD4 and CD8. Immature early thymocytes in the subcapsular region of the thymus do 
not express CD4, CD8, and TCR (CD4-cD8-TCR- or triple negative cells). As they 
differentiate, they progress to rearrange and express their TCR genes and become 
CD4+CD8+TCRlo thymocytes (double positive cells) localized to the cortex of the organ, 
in which stage they are also referred to as cortical cells. The CD4+CD8+TCRl0 cells are 
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subject to a selection process, in which cells bearing self antigen-reactive TCR undergo 
apoptosis (negative selection) and cells bearing TCR against foreign antigens remain 
alive and mature into either CD4+TCRhi or CD8+TCRhi cells (single positive or mature 
cells) localized in the medulla and ready to migrate to the periphery (positive selection). 
In general, T cells in the thymus are educated to recognize and to respond to foreign 
antigens. In addition to obtaining antigen recognition specificity by expressing TCR, T 
cells also acquire helper (CD4+) or cytotoxic (CD8+) functions during the intrathymic 
maturation process. These effector functions enable CD4+ T cells to produce 
lymphokines to facilitate the functions of other immune cells, and enable CD8+ T cells to 
punch holes in pathogen-infected cells and release cytotoxic molecules which lyse target 
cells and induce programmed cell death (Reviewed by Rothenberg, 1992; Weissman, 
1994). A large body of evidence showed that IL-2 gene expression in mature CD4+ T 
helper cells depends on activation signals delivered by engagement of TCR with antigen 
in the context with appropriate MHC on antigen-presenting cells and engagement of 
accessory molecules like CD28. Resting CD4+ T cells do not make IL-2. However, IL-2 
gene inducibility and possibly other effector functions in mature T cells are not acquired 
during the final stage of T cell maturation post-positive selection, but early in T cell 
development. 
For TCR a~ lineage, pre-T cells, early immature CD4-CD8-TCR- thymocytes and 
thymocytes from severe combined immune deficient mice (SCID), whose thymocytes 
arrest at the immature triple negative stage (see fig. 2, "ImmT"), are already competent to 
be induced to make IL-2 (McGuire & Rothenberg, 1987; Rothenberg et al., 1993; 
Rothenberg & Diamond, 1994). The expression of IL-2 is induced when these immature 
cells are stimulated with TCR mimicking pharmacological agents (TP N A23187) and 
interleukin-1 (IL-l). Therefore, in the adult thymus, prior to T -cell receptor gene 
rearrangement and therefore independent of positive selection, immature thymocytes 
already possess the competence to make IL-2. This finding indicates that early immature 
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T cells already have established internal signalling pathways and all the necessary IL-2 
gene transcriptional apparatus. Interestingly, this competence is lost or repressed when 
immature thymocytes start rearranging their TCR ~ chain gene. In addition, the IL-2 
receptor a. chain gene, like IL-2, cannot be activated in the late triple negative cells and 
throughout the entire CD4+cns+TcR+ stage (Rothenberg et al. 1993). Positively 
selected mature single positive thymocytes behave similarly to peripheral spleen 
lymphocytes. They regain the competence to make IL-2 and IL-2 receptor. Unlike their 
immature precusors, however, mature thymocytes do not require IL-l as a co-stimulus, 
indicating developmental changes with respect to signalling requirement after positive 
selection (Rothenberg et al., 1990; Rothenberg & Diamond, 1994). 
The earliest cells found to be competent to make IL-2 are triple negative immature 
thymocytes. Unfractionated bone marrow cells which contain T-precursor cells and other 
lineages of hematopoietic cells cannot be induced to make IL-2 (Rothenberg et al., 1990). 
However, it is possible that precursor T cells in the bone marrow, lymphoid progenitor 
cells, and hematopoietic stem cells are already in the process of approaching the 
activatable state. The ability to make IL-2 may be gradually acquired in an accumulative 
developmental process. The initial point could be at the generation of hematopoietic 
stem cells (Fig. 1). With each step of differentiation closer to mature CD4+ T lineage, 
cells are one step closer to becoming IL-2 inducible cells. On the other hand, cells that 
diverge away from CD4+ T lineage would either maintain or lose the partially gained 
IL-2 gene inducibility. For IL-2 inducible cells, they are still in the process to refining 
this inducibility. This is shown by the different activation requirements in immature and 
mature T cells. 
What is the biochemical basis which makes immature triple negative thymocytes 
and mature CD4+ T cells able to make IL-2? What makes mature CD4+ T cells 
independent of IL-l co-stimulation? As I mentioned in the overview, a number of 
transcription factors have been implicated in regulating IL-2 gene activation. However, 
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most of the work was done in T cell lines, and it is not clear whether non-transformed 
primary T cells also use the same set of transcription factors and whether these factors are 
similarly regulated. To address these questions, we first tested a thymoma cell line (EL4) 
which has similar responsiveness to activation signals as mature T cells. These EL4 
cells, like immature T cells also respond to IL-l co-stimulation by expressing higher 
levels of IL-2. In the first chapter, we defined a set of transcription factor DNA-binding 
activities in EL4 cells which are correlated with IL-2 gene activation. We also identified 
two positive regulators, AP-1 and NF-1eB, which are sensitive to IL-l regulation. The 
DNA-binding activities of both AP-1 and NF-KB are activation dependent and are further 
increased in the presence of IL-l during the activation. In chapter 2 we analyzed the 
DNA-binding activities of these transcription factors in immature, cortical, and mature 
thymocytes under both stimulated and unstimulated conditions. The results show that the 
ability to mobilize the same set of transcription factors is correlated with IL-2 gene 
inducibility in developing thymocytes. The inducible DNA-binding activities of two 
factors including NF-x:B are developmental stage dependent. Higher DNA-binding 
activity of NF-x:B is correlated with more mature cells. Interestingly, the low inducible 
binding ability of NF-1eB in immature cells can be alleviated by addition of IL-l to the 
cell culture, which may explain their IL-l dependent IL-2 gene activation. Therefore, we 
concluded that the acquisition of IL-2 gene inducibility during T-cell development is by 
acquiring both signalling pathways and activitable transcription factors. 
Acquisition and control of IL-2 gene inducibility 
The IL-2 gene inducibility is restricted to Thl cells. The so-called inducibility 
means that under normal conditions T cells do not make IL-2, whereas upon stimulation 
through TCR and accessory molecule engagement, they are induced to produce IL-2. 
Non-T cells, especially non-hematopoetic cells, do not have this inducibility, even if they 
receive activation signals that mimic the TCR signal. This inducibility or pre-activation 
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state can be interpreted molecularly at several levels during development as diagramed in 
figure 1. Like most tissue specific genes, the IL-2 gene most likely is neither expressed 
nor activatable in early embryogenesis. The generation of hematopoietic stem cells 
marks the frrst access toward IL-2 gene activation (marked 1 in Fig. 1), which may be 
represented by the alteration of chromatin structure (Siebenlist et al., 19S6). Those non-
hematopoietic cells would retain their IL-2 gene in the same state carried from the early 
embryo. The non-hematopoietic cells have the frrst level of negative control of IL-2 
gene. Differentiation of hematopoietic stem cells towards T lineage cells is accompanied 
by gaining more requisites for IL-2 gene activation, while differentiation towards other 
hematopoietic cells is accompanied by maintaining or losing the partially gained 
necessities. The differentiation towards either myeloid or lymphoid lineage has the 
second level of control, while differentiation to T or B cells marks the third level of 
controL The fourth level control is intrathymic T -cell development when IL-2 gene 
inducibility first becomes on, then off, then on again. The final control is at the terminal 
differentiation of CD4 vs. CDS and Th1 vs. Th2 cells. Unlike the IL-2 non-inducible 
cells diverged from other points, a less stringent control is also applied to CDS+ T cells, 
Th2 cells, and possibly B cells. Bone marrow cells and cortical CD4+cos+TCR1° cells 
cannot be induced to express IL-2 gene under conditions when immature triple negative 
and mature CD4+ cells can be stimulated to do so (Rothenberg et al., 1990). On the other 
hand, mature cos+ T cells, whose furiction is to recognize antigen in association with 
class I MHC molecules and to activate a set of killer-cell specific genes, can be induced 
to express IL-2 gene under certain conditions in vitro (McGuire & Rothenberg, 1987; 
McGuire et al., 1988). This result implies that the IL-2 gene is less stringently repressed 
in cos+ T cells. Similar results are also obtained in B cells and Th2 helper cells. 
Different from levels 1 and 2, controls from level 3 deal with cells whose precursors are 
able to activate IL-2 gene. My work is mainly focused on the intrathymic control of IL-2 
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gene inducibility, but the mechanisms used in this case may also apply to other levels of 
control. 
The newly generated naive CD4+ T helper cells are able to produce IL-2 along 
with some other lymphokines upon activation. However, depending on the antigen 
encountered and the genetic background of the animals, CD4+ cells can further 
differentiate to different effector T cells as defined by the sets of lymphokines they 
produce. In addition to common lymphokines they secrete, T helper cells can be either 
type 1 cells (Th1) which secrete IL-2, IFNy, TNFa and TNF~; or type 2 cells (Th2) which 
produce IL-4, IL-5, IL-6, IL-10, and IL-13 (Mosmann et al., 1986; Heinzel et al., 1989; 
Paul & Seder, 1994). However, similar to CD8+ T cells, Th2 cells under certain 
conditions can also make IL-2 (McGuire & Rothenberg, 1987; McGuire et al., 1988). 
EB-virus transformed B cells which are the last cells diverged from T lineage cells are 
also reported to be able to make IL-2 under certain conditions (Amigorena et al., 1992; 
Bonerot et al., 1992). 
In the first section of the introduction, I discussed the first acquisition of IL-2 
gene inducibility early during T -cell development. In chapter 2, we show that upon 
activation immature T cells already possess a complete set of transcription factors 
necessary for IL-2 gene activation. It is possible that the develomental process prior toT 
lineage commitment is a process where cells are gaining these transcription factors or 
gaining the inducibility of these transcription factors. The temporary loss of the IL-2 
gene inducibility in T cells at cortical stage of development may be due to temporary loss 
of the ability to utilize certain transcription factors. To understand how at each stage of 
development IL-2 gene can be regulated I will discuss several mechanisms which are 
generally used to control tissue-specific gene expression and discuss their application to 
IL-2 gene regulation. 
Methylation. Methylation of CpG dinucleotides in the genome has a potential role 
in regulating gene expression. A correlation between gene methylation and expression is 
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well-established. Hypomethylation of promoters is correlated in general with gene 
expression, and methylation is associated with the silencing of genes (Cedar, 1988; 
Brandeis et al., 1993). Gene methylation is considered responsible for maternal 
imprinting (Enver et al., 1988) and allelic X-chromosome inactivation (Riggs & Pfeifer, 
1992). Methylated genes can be stably propagated in vivo, in transgenes, or transfected 
into cells grown in culture. Treatment of cells with 5-azacytidine can activate normally 
inactive genes in the cells and make cells differentiate (Jones et al., 1990). Methylation 
was also shown to be essential for development, since mice homozygous for a mutant 
DNA methytransferase gene have stunted development and die at midgestation (Li et al., 
1992). Molecular mechanisms for transcription inhibition by DNA methylation can be 
categorized as follows: 
1. Methylated DNA can directly interfere with trans-acting factor binding. 
Activation of genes, therefore, depends on DNA demethylation. For example, 
methylation of the muscle-specific a-actin promoter results in transcriptional repression 
in both non-muscle and muscle cells (Paroush et al., 1990). Similarly, B cells cannot 
transcribe a methylated Ig 1e chain gene even if it is already rearranged, that is, with its 
promoter and enhancer brought close together for optimal expression (Lichtenstein et al., 
1994). Comparison of the human phosphoglycerate kinase gene promoters on inactive 
and active X chromosomes showed that the active unmethylated PGK promoter is heavily 
occupied by factors, whereas the inactive methylated promoter is free of footprints. 
Furthermore, the inactived PGK can be reactivated by treatment with 5-azacytidine. 
These results suggest that methylation of DNA prevents active regulators from binding to 
the promoter (Pieifer et al., 1990). 
2. Methylated CpGs can be bound by methyl CpG-binding proteins (MeCP1 and 
MeCP2). MeCP1 binds in vitro to sites containing multiple CpGs, while MeCP2 can 
bind to a single CpG (Meehan et al., 1989; Lewis et al., 1992). The binding of trans-
activators can be blocked directly or indirectly by MeCPs (Boyes & Bird, 1992). It has 
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been shown that transcription inhibition by methylation depends on both CpG density and 
promoter strength. Transcription of CpG-poor, weak promoters can be inhibited by 
methylation; while CpG poor, strong promoter will be less susceptable to methylation 
(Boyes & Bird, 1992). Tissue-specific genes are mostly CpG-poor and are methylated in 
non-expressing tissues (Bird, 1986). It is proposed that genes with a limited amount of 
methylated CpG in a weak promoter have a weak binding to MeCP, and that activation of 
genes during development depends upon the appearance of factors which are capable of 
displacing the weakly bound MeCP. Adding a strong enhancer, however, can restore 
transcription to sparsely methylated, but not to heavily methylated promoters (Boyes & 
Bird, 1992). In reference to the recent discovery, a function of a strong enhancer is to 
direct demethylation in addition to its transcription enhancing activity (Lichtenstein et al. 
1994). This is not only shown with transfected genes, but also with endogenous genes in 
developmenL For example, the expression of the methylated Ig K chain gene is enhancer-
dependent in pre-B cells, but upon differentiation to mature B cells, the gene loses its 
methylation, and expression is no longer enhancer-dependent (Kelley et al., 1988). These 
data suggest a competition between the activity of transcription factor and that of MeCPs. 
3. Methylation may change the chromatin structure. Unlike the PGK gene 
mentioned above, the promoter of the tyrosine aminotransferase (a CpG-deficient 
promoter), is occupied by sequence-specific transcription factors in expressing cells but 
not in non-expressing cells, even through the transcription factors are ubiquitous (Becker 
et al., 1987). Demethylating the gene in non-expressing cells by 5-azacytidine does not 
lead to factor binding nor gene activation (Weih et al., 1991). It has also been shown that 
methylated DNA is more resistant to nucleases even in cells deficient of MeCPs (Levine 
et al., 1991). These results suggest that something other than or in addition to 
methylation represses the gene expression. The nuclease-hypersensitivity experiments 
suggest that the chromatin structure changed upon methylation. Other evidence comes 
from studies of Ig gene V(D)J rearrangement. Introducing a densely methylated 
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minichromosome bearing the recombination signal sequences into a murine pre-B cell 
line showed a cell-replication dependent inhibition of V(D)J recombination. suggesting 
that replication induces methylated DNA into a heterochromatic structure (Hsieh & 
Lieber. 1992). 
Alteration of chrolnfltin structure. DNA in the nucleus is packaged into octamer 
nucleosomes composed of (H2A. H2B. H3. and H4)2 with two superhelical turns of 164 
bp of DNA wrapped around the octamer and histone H1 bound to the outside of 
nucleosomes. The polynucleosome filament is further compacted into a 30 run fiber by 
coiling to form a solenoidal structure with about 6 nucleosomes per tum. Higher order 
structures which account for the various forms of condensed and decondensed chromatin 
have been proposed. Transcriptionally active and inactive chromatin may each be 
characterized by different degrees of condensation. Endonucleases like DNase I 
preferentially cleave genes which are transcriptionally active. It has been suggested that 
active and potentially active genes reside within a chromatin configuration that is 
different from that of inactive genes. Active genes contain 'open' regions which are 
physically accessible to cleavage by nucleases. The appearance of a DNase I 
hypersensitive site corresponds to the disruption of one or two specifically phased 
nucleosomes (Gross & Garrard. 1988; Carr & Richard-Foy. 1990). The presence of 
ordered or phased nucleosome structure in chromatin correlates with tissue-specific gene 
repression and has been investigated using periodic chromatin cleavage patterns 
generated by various nucleases or chemical cleavage reagents. The phased nucleosome 
structure has been found in the enhancer region of the J3-globin gene, and the loss of 
nucleosome phasing is correlated with the capacity for J3-globin transcription in murine 
erythroleukemia cells (Benezra et al.. 1986). In yeast depletion of histone proteins results 
in the activation of many genes which are normally silent. In this specific case. the 
expression of newly induced genes in this system is trans-acting factor independent. 
Thus. the 'closed' chromatin structure can function as a general repressor of transcription 
21 
(Han & Grunstein, 1988). In another yeast example, a proposed global multiprotein 
transcriptional activator composed of SWil, SWI2/SNF2, SWI3, SNF5, and SNF6 
regulates a large number of genes. Mutations in any of the activator components leads to 
repression of target genes. Interestingly, revertants which express target genes include 
the alteration of histone H3, inactivation of an HMGl-like protein, and deletion of H2A 
and H2B (Peterson & Herskowitz, 1992; Sternberg et al, 1987; Kruger & Herskowitz, 
1991; Happel et al., 1991; Winston & Carlson, 1992). These results suggest that the 
multiprotein activator could interact with nucleosomes or with chromosome-binding 
proteins to antagonize the repressive effects of chromatin and facilitate the binding of 
other transcription factors. 
Chromatin structure affects both transcription initiation and elongation (Lorch et 
al., 1987). I will focus on the former issue in the present discussion. A number of tissue-
specific genes examined by in vivo footprinting studies showed that promoters in non-
expressing cells are free of sequence-specific trans-acting factors and that promoter 
occupancy occurs only in expressing cells. Among them are genes encoding liver 
tyrosine aminotransferase (TAT) (Becker et al., 1987), muscle creatine kinase (Mueller & 
Wold, 1989), MHC class II (Kara & Glimcher, 1991), MHC class I (Dey et al., 1992), 
transthyretin (Mirkovitch & Darnell. 1991), chicken 13-globin (Jackson et al., 1989). 
Although most studies do not directly address nucleosome assembly or disassembly in 
both non-expressing or expressing cells, it has been implied that at least in non-
expressing cells DNA is packaged into nucleosome and HI-containing chromatin. As 
was mentioned earlier, a large body of evidence has indicated that both nucleosomal 
cores and histone HI can act as global repressors of transcription and that gene activation 
is achieved by sequence-specific transcription factors which function both to counteract 
the chromatin-mediated repression (antirepression) and to facilitate the inherent 
transcripiton process (Adams & Workman, 1993; Croston & Kadonaga 1993). Two 
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models have been proposed regarding the role of chromatin structure in transcriptional 
repression (Felsenfeld, 1992). 
The first model suggests that there is a dynamic equilibrium involving 
competition between the transcription factors and histone octamers for sites in non-
dividing cells. In two cases, glucocorticoid receptor (GR) has been indicated to compete 
for DNA binding and induces, in a cell-cycle independent manner, remodeling of the 
chromatin structure, which allows binding of other transcription factors. For instance, the 
mouse mammary tumor virus (MMTV) promoter has a phased array of six nucleosomes 
in the nucleus. One of the positioned nucleosomes excludes a group of transcription 
factors including the glucocorticoid receptor (GR) and nuclear factor 1 (NFI) from the 
promoter before glucocorticoid treatment. Hormone induction of the promoter does not 
change the concentration and DNA binding affmity of NFI, but results in hypersensitivity 
around the nucleosome to nucleolytic agents and hormone-dependent loading of a 
transcription preinitiation complex including NF1 following the chrornatim structural 
transition (Archer et al., 1992; Pina et al., 1990). Although this finding is from a viral 
promoter, similar results are also obtained from the promoter of a cellular gene, a liver-
specific tyrosine aminotransferase (TAT) gene. A DNase !-hypersensitive site which . 
results from the displacement of two specifically phased nucleosomes is seen at position 
-2500 of the promoter following hormone induction. Further analysis revealed that this 
region contains a ORE and a liver-specific transcription factor HNF5 binding site that are 
partially overlapping. GR is able to bind its site in vitro. However, glucocorticoid 
treatment only results in HNF5 binding to the site in vivo. A natural internal control has 
shown that a hormone-independent DNase !-hypersensitive site further upstream is 
constitutitively bound by HNF5 (Rigaud et al., 1991). These findings clearly indicate 
that HNF5 binding to the proximal site depends on a hormone-induced alteration of 
chromatin structure. Another well-illustrated example is the control of the yeast acid 
phosphatase gene PH05. The promoter of the PH05 gene contains two pairs of sites for 
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trans-activating proteins PH02 and PH04. One of the PH04 sites is located in the linker 
DNA between two phased nucleosomes, which also overlaps the DNase I hypersensitive 
site. The other three sites are buried in the two phased nucleosomes. During induction of 
the gene in the absence of phosphate, displacement of the adajcent four nucleosomes 
neighboring the linker DNA containing both DNase I hypersensitive site and PH04 site is 
observed, which results in exposing the second PH04 site and two PH02 sites (Almer et 
al., 1986). Replacing the DNA wrapped around nucleosome covering two sites with 
either a satellite DNA which has a high affinity for histones or a derivative of a pBR322 
DNA segment alters the promoter, making it either more resistant or more susceptible to 
induction, respectively (Straka & Horz, 1991). This suggests that resistence to 
nucleosome displacement by satellite DNA does not relieve of the repression. The 
nucleosome displacement is shown to be initiated by PH04 binding to its site at the linker 
sequence, since deleting this PH04 site inhibits the transcription initiation of the PH05 
gene (Fascher et al., 1993). 
The second model proposes that there is a 'pre-emptive' competition for binding 
sites. As shown in a number of in vitro chromatin assembly experiments, depending on 
the order of factor addition, adding pol II transcription factor first will exclude the histone 
octamer binding and vice versa (Workman & Roeder, 1987). In the presence of 
transcription factors, the assembly of a transcriptionally active complex can be less 
dependent on the order of TFIID and histone additions (Workman et al., 1990; 1991). 
Extending the in vitro data would predict that chromatin changes would only occur 
during DNA replication when the site is exposed at the replication fork before chromatin 
assembly. Acquisition or repression of a tissue-specific gene expression, or 
establishment of a pre-activation state in proper cells, occurs most likely in dividing cells 
and is irreversible once the cell is terminally differentiated. As mentioned earlier, by in 
vitro DNase I footprinting method, trans-acting factors present in TAT-non-expressing 
cell nuclei bind to the TAT promoter region equally well as in TAT-expressing liver cell 
24 
nuclei. Demethylating the gene in non-expressing cells also failed to activate it, 
indicating that the chromatin structure is in a permanently repressed configuration 
inaccessible to activators once cells acquire the non-liver cell fate (Becker et al., I987; 
Weih et al., I99I) 
However, there are some experimental data which seem difficult to reconcile with 
the pre-emptive model. In heterokaryons from cell fusion experiments, tissue-specific 
genes can either be turned on in the nuclei of cells which normally do not express them or 
turned off in nuclei which expressed them previously (Blau, I989). In contrast to the 
differentiation process when cells are in cycle, the conversion of gene expression in 
heterokaryons is independent of DNA replication. Although it is thought that the degree 
of activation is contingent upon the history of the nuclei exposed to a series of 
developmental cues to progress from undifferentiated zygotes to specific tissue, this 
process is not understood molecularly. In vitro biochemical studies demonstrate that a 
promoter template with phased nucleosomes assembled in the absence of HI can be 
activated with a sequence-specific DNA-binding activator, Gal4-VPI6, but it cannot be 
activated when HI is also packaged into the chromatin template except during the process 
of template replication (Kamakaka et al., I993). In heterokaryons as long as tissue-
specific genes which are normally silent in one partner nucleus are not heavily packaged 
with HI, they may be activated by factors diffused from the other nucleus. The ability to 
reactivate tissue-specific genes in heterokaryons may depend upon the concentration and 
modification of histone proteins. 
Methylation and chromatin structure may both be involved in IL-2 gene 
regulation early in development, during the generation of hematopoietic stern cells and in 
early hematopoiesis which corresponds to stage I as shown in figure 1. General 
inspection of the gene reveals that like other tissue-specific genes, the IL-2 gene 
promoter/enhancer region is poor in CpG. Seventeen CpG pairs are found in 2800 bp 5' 
regulatory sequence with the frequence of I/165, equivalent to the human y-globin gene 
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(11126) of which it has been shown that methylation alone is sufficient to inhibit the 
transcription (Boyes & Bird, 1992). Unfortunately, little is known about the methylation 
status of the IL-2 gene especially in relation to its inducibility. However, there are two 
examples of gene regulation in thymocytes by developmentally regulated demethylation. 
The demethylation of a gene encoding aT-cell specific CD3 ~chain is tightly correlated 
with its expression in thymocytes on day 18 of gestation (Hsu et al, 1992), while the 
demethylation of the CD8 gene is also coupled with the onset of its expression during the 
transition from CD4-CD8- to CD4+CD8+ stage (Carbone et al., 1988). Similarly, 
methylated Ig K gene in pre-B cells becomes demodified once the cells progress to the B 
cell stage. This developmental stage-specific demodification is independent of Ig gene 
rearrangement and transcription (Kelley et al., 1991; Lichtenstein et al., 1994). It is 
possible that at stage 1 there is a demethylation process accompaning the generation of 
hematopoietic stem cells. 
The chromatin structure for the IL-2locus, on the other hand, is better understood 
but our knowledge is far from satisfactory. There are at least three different 
configurations of IL-2 chromatin structure according to DNase I hypersensitivity studies 
(Siebenlist et al., 1986). Non-hematopoietic cells do not have any nuclease-sensitive 
sites, while resting T cells and some hematopoietic cell lines have three tissue-specific 
sites (upstream of the promoter, -300bp, and first intron). Activated IL-2 producing T 
cells have a fourth nuclease-hypersensitive site around the promoter region (-100). The 
interpretation for the lack of nuclease-sensitive sites in non-hematopoietic cells would be 
that the tightly packaged chromatin is resistant to direct nucleosome and histone H1 
disruption or displacement by trans-acting factors. The relatively 'open' chromatin 
structure in resting T cells and T -cell related hematopoietic cells distinguishes them from 
the former cells. These two distinct chromatin configurations could be acquired by the 
pre-emptive mechanism during the tissue differerentiation process. It can be 
hypothesized that in response to specific developmental cues IL-2 gene-specific 
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demethylation may occur and may be followed by alteration of the chromatin 
conformation during the progression to become hematopoietic stem cells only. The 
chromatin structure of IL-2 locus in non-hematopoietic cells would remain in a locked 
configuration which is constitutively inherited in all cell derivatives. It would be 
predicted that introducing trans-activators from activated T cells to their nuclei by 
forming heterokaryons with T cell nuclei would not be able to activate the gene. For 
these non-hematopoietic cells both methylation and repressed chromatin structure are 
likely to be the major mechanisms used to repress the IL-2 gene. Other repression 
controls may also exist but probably play a minor role. 
What does the presence of constitutive nuclease-sensitive sites in hematopoietic 
cells mean? It could indicate a relatively 'open' structure which may make the proximal 
promoter region more accessible to basal transcription factors than it would be with a 
closed configuration. Biochemically, this can be achieved by changing the positioning or 
phase of the nucleosomes which flank these hypersensitive sites. In doing so, two short 
sequences that are separated by the equivalent of one superhelical tum of DNA could be 
brought into close lateral proximity by assembling them into the same, rather than into 
neighboring nucleosomes. Alternatively, changes in the position of nucleosomes could 
be responsible for defining the rotational orientation of the major and minor grooves 
relative to the histone octamer and could place a sequence within an accessible linker 
region, thus, poising the promoter for trans-acting factor assembly. The hypersensitive 
site in the -300 bp region may, in particular, be essential for repositioning the sites for 
CACCC and NF-AT binding, which may serve to create the inducible hypersensitive site 
further downstream (to be discussed more in later sections). Regions of DNase 
hypersensitiy may have sites for specific trans-acting factor binding, which may exert an 
anti-repressive effect (Croston & Kadonaga, 1993). Overall, the specific protein-DNA 
interactions at these sites may serve as a pre-requisite for IL-2 gene expression. And this 
step may possibly occur prior to the differentiation to T lineage cells. However, these 
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induction-independent hypersensitive sites are necessary but not sufficient to activate 
IL-2. IL-2 expression is correlated with the stimulation-dependent nuclease-
hypersensitive site. The appearance of this site is likely to be cell-cycle independent, 
since IL-2 mRNA can be detected 30 min after stimulation, while it takes 18-24 h to 
complete a cycle. In contrast to the other three sites, disruption of nucleosomal cores and 
histone Hl at the promoter site is likely to be a dynamic quasi-equilibium competition 
between stimulation-dependent trans-acting factors and histone octamers. The 
hypersensitive sites examined in limited types of cells suggest that the inability to express 
IL-2 gene in non-Th1 hematopoietic cells (stages 2 through 5 in Fig. 1) is unlikely due to 
a repressed chromatin structure, but instead repression is more likely due to a repressor or 
a lack of activators. In support to this hypothesis, CD8+ T cells and some malignantly 
transformed B cell lines can make IL-2 under certain conditions, while under the same 
conditions non-lymphoid cells are not able to make IL-2 (Rothenberg et al., 1990; 
McGuire & Rothenberg, 1987; McGuire et al., 1988; Amigorena et al., 1992; Bonnerot et 
al., 1992). 
Repressors and negative regulators. By interacting with the cis-elements in a 
promoter region a repressor could directly inhibit the general transcription machinery. A 
negative regulator-mediated gene repression can occur at multiple levels in the 
transcription initiation process. For example, it may interact directly with trans-
activators to block their DNA binding domain or the activation domain. 
The Drosophila homeodomain gene even-skipped (eve) is an example of a 
repressor interfering with the pre-initiation complex assembly. Upon binding to the 
hemoedomain-binding sites eve can inhibit activator-independent transcription, 
suggesting that eve can directly interact with the general transcription machinery 
(Johnson & Krasnow, 1992). Direct binding of repressors to the promoter region is also 
illustrated in J:3-interferon gene regulation. Upon induction the repressor bindings are 
either dissociated or displaced by an activator protein (Zinn & Maniatis, 1986). It is 
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likely that the repressor binding activity is inactivated or is competed by the activator 
following viral infection. In another example, studies using a fusion cell system showed 
that in hepatoma-fibroblast hybrids liver-specific genes like tyrosine aminotransferase 
and albumin are repressed. This inhibitory effect is directed by a tissue-specific control 
element found in the albumin gene, and may implicate a possible repressor interaction 
(Petit et al., 1986). 
A more efficient way to control gene expression has recently been described. A 
single gene can generate either a positive or a negative regulator depending on various 
post-transcriptional modifications, in most cases by alternative RNA splicing. In these 
cases, full length proteins act as activators, while truncated ones which have usually lost 
the activation domain act as repressors. Some known genes which are subject to this 
form of modification are erbA2 (Koenig et al., 1989; Rentoumis et al., 1990), a proto-
oncogene encoding the a subtype of the nuclear thyroid hormone receptor; mTFE3, a 
gene encoding an Ig enhancer binding protein (Roman et al., 1991); fosB (Dobrzanski et 
al., 1991; Yen et al., 1991; Nakabeppu & Nathans, 1991); and CREM, a gene encoding a 
cAMP-response element modulator which is an antagonist of cAMP-induced 
transcription (Foulkes et al., 1991). Another way to generate activator and repressor from 
the same gene is by alternative translation initiation. For example, by doing so, the 
mRNA that encodes a liver-enriched transcription factor, called LAP, can also encode a 
transcription inhibitor LIP, due to initiation downstream of an N-terminal activation 
domain by translation initiation 3' to LAP (Descombes & Schibler, 1991). In all of these 
cases, the DNA binding and dimerization domains remain intact and inhibition of gene 
activation is achieved by either competing directly with activator DNA binding, by 
formation of inactive heterodimers with activator proteins, or by competition for 
accessory transcription factors. 
One other interesting aspect of this type of regulation as well as other regulations 
in general is that the ratio of activator vs. repressor can be modulated in a temporal and 
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spatial fashion. Thus. developmental cues also influence the post-transcriptional and 
translational modification steps. which in tum regulate gene expression. An extension to 
these data is the discovery of chromosomal relocalization of a heat-shock transcription 
factor (HSF) during heat shock. which can act as both an activator and a repressor. Heat 
shock induces puffs in Drosophila polytene chromosome. which include heat-shock genes 
that are actively transcribed. HSF is known to be an active regulator for heat shock 
genes. Normally HSF forms an oligomer with homogenous chromosomal distribution. 
upon heat-shock induction the inactive oligomers form active multimers and relocalize to 
discrete sites in the chromosome. Interestingly. these discrete sites include not only the 
heat-shock puff sites but also some developmental loci that are normally repressed during 
heat shock. Genes within this depressed loci include the ets-related protein and a steroid 
receptor DNA-binding protein. Thus. HSF can act both as an activator to induce heat-
shock genes and as a repressor to inactivate normal cellular transcription. The 
assumption from this experiment argues the original thought that repression during heat 
shock was controlled by some general stress-induced defect of the transcriptional 
machinery instead of a specific transcription factor (Westwood et al .• 1991). 
Negative regulation of the IL-2 gene by a repressor or a negative regulator may be 
implied at two levels. One is by regulating initiation and rate of the RNA synthesis. and 
the other is by regulating the transiency of IL-2 expression. A zinc-finger protein 
induced in stimulated T cells binds the promoter region at -1011-110. and this can 
negatively regulate activity of the -548 bp IL-2 promoter (Williams et al.. 1991). 
Although the IL-4 secreting Th2 cell clone (DlO) cannot normally express IL-2. 
treatment with cycloheximide 3 hr after stimulation induces IL-2 expression and suggests 
that the synthesis of an IL-2 gene repressor is required to inhibit IL-2 expression and the 
repressor is inhibited by the cycloheximide treatment (Munoz et al.. 1989). Both 
experiments might address the effect of the same repressor which controls the transient 
fashion of expression once the gene is activated. Mapping the regulatory element by 
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comparing the activities of promoters containing different lengths of 5' promoter 
sequences revealed that piL2(-1219) has two fold lower activity than piL2(-578), while 
piL2(-753), piL2(-1219) with deletion of -1002 to -579, and pll.2(-578) express equally 
well (Novak et al., 1990). These results suggest that a sequence from -1000 to -750 has a 
negative effect on transcription. This region is not very well conserved between mouse 
and human yet it contains stretches of poly d(CA), which may be significant since poly 
d(CA) stretches are also found in other murine cytokine genes as well (Novak et al., 
1990). On the other hand, this fragment is not conserved, so that even if it has an 
inadvertent negative regulatory effect, it may not be used for human ll.-2 gene regulation. 
Using Xenopus oocytes as an assay system, Mouzaki et al. reported the presence 
of a repressor activity in resting spleen T cell extracts. This is shown by injecting the 
IL-2 gene and spleen cell extracts into Xenopus oocytes. Since whole-cell extracts were 
used, much of what is assayed may be cytoplasmic factors. The injected IL-2 gene has a 
basal level of expression which can be repressed after injecting extracts from resting 
spleen cells. In contrast to the extract from resting spleen T cells, extracts from brain, 
liver, and kidney cells do not have this repressor activity. Surprisingly, injecting extracts 
from stimulated spleen cells does not augment the transcription unless it is coinjected 
with unstimulated extracts, indicating that there is an anti-repression activity in the 
stimulated extract (Mouzaki et al., 1991). As CD4+ T cells differentiate further to 
become memory T cells they lose the repressor activity (Mouzaki et al., 1993). The 
repressor activity is exerted at ( -292/-264) which overlaps the distal NF-AT site (Mouzaki 
et al., 1991). Could this repressor factor be the cytoplasmic NF-AT component (NF-
ATc)? Since whole cell extract is used, the inactivated phosphorylated NF-ATc may 
interact with its cognate site in association with AP-1 from the oocyte and inhibit IL-2 
gene transcription. It has been shown that phosphorylated NF-ATc in the presence of 
AP-1 can bind to DNA (Flanagan et al., 1991; Clipstone et al., 1992). The anti-repressive 
effect of activated extracts can be attributed to either the active form of NF-ATc in 
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activated extracts which competes with the inactive form of NF-ATc, or to the activation 
of bound NF-ATc through dephosphorylation with phosphatase from activated extracts 
(Schreiber & Crabtree, 1992). Evidence supporting the role of NF-ATc as a repressor 
include results from injecting extracts of the brain, liver, and kidney cells which do not 
have this repressor activity, and the fact that NF-ATc was reported to beaT-cell specific 
factor (Shaw et al., 1988). If NF-ATc is the repressor in this experiment, does this kind 
of repression necessarily occur in resting T cells? Probably not. NF-ATc in resting T 
cells is located in the cytoplasm, and only upon receiving the activation signals does it 
become dephosphorylated and is able to mobilize to the nucleus. It is not clear how this 
repressor activity as measured by the injection assay disappears as CD4+ T cells 
differentiate further to become memory T cells (Mouzaki et al., 1993). Unfortunately, the 
memory T cells generated in this experiment were not checked for their ability to make 
IL-2. They could be still in activated state and are making IL-2, or they are anergized and 
unable to make IL-2. It would also be interesting to see whether stimulated memory T 
cells are similar to stimulated spleen T cells and have anti-repression activity. This 
comparison would allow us to determine whether activation requirements change when T 
cells differentiate. 
Regulation of positive regulator availability. Control of tissue-specific genes by a 
gradient distribution of transcription factors is best shown by several Drosophila 
morphogens. The mRNA for the anterior determinant bicoid is initially concentrated in 
the anterior pole of the egg. Mter fertilization, the bicoid protein subsequently diffuses 
and is selectively degradated to form an anterior to posterior concentration gradient that 
extends over the anterior two thirds of the embryo. The bicoid protein is a sequence-
specific DNA-binding protein, and regulates a number of gap genes, including a gene 
called hunchback. In contrast to the anterior-posterior gradient distribution of the bicoid 
gene product, the hunchback protein is distributed homogeneously in the anterior half of 
the embryo and has a sharp posterior boundary. Varying the concentration of either 
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bicoid protein or the number of bicoid binding sites in the hunchback promoter can move 
the hunchback boundary forward or backward (Johnston & Niisslein-Volhard, 1992). 
Concentrations of bicoid protein below a certain limit result in no activation of the 
hunchback gene. This activator dosage dependent transcription is called a threshold 
phenomenon. Another example of the developmental control of transcription factors is 
the differential regulation of GAT A-1 and Sp-1 in primitive and definitive lineages of 
chicken erythrocytes. Higher levels of GATA-1 and Sp-1 in primitive erythrocytes are 
correlated with the expression of a primitive lineage-specific globin gene (Minie et al., 
1992). 
Decreasing protein synthesis or increasing protein degradation is one way to 
physically reduce the number of activator molecules, while specific modification or 
dimerization can be used to mask the nuclear localization signal or DNA-binding domain 
and affect the protein's function. For example, the gradient of dorsal protein, another 
Drosophila morphogen which determines the dorsoventral axis, is controlled by nuclear 
localization. Different zygotic genes are activated in response to a spectrum of 
concentrations of nuclear localized dorsal protein (Johnston & Niisslein-Volhard, 1992). 
The nuclear localization of the dorsal protein in the ventral and lateral side of the embryo 
is triggered by the IL-l receptor-like membrane protein Toll in response to the active 
form of spatzle protein. It is proposed that the gradient distribution of the dorsal protein 
along the ventral-dorsal axis is generated by the localized proteolytic processing, which 
generates processed, active spatzle protein at the ventral side of the embryo (Morisato & 
Anderson, 1994). 
Direct blocking of an activation domain by a negative regulator has been 
demonstrated for c-myc gene regulation. The cell-cycle control gene c-myc is 
developmentally regulated in B cells. It is on in early B cells but off in terminally 
differentiated plasma cells. Its expression during development is inversely correlated 
with the expression of a negative regulator called myc-PRF, which binds to the c-myc 
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promoter and shuts off transcription (Kakkis et al. , 1987). Biochemical studies showed 
that the site for myc-PRF is adjacent to the site for myc-CFl, an activator for the c-myc 
gene. Both factors can bind to their sites simultaneously and are physically associated. 
This implies that in plasma cells high levels of myc-PRF allow formation of a multi-unit 
complex containing myc-PRF, myc-CFl, and myc DNA, which masks myc-CFl (Kakkis 
et al., 1989; Riggs et al., 1991). Masking the activation domain can also be achieved by 
post-translational modification of activation domains. 
There are many examples of variation in the availability of trans-activators by 
dimerization with an inhibitory protein. Negative regulators which function by 
complexing with activator proteins include llCB, IP-1, hsp90, and ld. llCB dimerizes with 
NF-lCB, but upon activation by TPA, IL-l, or TNFa, Ix:B becomes phosphorylated and 
releases NF-x:B which subsequently binds DNA (Baeuerle & Baltimore, 1988). IP-1 
behaves similarly to lx:B but instead it associates with AP-1 and prevents its DNA 
binding. Phosphorylation of IP-1, mediated by cAMP-dependent protein kinase A, 
releases AP-1 in both the nucleus and the cytoplasm (Auwerx & Sassone-Corsi, 1991). A 
heat shock protein encoded by the hsp90 gene associates with the glucocorticoid receptor, 
and blocks its transcriptional activation function. Binding of steroids to the receptor 
causes dissociation of hsp90 and releases the receptor, which is then able to bind DNA 
(Picard et al., 1988). Myoblasts express MyoD family proteins which cannot activate 
muscle-specific genes at that developmental stage. Id, an HLH protein, associates with 
MyoD in the myoblasts and the resulting Id-MyoD heterodimers fail to bind DNA. 
During myocyte differentiation, down-regulation of the Id protein permits dimerization of 
MyoD family member proteins which can now bind DNA (Benezra et al., 1990). 
How does a reduction in the nuclear concentration of positive regulators result in 
no or significant transcription? What is the mechanism of this threshold phenomenon? 
In vitro biochemical studies using a 5xV AG4-VP16-site containing the adenovirus E4 
minimal promoter template either naked or assembled with nucleosomes and Hl proteins 
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showed that with increasing concentrations of GAL4-VP16 proteins, the naked template 
has a gradual linear increase in transcription over the basal level of activation seen in the 
absence of GAL4-VP16. On the other hand, the chromatin template shows a quantum 
non-linear increase in transcription from no expression at zero or low levels of GAL4-
VP16 to high expression at higher levels of GAIA-VP16. The reproduced threshold of 
activation with this template indicates that it is the repressive effect of chromatin 
structure which accounts for lack of expression with an insufficient amount of activator. 
Higher amounts of activator are required for both anti-repression and trans-activation of 
genes (Laybourn & Kadonaga, 1992). 
As briefly mentioned earlier, the differentiation stages 2 and 3 in figure 1 might 
be points where lymphoid and T cells become more competent to express IL-2 gene by 
acquiring the ability to activate T -cell specific transcription factors and the ability to 
express high levels of both T-cell specific and certain general transcription factors upon 
activation. Non-lymphoid or non-T cells at each of these points do not undergo this 
acquisition process. For instance, a pre-mast cell line (32D) (differentiated from stage 2) 
has been shown to have decreased NF-AT and AP-1 binding activities upon stimulation 
(chapter 4). A similar mechanism could also apply to B cells developed from stage 3. 
However, different from pre-mast 320 cells, B cells are one or more steps closer toT 
cells. This may indicate that they have more characteristics ofT cells in terms of IL-2 
gene inducibility. In fact, it has been shown that B cells from transgenic mice with 
(NF-AT site)3-SV40 large T antigen clearly express T antigen upon induction in vitro. 
But their kinetically slow expression of IL-2 gene may suggest that their ability to 
mobilize NF-AT or some other transcription activators is less ready than T cells and they 
require longer time to accumulate high enough concentration of certain factors (Verweij 
et al., 1990). Also as mentioned earlier, that EB-virus transformed B cells can make IL-2 
under certain conditions (Amigorena et al., 1992; Bonnerot et al., 1992). Most of the 
transcription factors described above are not T-cell specific or IL-2 gene specific. 
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Teleologically, in addition to requiring the ability to express T-cell specific transcription 
activator NF-AT and being able to activate it, IL-2 gene inducibility could also be 
regulated through increasing the nuclear concentration or availability of those T -cell non-
specific factors. This may be particularly true for T cells at stages 4 and 5. For example, 
in chapter one we showed that increasing the DNA-binding activities of AP-1 and NF-KB 
by co-stimulation with IL-l superinduced the level of IL-2 gene activation. Similarly, the 
requirement of IL-l co-stimulation in immature T cells is another example showing that 
NF-KB, a non-T cell specific transcription activator can be regulated developmentally. In 
IL-2 producing cells, specifically reducing the nuclear concentration of certain factors or 
affecting the trans-activation activity of certain factors has been shown to decrease the 
IL-2 inducibility. For example, inhibition of a Ca2+-calmodulin-dependent phosphatase 
by treatment with an immunosuppressant cyclosporin A specifically blocks the nuclear 
translocation of NF-ATc and results in no IL-2 gene activation (Liu et al., 1991; 
Clipstone et al., 1992). 
We have discussed the first acquisition of IL-2 gene inducibility in immature 
triple negative T cells. Point 4 in figure 1 indicates the transitions from immature triple 
negative T cells to cortical double positive TCR1°, and to single positive TCRhi T cells. 
We also know the fact that the transition from CD4-CD8-TCR- immature cells to 
CD4 +CD8+TCRlo cortical thymocytes, and then positive selection to single positive 
TCRhi mature cells are accompanied by changes in the regulation of the IL-2 gene from 
inducible, to non-inducible, and then to inducible again. Could the inability of 
CD4+CD8+TCRlo thymocytes to make IL-2 be attributed to a repressed chromatin 
structure? Most likely not. Remodeling of chromatin structure can be dependent or not 
be dependent on DNA-replication. However, those dependent on DNA-replication are 
usually more stably inherited, while those independent seem more reversible. The 
transition from IL-2 inducible CD4-CD8-TCR- immature thymocytes to IL-2 non-
inducible CD4+CD8+TCRlo cells does require several rounds of proliferation, which may 
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give cells an opportunity to remodel the chromatin structure and to render the promoter-
enhancer region inaccessible to trans-acting factors. However, the positive selection 
process which transforms the CD4+CD8+TCRlo back to IL-2 inducible CD4+TCRhi or 
CD8+TCRhi cells does not involve cell proliferation. Thus in the absence of proliferation 
there is little chance for the chromatin structure to transform back to an activatable state. 
Furthermore, since a pattern of hypersensitive sites associated with the activatable 
configuration is also stably inherited in other hematopoietic non-T cells which cannot be 
induced to express IL-2 (Siebenlist, et al., 1986), it is not inconsistent that these sites 
remain in CD4+CD8+TCRI0 cells. Although circumstantial evidence seems to favor that 
there is no change of chromatin structure during intrathymic development, it would still 
be necessary to demonstrate this either directly by performing the DNase I mapping or 
indirectly by showing its IL-2 expression under certain circumstances. 
The cortical stage in T-cell development is coupled with many changes. The IL-2 
gene is not the only gene whose inducibility is repressed. For example, the IL-2 receptor 
a gene is constitutively expressed in early triple negative immature cells, non-
constitutive, but inducible in late stage triple negative immature cells, and completely 
non-inducible in CD4+CD8+TCR1° cells. It is reversed to be non-constitutive, but 
inducible again in post-positively selected cells (Boyer & Rothenberg, 1988; Rothenberg 
et al., 1993). In addition to these inducible genes, a number of constitutively expressed 
genes like the IL-2 receptor y gene and the apoptosis-protective bcl-2 gene are also 
temporarily repressed during this transition (Cao et al., 1993; Moore et al., 1994). Instead 
a number of genes associated with programmed cell death, including Fas, are upregulated 
or become inducible in cortical thymocytes (Andjeli'c et al, 1993; Owens et al., 1991); as 
if these cells switch to a semi-suicidal mode ready to undergo apoptosis at any moment. 
Both the ectopic expression of bcl-2 in bcl-2 transgenic cortical thymocytes and the in 
vivo administration of soluble Fas protein, which blocks the Fas ligand can reduce 
thymocyte apoptosis (Sentman et al., 1991; Strasser et al., 1991; Cheng et al., 1994). 
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Cortical cells may not interpret signals transduced through Fas in addition to signals 
generated by the high avidity engagement of epithelial cells as an activation signal as 
mature T cells do but as a death signal (Hogguist et al., 1994; Ashton-Rickardt et al., 
1994). Transcription factors used to induce genes like IL-2 may not be activated in 
cortical cells because of the nature of the signal, or the factors may be activated but then 
are used instead to activate genes for programmed cell death. In chapter 2 and 3, we will 
specifically examine the availability of the transcription activators in cortical cells by 
comparing DNA-binding activities in immature, cortical, and mature thymocytes and we 
will analyze at which level the factors with altered binding activity are regulated. 
Once mature CD4+ T cells acquire this competence, the regulation of IL-2 gene 
continues during the final differentiation to Thl and Th2 cells (Fig. 1, stage 5). Naive 
CD4+ cells produce IL-2 upon stimulation. Memory CD4+ cells, on the other hand, 
produce either IL-2, IFNy, lNFa and lNF~. or IL-4, IL-5, IL-6, IL-10, and IL-13 upon 
induction. Memory cells making the former set of cytokines are designated Th 1 cells, 
while memory cells making the latter are Th2 cells. Activati·on of a Thl response favors 
the development of cellular immunity by enhancing the microbicidal activity of 
macrophages; while activation of a Th2 response facilitates humoral immunity by 
enhancing B cell antibody production. By varying culture conditions, Thl and Th2 cells 
may develop directly from a naive T cell which produces IL-2 predominantly (Rocken et 
al., 1992). Alternatively, Th1 and Th2 cells may arise from a IFNy and IL-4 producing 
ThO cell, which is the cell in the developmental stage between naive and memory T cells. 
A common progenitor for Thl and Th2 cells is best demonstrated in transgenic mice 
expressing the IL-4 promoter driving herpes simplex virus thymidine kinase. Activation 
of the cytokine promoter in IL-4 expressing cells induces the synthesis of thymidine 
kinase and renders the cell sensitive to killing by ganciclovir. Culture of naive CD4+ T 
cells from transgenic mice in conditions which allow naive T cells to differentiate to 
either IFNy-producing Th1 or IL-4 producing Th2 cells does not give rise to IL-4 
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producing Th2 cells nor IFNy producing Th1 cells when ganciclovir is included in the 
beginning of the culture. Native CD4+ T cells from negative controllittermates produce 
both types of cells under same conditions (Kamogawa et al., 1993). The progression to 
Thl or Th2 is shown to be more instructive. Differentiation from either naive T cells or 
ThO cells to Th1 or Th2 eels can be induced by cytokines like IL-2, IL-4, IL-12 and IFNy. 
Both in vitro and in vivo studies have demonstrated that IL-2+1L-4 directs T cells to 
produce a Th2-like response, which is inhibited by IFNy, whereas IL-2+1L-12 drives a 
Th1-like response, which can be inhibited in the presence of IL-4 (Seder et al., 1992). 
The preferential induction of Thl development by macrophages is also correlated with 
their secretion of IL-12 cytokines (Hsieh et al., 1993). It appears that these cytokines 
may cause irreversible differentiation to Th2 or Th1 end states, not just a strongly biased 
short-term response. Therefore, cytokine-cytokine receptor mediated signals are able to 
determine Th 1 and Th2 differentiation. It is then necessary to address what nuclear 
targets are controlled by these differentiation signals. A number of experiments 
discussed below indicate that the repression of either IL-2 or IL-4 gene inducibility is 
reversible under certain conditions. Therefore, DNA methylation or repressed chromatin 
structure is less likely to be involved in Thl and Th2 differentiation, but sequence-
specific transcriptional activators or repressors are more likely to be the nuclear target of 
these differentiation signals. 
The proximal promoter region of IL-4 gene contains four NF-AT-like sites. 
Recent studies have shown that the factor(s) bound to one of the NF-AT-like site in the 
IL-4 gene promoter did not contain an AP-1 factor (Rooney et al., 1994), in other words, 
AP-1 may not be involved in IL-4 gene activation. Cotransfection of a Th2 clone with 
the eukaryotic initiation factor 4E (eiF-4E) was able to induce IL-2 gene expression and 
augment NF-AT binding activity. Since AP-1 is the component of NF-AT which 
requires de novo protein synthesis, the above results may imply that the overexpression of 
eiF-4E induced the synthesis of proteins including AP-1 and other IL-2 regulatory factors 
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which are deficient in Th2 cells (Barve et al., 1994). Not surprisingly, there are also Th2-
specific IL-4 gene regulators which are similarly controlled in Th1 cells. For instance, 
when using either the entire ll..,-4 5' regulatory sequence or a multimerized site from the 
IL-4 promoter, the reporter gene was only induced in IL-4 producing Th2 clones but not 
in IL-2 producing Th1 clones (Bruhn et al., 1993; Lederer et al., 1994). Therefore, it 
appears that the divergence of cytokine gene expression in Th1 and Th2 cells may be 
limited at least in part by the amount of gene-specific positive regulatory factors. This 
was also supported by the fmding that hybrids produced by the fusion of BW5147 (a 
Thl-like thymoma cell line) and a Th2 clone express both IL-2 and IL-4 (Hagiwara et al., 
1988). Is AP-1 a likely nuclear target that are involved in Th1 and Th2 determination? 
Could AP-1 also be differentially regulated by IL-2+IL-4 and IL-2+IL-12? One study 
using a human myeloid cell line, HL-60, demonstrated that the commitment to either 
macrophage or granulocyte lineage pathways is correlated with the level of AP-1 
induction (Mollinedo et al., 1993). Cross-linking they chain which is now known to be 
shared by both IL-2 receptor and IL-4 receptor has been shown to be able to activate 
c-myc, c-fos and c-jun (Arso et al., 1993). The exact nature of the combined signal from 
IL-2R and IL-4R or from IL-2R and IL-12R remains unknown. However, experiments 
based on the in vitro assay system can be designed to determine what controls the 
differentiation pathways of naive T cells. 
In summary, although four general mechanisms of gene regulation are mentioned 
here, they do not work independently. Each event can be in sequential order or act 
simultaneously. For example, demethylation of DNA can lead to an alteration of 
chromatin structure which in tum becomes accessible to transcription activators. 
However, this open or partially open chromatin structure together with general or basic 
transcription factors may be necessary but may not be sufficient to ensure gene activation. 
Inhibition of repressor activity or activation of transcription activators may be required to 
sufficiently induce gene expression, particularly the expression of those tissue-specific 
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genes. As for the IL-2 gene, at differentiation stage 1 demethylation and alteration of 
chromatin structure may be involved to initiate a pre-activatable IL-2 locus. At points 2 
and 3, an active process of activating both T-cell specific and non-T cell specific 
transcription activators which are implicated for IL-2 gene regulation could occur. At 
points 4 and 5, fine tuning of the DNA binding activity or trans-activation activity 
induced by differentiation signals determines whether to maintain or lose IL-2 gene 
inducibility. 
Study of IL-2 gene regulation by in vivo footprinting techniques 
Work from enhancer mapping, cis-element footprinting, gel shift binding assays, 
and finally the purification and cloning of specific factors yielded significant information 
which laid the foundation for us to understand how the IL-2 gene can be regulated. A 
number of transcription factors examined apparently do not require an activation signal in 
order to bind DNA, such as the octamer protein and factors which bind the CACCC sites. 
Others, however, definitely need activation signals. PKC activation induces the synthesis 
of AP-1, the nuclear translocation of NF-x:B, and the binding of the lesser known 
TGGGC factor; while Ca2+ mobilization causes dephosphorylation of NF-ATc which is 
then able to translocate to the nucleus. Almost all of these factors, except NF-ATc, are 
not T-cell specific. We still do not understand how the cell-type specificity of the IL-2 
gene is achieved given the fact that many of the positive regulatory factors mentioned 
above are not specific to IL-2-producing cells. Different gene repression mechanisms, 
like DNA modification, repressed chromatin structure, repressor binding and lack of 
activator, etc. have been discussed above. Previous studies from this lab and others have 
shown that a lack of certain factors correlates with lack of gene expression, but it is not 
clear exactly how this is accomplished, e.g., how other factor DNA-binding activities are 
affected by the lack of certain factors. 
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The in vivo footprinting technique has been used to study the regulation of a 
number of genes and has proven to be a useful approach to address the DNA binding or 
similar kinds of questions which cannot be solved by other in vitro biochemical analyses. 
These studies revealed several patterns of protein-DNA interaction with respect to genes 
and cells examined. Some constitutively expressed tissue specific genes, like the Ig 
heavy chain gene (Ephrussi et al., 1985), the liver-specific TAT gene (Becker et al., 
1987), the MHC class I gene (Dey et al., 1992), the class II gene (Kara & Glimcher, 
1991), and the muscle specific MCK gene (Mueller & Wold, 1989), etc, have their 
regulatory regions occupied with trans-acting factors only in gene-expressing cells. In 
cells which do not express the gene, the regulatory region is free of specific protein-DNA 
interactions. Neither repressor nor ubiquitous positive regulatory proteins are bound to 
DNA in these cells. The unoccupied state remains in the TAT gene which is not blocked 
by methylation (Weih et al., 1991). These results strongly suggest that the chromatin 
structures may be differentially constructed which enable some genes to be expressed 
constitutively in one but not the other configuration. 
Studies of ~-interferon, a relatively ubiquitously expressed and induction-
dependent gene showed that two sites in the promoter region are occupied by repressors 
in uninduced cells, but upon viral infection, the repression-associated binding is displaced 
with activator binding (Zinn et al., 1986). In this case, it is the repressor binding that 
results in non-expression. The regulation of the metallothionein-1 gene is another 
example in which the basal level of expression is controlled by the interaction of a set of 
transcription factors with the enhancer sequence. Upon metal induction, new protein-
DNA complexes are assembled and transcription activity increases, suggesting that 
increased transcription is correlated with new factor binding (Mueller et al., 1988). One 
exception that is different from all the cases given above is the regulation of two 
immediate early genes c-fos and c-jun, which encode components of AP-1. In the non-
expressing state, the serum-response element on c-fos gene promoter is occupied even 
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before serum-induction, and serum induction does not change the binding (Herrera et al., 
1989). Similarly, multiple sites in the c-jun promoter are occupied before induction by 
UV-irradiation and remain unchanged after irradiation (Rozek & G. P. Pfeifer, 1993). 
The situation with c-jun and c-fos may indicate a committed state. 
The examples given are of either tissue-specific genes or induction-dependent 
genes, both of which are not like the IL-2 gene. As a rule, gene expression is 
accompanied by the presence of a set of sequence-specific protein-DNA interactions at 
the regulatory region. No gene expression, on the other hand, can have various 
footprinting patterns, which may be correlated with the mechanisms used to repress the 
gene. What can be said about the IL-2 gene? We can be sure that in activated, IL-2 
producing T cells, the IL-2 gene promoter region is occupied by trans-acting factors. We 
could guess that in the IL-2 gene non-expressing state, there would be either no sequence-
specific factors bound to the DNA as seen for tissue-specific genes in non-expressing 
cells; or a repressor bound to the DNA as seen in the ~-interferon gene; or a constitutively 
expressed factor bound to DNA as in c-fos and c-jun genes. The last type might be 
expected in resting T cells. In any case, resolving this question is essential for us to 
understand the mechanism of how the IL-2 gene is repressed in non-T cells, and in resting 
T cells, and how it is activated. In chapter 4 and 5 , we report the results of in vivo 
footprinting studies for the IL-2 gene. This work was begun in close collaboration with 
Paul Garrity and Barbara Wold. 
Modulating IL-2 gene expression by accessory signals 
The T-cell activation signal transduction pathway can be simplified as follows: 
activation signals delivered by T cell receptor and accessory receptors first induce 
tyrosine phosphorylation on CD3 rand ' chains, two components of TCR, by p56lck or 
p59fyn_ The SH2 domain of ZAP70, another tyrosine kinase, is then able to associate 
with the' chain (Chan et al., 1992; Irving et al., 1993). Tyrosine kinases recruited by the 
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phosphorylated s chain, like ZAP70, are able to activate phospholipase Cy, which in turn 
catalyzes the cleavage of PIP2 into IP3 and DAG. IP3 will induce Ca2+ mobilization and 
DAG will activate protein kinase C (Reviewed by Weiss and Imboden, 1987; Weiss and 
Littman, 1993). Both initial PTK activation and down-stream PKC activation can 
independently lead to Ras activation and trigger the Raf-1, Mek, and MAK signalling 
pathways (Downward et al., 1992; Crews and Erikson, 1993). Activation of primary 
mature T cells requires both a TCR signal and a costimulatory signal. Induction through 
TCR alone will render T cells unable to make IL-2 (anergized state), even if the accessory 
signal is added later (Schwartz et al. 1989). The current view regards the CD28 
transduced signal as the accessory signal, although the precise biochemical events 
initiated by CD28 are not clear at the moment. The basic two branch-signal pathways 
triggered by TCR alone in T leukemic or tumor lines can together activate some 
transcription factors, and can independently activate different factors as well. For 
example, NF-AT activation requires PKC for AP-I and Ca2+ for the cytoplasmic 
component; NF-KB and c-fos, on the other hand, can apparently be activated by PKC 
alone. 
Cell-cell interaction involves multiple types of receptor-ligand engagement. T 
cells express multiple molecules on their surface, and recognition of antigen presented by 
APC is not only limited to the TCR-Ag/MHC ligation. Surface receptors like CD28, 
CD45, and some adhesion molecules also participate in recognition and activation by 
interacting with their ligands. Thus, the significantly increased avidity of the cell-cell 
interaction will greatly facilitate the transduction of activation signals. Signals delivered 
by other accessory molecules on T cells and by hormone receptors may synergize with or 
antagonize the activation signal in regulating IL-2 gene transcription. One such example 
is the interaction of the IL-l receptor with interleukin-1 which is secreted from antigen-
presenting cells. We are interested in the mechanisms of how cells integrate the TCR 
activation signals with signals from interleukin-1. The activation of certain serine-
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threonine kinases by IL-l may synergize with PKC. Ultimately all these different signals 
will be interpreted at the level of trans-acting factor activation and in turn gene 
activation. For instance, as described above, anti-CD28 costimulation induces activation 
of a novel transcription factor and synergizes with the TCR signal in IL-2 gene 
transcription (Fraser et al., 1991). 
As discussed earlier in the introduction, the other significance of studying the IL-l 
effect is its developmental relevance. Immature CD4-CD8-TCR- thymocytes can be 
induced to express IL-2, but in addition to signals that mimic TCR activation they also 
require IL-L Mature T cells do not need an IL-l-mediated accessory signal to be induced 
to make IL-2. Although in chapter 1, we investigated the mechanism of the IL-l 
synergistic effect using the EL4 thymoma cell line, the results may apply to immature 
cells as welL 
In addition to the synergistic effect of certain accessory signals, there are signals 
delivered through other molecules or by pharmacological agents which antagonize the 
TCR signal and down-regulate the IL-2 gene. For example, the immunosuppressant 
cyclosporin A can selectively suppress IL-2 gene activation. As reviewed earlier in the 
introduction, cyclosporin A blocks the Ca2+ branch of the activation signal by inhibiting 
a calcium-calmodulin dependent phosphatase activity, which in turn blocks the 
translocation of NF-ATc. Reduction of activator availability was one of the gene 
repression mechanisms I discussed before. But a remaining question is how this affects 
further down-stream events, such as the DNA binding of other cyclosporin A-insensitive 
factors. Could they still form protein-DNA complexes without NF-AT and simply slow 
down the transcription? Could some other factors fill the sites, or is there no binding at 
all? These are the questions we study in chapter 4. Similarly, we also examine the effect 
of another signal mediated through the cAMP-dependent protein kinase A pathway in 
chapter 5. It has long been observed that elevating cAMP could antagonize the TCR 
activation signals and reduce IL-2 transcription. Although it is not known exactly how 
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the activation of protein kinase A inhibits the TcR activation signal, it has been shown 
that the type I PKA regulatory subunit becomes associated with the TCR complex upon T 
cell activation, suggesting that part of the block may be at an early step of signal 
transduction (Skalhegg et al. 1994). We have also shown, however, that signalling 
downstream of the TCR is also affected, as cAMP even inhibits activation through 
TPA+A23187. We analyzed whether the activity of any of the nuclear factors would be 
interfered with by this signal and examined the in vivo protein-DNA interaction in the 
IL-2 promoter region in activated T cells in the presence of the cAMP-elevating agent, 
forskolin. Understanding how reducing the availability of certain, but not all, trans-
acting factors could result in gene inactivation will certainly enlighten us as to how, in 
general, gene repression can be achieved, especially regarding different types of cells or 
tissues. 
T cell lines vs. primary T cells 
Because of the difficulties in isolating and transfecting mature helper T cells, we 
selected EL4 cells for some of the work because they are easy to populate and to 
transfect. The murine thymoma cell line EL4 and the human T leukemic cell line Jurkat, 
are two commonly used model T helper cell lines for studying lymphokine gene 
regulation and signal transduction. As regarding to IL-2 gene expression, EL4 cells do 
respond similarly to real T cells, although not identically. Accessory signals which up or 
down-regulate the IL-2 gene in immature or mature T cells also have same effect in EL4 
cells. There are, however, several characteristics which separate EL4 cells from normal 
mature IL-2 producing T cells. First, EL4 cells can be induced to express the IL-4 gene 
as well, which is a type-2 helper T cell specific gene (Novak & Rothenberg, 1990). 
Second, activation of protein kinase C by TP A in the absence of calcium ionophore is 
sufficient to induce IL-2 expression. Third, EL4 cells are cycling cells, but they are not 
refractory to stimulation signals. These 'abnormalities' may be attributed to their tumor 
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phenotype or to the fact that they represent a specific stage of T cell development. 
Therefore, these cells may not truthfully reflect the state of mature T helper cells in vivo, 
nor a particular stage ofT-cell development. Nevertheless, the accuracy in IL-2 gene 
expression provides a convenient and direct system to study the transcriptional regulation 
ofT helper specific genes. Naturally, caution and more extensive studies are necessary 
when generalizing the results to normal cells. 
A recapitulation of the contents of each chapter is as follows. Chapter 1 describes 
the synergism of interleukin-1 with the T-cell receptor signalling pathways for IL-2 gene 
induction, and further reveals that IL-l costimulation enhances the DNA binding of 
transcription factors NF-KB and AP-1. This enhancement is not coupled with cAMP 
elevation. Chapter 2 studies the molecular basis for changes in IL-2 gene inducibility 
during thymocyte development and shows that under certain stimulation conditions, both 
early immature and mature thymocytes are equally able to mobilize a set of transcription 
factors in order to express the IL-2 gene. The inability to activate the IL-2 gene in 
cortical thymocytes is correlated with their defective DNA-binding activity of NF-AT 
and AP-1 upon stimulation. Chapter 3 further shows that in cortical thymocytes the 
induction of c-fos, fosB, and fra-2 genes is reduced at the mRNA level and implies that 
the defective DNA-binding activity of NF-AT and AP-1 may be due to the reduction of 
Fos proteins and the subsequent failure of Jun-Fos dimer formation. In chapter 4, 
utilizing in vivo footprinting analysis, we demonstrated that the contact of trans-acting 
factors and the IL-2 promoter is an all-or-none pattern. The interaction is only correlated 
with the presence of both induction-dependent and induction independent factors in the 
stimulated T cells. A lack of protein-DNA complexes at the IL-2 promoter is correlated 
with the presence of only induction-independent factors in resting T cells and in non-T 
cells. Failure to activate factors including NF-AT upon stimulation in the presence of 
cyclosporin A also results in a lack of factor-DNA complex assembly in the promoter 
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region. These results indicate a combinatorial and coordinated interaction of transcription 
factors with the IL-2 gene. In chapter 5, a similar approach, which combines the in vitro 
and in vivo DNA binding assays, is taken to examine the IL-2 gene inhibition mechanism 
by elevating the intracellular cAMP. We demonstrate that forskolin costimulation 
specifically blocks the DNA binding activity of certain factors including NF-x:B, but not 
NF-AT. This blocking also results in no occupancy in the IL-2 promoter. The results 
strongly indicate that the stable protein-DNA complex assembly requires the 
combinatorial coengagement of all the distinct factors. 
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Figure 1. Developmental control of IL-2 gene inducibility. 
HSC, hematopoietic stem cell; SC-1, lymphoid stem cell; 
SC-M, myeloid stem cell; CFU, colony forming unit; E, 
erythrocyte; Meg, megakaryocyte; M, macrophage; G, 
granulocyte; Neu, neutrophil; Eo, eosinophil; b, basophil; p, 
platelet; B, B lymphocyte; T, T lymphocyte. 
69 
TCR CD28 
Figure 2. Diagram of signalling pathways and interaction 
of trans-acting factors with the IL-2 promoter. 
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The macrophage-derived cytokine interleukin-1 (IL-l ) can provide a second signaJ with antigen to elicit 
production of interleukin-2 (IL-2) by helper T cells. The pathway(s) involved remains controversial, with 
protein kinase C and cyclic AMP (cAMP) invoked as possible second messengers. In the murine thymoma 
EL4.El, IL-l could synergize with the phosphoinositide pathway, because the cells made higher levels of IL-2 
in the presence of IL-l than could be induced by phorbol ester plus calcium ionophore alone. IL-l is unlikely 
to act through a sustained increase in cAMP in these cells because it did not raise cAMP levels delectably and 
because IL-l and forskolin had opposite effects on IL-2 gene expression. Inducible expression of a transfected 
reporter gene linked to a cloned fragment of the murine IL-2 gene promoter was initially increased by IL-l 
costimulation, implying that IL-l can increase the rate of transcription of IL-2. The minimal promoter 
elements required for IL-l responsiveness were located within 321 bp of the JL-2 RNA cap site, and further 
upstream sequences to -2800 did not modify this response. IL-l costimulation resulted in enhanced activity of 
both an inducible ~F-KB-Iike factor and one of two distinct AP-1-like factors that bind to IL-2 regulatory 
sequences. Neither was induced, however, by IL-l aJone. Another AP-1-like factor and NF AT -1, while 
inducible in other cell types, were expressed constitutively in the EL4.El cells and were unaffected by IL-l. 
These results are discussed in terms of the combinatorial logic of IL-2 gene expression. 
lnterleukin-1 (IL-l) is a potent mediator of cellular func-
tion that is produced primarily by act ivated macrophages 
(19). and a role for IL-l in T-cell activation has been 
demonstrated in a number of experimental systems (7, 8, 25). 
In vitro, IL-l synergizes with mitogenic lectins or anti-T-cell 
receptor (TcR) antibodies to induce expression of interleukin 
2 (IL-2) and IL-2 receptor a-chain genes (13 , 18. 44). In these 
roles, IL-l can be replaced by tumor-promoting phorbol 
esters (e .g .. 12-0-tetradecanoylphorbol 13-acetate [TPA]) 
(11). As IL-l was known to provide a necessary. antigen-
nonspecific signal for T-cell activation (9), this apparent 
equivalence with TPA initially suggested that its action 
might result from activation of protein kinase C (28). How-
ever. IL-l does not promote phosphoinositide hydrolysis or 
cause protein kinase C translocation to an active membrane-
bound form (1). It therefore seems unlikely that its role is to 
augment the low levels of diacylglycerol produced by TcR-
mediated phosphoinositide breakdown. More recently, it has 
been demonstrated that IL-l treatment of the human T-cell 
leukemia line Jurkat causes increased production of two 
protein kinase C cofactors , phosphatidylserine and diacyl-
glycerol , the latter from hydrolysis of membrane phosphati-
dylcholine (23 , 34). However. because Jurkat lacks conven-
tional IL-l receptors (1L-1Rs) (34) . the significance of these 
results for other T cells is unknown. 
The studies that have reported a costimulatory role for 
IL-l have usually demonstrated this effect on cells subopti-
mally stimulated with mitogenic lectins (13, 15. 18. 44). 
Several laboratories have obtained results that call into 
doubt the notion that IL-l is necessary at all for the 
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high-level production of IL-2 when the TcR signal is opti-
mized. We have shown that when fresh splenic T cells 
produce IL-2 in response to TPA and the calcium ionophore 
A23187. their response is both independent of and insensi-
tive to added IL-l (35. 36). Lichtman et al. (21) have 
obtained similar results with a panel of cloned antigen-
dependent T Hl cell lines stimulated with an anti-CD3 mono-
clonal antibody. Two other groups have shown that long-
term T Hl (IL-2-producing) lines may lack IL-lRs altogether 
(14, 20). Thus , these systems do not provide access to any 
unique pathway through which IL-l may act. 
Recent data suggest. however. that a requirement for IL-l 
may reflect the developmental status of a T cell. These 
differences are most apparent in induction of IL-2 expression, 
a response subject to complex regulation (16. 27. 32). Mature 
TcR + thymocytes resemble peripheral T cells in their insen-
sitivity to IL-l when they are stimulated to produce IL-2 in 
response to TPA plus A23187. These chemical proxies for 
mediators of the phosphatidylinositol bisphosphate hydroly-
sis pathway may be able to induce IL-2 expression in all 
mature T cells. for they can al o elicit high-level responses in 
most fresh peripheral eng+ cells (24). cells which generally 
do not express IL-2 mR A in response to either antigen or 
mitogenic lectins. In contrast , however. immature TcR-
double-negative thymocytes do not make IL-2 in response to 
TPA and A23187 at all unless IL-l is present (35. 36). Thus, 
these immature thymocytes differ from their more mature 
descendents in two important aspects of their IL-2 inductive 
signal requirements. First. in these cells. pho phoinositide 
pathway agonists are insufficient to activate IL-l expression. 
Second. they possess a pathway allowing IL-l effects to 
synergize with phosphoinositide pathway mediator . 
Here we repon that the cloned murine thymoma EL4.El 
possesse characteristics of both immature and matu re IL-2 
producers. Like mature T cells. it can respond to phorbol 
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e'>t<!r and ionophore alone!. In addition. it posses~e a trait 
norma II~ a~sociated '' ith immature thymocyte~. name! ~. 
re,pon'>iveness to IL-l as a co-.timulu~ with TPA plus 
X~:\187. We have used these cell'> to e.\plore the mechanism 
b~ '' hich the \) nerg) bel\\ <!en IL- l and TPA plu~ A23187 
occur-.. 
~lA TERlALS A;\'D METHODS 
Reagents. TPA and A23187 ''ere from Sigma or Calbio-
chem. They were dissolved in dimethyl ulfoxide to final 
concentrations of 10 flg/ml and 0.37 mg mi. respectively. a nd 
~tored m small a m pies at - 20°C. Recombinant huma n a nd 
mouse IL-ln CIL-1) wa~ purcha'>ed from Genzyme. The 
spec ific activit y. a reported b) the upplier. was 10M U 1mg. 
Cells. EL4.El. a mouse IL-2-producing thymoma cell line 
(originally donated by V. Paet kau. University of Alberta). 
and the human T-cell leukemic line Jurkat (generously 
provided by G. Crabtree. Stanford Uni versit y) were grO\\ n 
in RPMJ 1640 supplemented with lOCf fetal bo' ine '>erum. 2 
mM L-glutamine. 50 flM 2-mercaptoethanol. a nd a ntibiotics. 
Plasmids. The series of plL2-CAT plasmids containing 
,·arying lengths of the mouse IL~2 gene 5' DNA linked to the 
bacterial gene for chloramphenicol acetyltransferase (CA T l 
has been described in deta il <30). Briefly. cloned fragments 
of the IL-2 gene : ·-Ranking region. a ll terminating 3' at -45 
(Ill the 5 · untranslated region). were ligated to the CAT gene 
from pTK-CAT in the vector pSP65 (Promega). They are 
de ignated piL2(- X). where X is the 5' -terminal nucleotide . 
relative to the IL-2 transcriptional start site. that is present in 
the construct. All plasmids were purified in CsCl-ethidium 
bromide density gradients before use. 
Transfections and CAT assays. Transfecrion of logarithmi-
cally growing cell was by DEAE-dextran facilitation as 
described elsewhere (30). In short. cells were washed in 
erum-free Dulbecco modified Eagle medium with 10 mM N-
2-hydroxylethylpiperazine-N' -2-ethanesulfonic acid (HEPES: 
pH 7 .0) (DME/H) and then suspended at 107/ml in a trans-
fection cocktail containing 250 flg of DEAE-dextran (molec-
ular weight. 2 x 106 ) per mi. 0.1 mM chloroquine. and 10 flg 
of supercoiled plasmid D A per mi. all in DME/H. After 
incubation for 30 to 60 min at 37°C in 7o/c CO~. cells were 
pelleted. washed. and plated into 4 to 12 identical cultures. 
Approximately 20 h after plating. cells were stimulated with 
TPA and A23187 at final concentrations of 10 and 37 ng/ml. 
respectively. These dosages were previously determined to 
be optimal for both IL-2 mRNA expression and secretion 
over 18 to 20 h in the population overall. Some of the cells a lso 
received IL-l to the indicated concentrations. Human recom-
binant IL-1n wa found to be a effective as the mou e 
version on EL4.E1 cells and was u ed in most experiments. 
Cells \vere ha rvested after various times of stimulation. 
and extracts from equivalent numbers of cells were assayed 
for CAT activity in a 5-h assay a de cribed previously (29). 
R:'-IA analysis. Cytoplasmic R."lA was extracted by the 
method of Fa,·aloro et al. {12). The R A from equivalent 
cell numbers wa electrophoresed in denaturing 1 CJC agarose-
formaldehyde gel . s tained with ac ridine orange to vi ualize 
the rR, A. and then blotted o nto nylon membranes t Nyt ran: 
Schleicher & Schuell ). The RNA wa fixed to the membrane 
by ba king at 80°C for 60 min . H} bridization probes were 
generated by random priming of cDNAs for mouse IL-2 (46) 
and mouse skeletal a -actin CS. Sharp and .. Davidson. 
unpubl ished data) a described el e\\ here (30). Hybridiza-
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tions were carried out for 20 h at 42°C in : x SSPE-507c 
formamide-0.2<;( sodium dodecyl sulfate (SDS)-5X Den-
hard! solution-10'1 dextran sulfate. Filters were washed three 
times a t room temperature for 1 min each in 2 x SS((SSC is 
0.15 ~1 NaCI plus 0.015 M sodium citrate-0.2o/c SDS-0.057c 
sodium pyrophosphate. follO\\ed by two 30-min washes at 
68,C in O.:! x SSC-0.10 SDS-0.05"C sodium pyrophosphate. 
Filter~ we re expo~ed to film at -7o~c with a n intensifying 
screen. and autoradiogrdms in the linear respon:,e range were 
densitometricall y scanned. The amount of IL-2 mRNA was 
normalized with respect to the actin signal. 
cAMP determination. EL4.El cells were resuspended in 
medium at a concentration of 1.2 x 106/ml and were stimulated 
at 37¢C as indicated in Table 2. Cell extracts were assayed for 
cyclic AMP (cAMPl b) using a competition binding assay 
(RPA.509: Amersham) as de~cribed elsewhere (T. J. ovak 
and E . V. Rothenberg. Proc. atl. Acad. Sci. USA. in press). 
Extracts were acetylated before assay to increa~e sensitivit y. 
:\uclear extracts. Nuclear proteins were extracted accord-
ing to publi hed procedure (6. 8: G . Crabtree. personal 
communication) from cells that had been stimulated for 3 to 
4 h under the conditions de cribed for Fig. 4 a nd T able 3. 
Proteins extracted by either method gave similar results in 
gel mobility shi ft assays. and the data presented in Table 4 
were obtained by using both types of extraction protocols. 
Extracts were stored at -sooc until use . 
Gel mobility shift assay. Mobility shift assays were carried 
out essentially as described elsewhere (3). with minor mod-
ifications . Synthetic double-stranded oligonucleotides were 
end labeled by filling in with ei ther 35S- or 32P-Iabeled dTTP 
and dATP. For binding assays. 2.5 to 5.0 flg of nuclear 
protein was incubated for 15 min at 25°C with - 0.1 ng of 
probe in the presence of a nonspecific competitor, usually 
0.5 f.Lg of poly(dl · dC) for NF-KB. 0.25 to 0.5 flg of poly(dl 
· dCl for AP-1 0 and AP-l p. or 2.5 to 10 f.Lg of poly(dA · dT) 
for NFAT-1. 
Complexe were separated from free probe by electropho-
resis through 8o/c acrylamide gels which were cast and run in 
low-ionic-strength buffer. Gels were dried and exposed to 
film at -70°C with intensifying screens. For experiments 
with 35S-Iabeled probes. gels were fixed in Amplify (Amer-
sham) and complexes were detected by ftuorograph y. 
For competition binding studies. 2.5 to 5.0 flg of nuclear 
extract was preincubated for 15 min a t 25°C with the 
indicated molar excess of competitor D A (either a syn-
thetic oligonucleotide or a cloned genomic fragment ) before 
addition of labeled probe . 
The synthetic oligonucleotides contained the binding sites 
for FAT-1. F-KB. AP-l p and AP-1 0 as found upstream of 
the mouse IL-2 gene (30) and were of the following se-







5. -GATCCGGCTGACTCATCAGTAG-3 . 
5. -AATTCCAGAGAGTCATCAG·3' 






5 -AATTCGCCTTCTGT ATGAAACAAA TTTTCCTCTT · 3' 
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TABLE I. Effect~ of different '>limuli on IL-~ production by 
EL4.El cells 
IL·! mer ft.: mil• 
Sumulauon" 
E:\pt I Expt 2 
one < 4 < 4 
TPA 2:6 386 
IL-l < 4 < 4 
TPA - A~3187 307 448 
TPA + A23187 _._ IL-l 1.280 614 
TPA + A23187 + forskolin 106 :!04 
" Cells \\Cre incubated for 20 h in the pre;cnce or ab;ence ofTPA <35 nM1. 
A~3187 1140 oM). IL- l COt.; ml). and forskolin flO f.ll\1). Confirmat1oo of the 
inhibnor~ etTec" of for>kolin at the R:'\A lc,el is pre,ented by NovaJ.. and 
Rothenberg lin pre;s). 
• Titer m supernatant>. determined b} colorimetric a">sa~ on CTLL-" cell; 
a' pre\lou'l~ descnbed 1361. The pre.ence of IL-l in the assa:r 'upematant> 
ha> no effect on the indicator cells (361. and the addition of forskolin did not 
interfere with the quanlltative detection of IL-" in a control experiment !after 
adJU<;tment to 10 f.LM forskohn. a sample wnh 450 U of I L-~ per ml ga' e a titer 
of 530 U of IL-" per ml in this a'say: E. V. Rothenberg. unpubli;hed data). 
RESULTS 
IL-l is a costimulus for IL-2 expression by phorbol ester-
and ionophore-treated EL4.El ceJJs. The E L4.El thymoma is 
a convenient muri ne model for studies of IL-2 gene expres-
sion. but it differs from normal T Hl cells in several ways. 
First. it i responsive to TPA alone. A Ca2+ costimulus 
A. 5h 
TPA + A23187 + + + + 
IL-l (UNJTSIML) 0 0 2.5 20 0 0 
<X-ACTIN 
IL2 




0 @ e ® 
2 3 4 5 
elicit higher levels of IL-2 but is not required. Second. 
unlike normal mature T celb (35). it show synergy between 
IL-l and TPA - A23187. These features are illu trated in 
Table 1. \\ hich presents typical yields of IL-2 from EL4. El 
cells after 20 h of stimulation under different conditions. The 
addition of calcium ionophore generally increa ed the levels 
of IL-2 relati>ve to those elicited by TPA alone. to a maxi-
mum level that could not be surpassed by increasing the 
do ·es of TPA - A23187 (data not shown). The further 
addition of IL-L however. resulted in even higher levels of 
IL-2 secretion. Neverthele s. IL-l alone did not stimulate 
any detectable production of IL-2. Thus. the effect ofTL-1 in 
these cells was to potentiate the effects of the TPA and 
A23187 stimuli on IL-2 syn thesis. Such a potentiation could 
operate at pretranscriptional. posttranscriptional. or post-
translational levels. To dissect the basis for these differences 
in cumulative JL-2 synthesis over 20 h. we examined the 
time course of IL-2 R A accumulation. 
The accumulation of IL-2 tran cripts in EL4.El cells 
stimulated with TPA + A23187 alone was rapid and bimodal 
(Fig. lA. lanes 2, 6 . and 10). IL-2 mR A levels peaked 
around 5 h and declined slowly during the next 13 h. 
Costimulation of EL4.El cells with 2.5 or 20 U of IL-l per 
ml resulted in a rwo- or sixfold increa e. re pectively, in IL-2 
mRNA at 5 h (Fig. lA. lanes 1 to 4). This effect wa primarily 
observed at early times of stimulation. At 12 h the enhance-
ment due to IL-l was only 1.5-fold (Fig. lA, lanes 6 to 9). 
12h 18h 
+ + + + + 
2.5 20 0 0 2.5 20 
-2as 
-18s 
7 8 9 10 11 12 
6 7 8 9 10 11 12 13 14 
FIG. L IL-l costimulation of IL-::! induction: effect on the IL-::! promoter. (A) Gel blot of cytoplasmic RNA extracted from unstimulated 
or timulated EL4.El cells. Cells were stimulated as indicated for 5 to 18 h. and RNA from 106 cells was extracted. electrophoresed on a 
denaturing l 'k agarose-formaldehyde gel. transferred 10 a nylon membrane (Nytran). and hybridized to cO!\ A probe~ for IL-2 and skeletal 
a.-actin. (B) CAT assay of extracts from EL4.El cells transfected with p!L2( - :!800). Cells were stimulated as for panel A. Each lane 
represents the extract from transfected cells stimulated under condition identical 10 tho e of the ample used for the corresponding lane of 
the RNA gel blot. Extracts were assayed at 37"C for 5 h. Lanes 13 and 14 represent negative and positive assay controls. respectively. Positive 
control contains commercial CAT enzyme. [C). Unacetylated chloramphenicol: [CA). monoacetylated chloramphenicol. 
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FIG. 2. Normalized time courses of IL-2-CAT expression in the presence or absence ofrecombinant IL-1o:. (A) Time courses for EL4.El 
cells transfected with piL2(-321), plL2(-1890). and piL2(-2800l. Calculations for each plasmid were done separately. Each experiment 
consisted of six datum points: 5 h. 12 h (data not shown). and 18 h stimulated :!: 20 U of human recombinant !L-lo per ml. CAT activity per 
106 cells was normalized with respect to the highest val ue in that experiment (in all but one case this was the 18-h sample without IL-l). 
Results are the means :!: standard errors of the mean of two to five separate experiments except for the plL2( -1890) 5-h values. which were 
determined in one time course. (B) 'ormalized CAT assay curve for transfected Jurkat cells. Experimental conditions and calculations were 
exactly as for panel A. Open symbols, p!L2(-321): closed symbols, p!L2(-2800). Data are from one experiment. 
and by 18 hIL-l ceased to augment the level of steady-state 
IL-2 mRNA (Fig. lA. lanes 9 to 12). The early increase and 
later loss of IL-2 RNA makes it likely that IL-l costimulation 
increases the transcription rate but not RNA stability or 
translational efficiency. 
No IL-2 mRNA was detected when EL4.El cells were 
stimulated for 5 h with 20 U of IL-l per rni in the absence of 
TPA, alone or in combination with 37 ng of A23187 per ml 
(not shown). This inability to respond to IL-l plus ionophore 
is in contrast to results reported by others for several 
IL-l-independent cell lines (43, 47), possibly because of the 
lower concentration of ionophore used here (37 ng/ml = 70 
ll!\1. compared with 250 to 500 nM). The failure of IL-l to 
substitute for TPA suggests that it cannot duplicate the 
effects of TP A on protein kinase C. 
Costimulatory effects of IL-l are mediated through the IL-2 
gene promoter. To determine whether the IL-2 gene pro-
moter was responsible for mediating this positive effect , we 
used a series of piL2-CA T plasmids that contains various 
lengths of IL-2 5'-flanking DNA, including the transcrip-
tional start site. driving expression of CAT (30). In this way 
we could assay transcriptional initiation without concern for 
regulatory variations in mRNA stability (22) since, unlike 
authentic IL-2 mRNA. the CAT 3' untranslated region does 
not contain the AUUUA motifs that target lymphokine 
transcripts for rapid degradation (33. 38). Note that the CAT 
assay measures the translation product of the induced RNA. 
not the RNA directly. 
Transfection experiments using IL2-CAT plasmids sug-
gest that IL- l can increase the rate of transcription from the 
IL-2 gene promoter. even in cells optimally stimulated with 
TPA and ionophore. Several piL2-CAT plasmids were trans-
fected into EL4.El cells along with pRSV-CAT as a positive 
control. CAT activity was measured after 5. 12. and 18 h of 
stimulation with TPA and A23187 in the presence and 
absence of IL-l (Fig. lB and 2). A CAT assay of cells 
transfected with plL2(-2800) is shown in Fig. lB. Expres-
sion of the transfected IL-2-CA T gene required an appropri-
ate inductive signal because unstimulated cells contained no 
enzyme activity (Fig. lB , lanes 1. 5. and 9). Thus. even when 
introduced as a naked DNA template. the IL-2 gene pro-
moter was not promiscuously transcribed in these cells. 
EL4.El transfectants stimulated with TPA plus A23187 
contained easily detectable CAT activity at 5 h (Fig. lB.lane 
2), which would be expected if the peak in endogenous IL-2 
mRNA seen at this time resulted from transcriptional acti-
vation of the IL-2 gene promoter. CAT activity in these cells 
continued to rise over the next 13 h, reaching a maximum at 
18 h, the latest time examined. This increase in CAT activity 
occurred even as the steady-state level of endogenous IL-2 
mRNA dropped (Fig. lA). possibly indicating greater stabil-
ity of the IL-2-CAT mRNA. 
The addition of IL-l to the stimulation regimen had two 
dramatic effects. First , cells stimulated in the presence of 
IL-l contained up to 2.5 times as much CAT activity per cell 
at 5 has did those stimulated with TPA and A23187 alone 
(Fig. lB, lanes 1 to 4, and Fig. 2A). This effect was IL-l dose 
dependent because the enhancement was greater with 20 
than with 2.5 U/ml. 
Second. the increase was transient, like the effect on 
endogenous IL-2 mRNA. Not only did IL-l completely 
cease to enhance the steady-state level of IL-2 mRN A at 18 
h (Fig. l A, lanes 10 to 12). it also ceased to increase the 
amount of CAT activity per cell. In fact. CAT activity 
induced in the presence of IL-l was now at least 60 to 70% 
lower than in cells stimulated without IL-l (Fig. 2A). The 
mechanism of this late decrease is not fully understood but 
may be nonspecific. At 18 h. the positive control plasmid, 
pRSV-CAT. was also expressed at levels 31% lower in cells 
costimulated with IL-l than in cells stimulated without IL-l 
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TABLE 2. Failure of IL-l to increase c AMP in stimulated 
EL4.El cells 
cAMP concn 
Stimulation Time !fmoi·IO• cells!" 
conditJOnlii0 (man) 
EApt I Expt 2 
~o s timula tion 350 320 
TPA + A23187 15 300 320 
30 250 310 
60 271 380 
TPA - A23187 - 20 U of IL-1/ml 15 246 300 
30 308 340 
60 258 460 
TPA - A23187 ~ 10- ' M forskolin 15 ND 460 
30 ND 470 
60 ND 750 
TPA + A23187 - 10- 5 M forskolin 15 ND > 4 .000 
30 ND > 4 .000 
60 ND > 4.000 
" EL4.El cells were stimulated w11h TPA (10 ng./ml)- A23187 (37 nglm)) at 
a densitv of 1.2 x 106iml. 
" ~.Je~sured by using a commercial assay kit as described in Materials and 
Methods. All values are from assays with acetylated standards and samples. 
The high values for samples with 10- 5 M forskol in were corroborated by 
reassay with nonacetylated standards and samples. NO. :-Jot done. 
(see below and Table 3). By contrast , the early enhancement 
of CAT expression from the IL-2 gene promoter was pro-
moter specific. Expression of pRSV -CAT in stimulated 
EL4.El cells was not affected by the presence of IL-l when 
examined after 3 or 5 h of stimulation (unpublished data). 
This result suggests that at later times, IL-l caused a general 
decrease in CAT expression, possibly via reduced transla-
tional efficiency, which was distinct from its promoter-
specific transcriptional enhancing effects seen at 5 h. 
Possible mediators contributing to t he effects of IL-l on 
EL4.El ceUs. (i) lL-lR. The effects of IL-l on the IL-2 gene 
promoter require the expression of IL-lR, as demonstrated 
by the results from identical transfection experiments using 
IL-lR- Jurkat cell s instead of EL4.El cells. A time course 
of TL-2-CA T expression in Jurkat cells is shown in Fig. 2B. 
These cells showed much slower kinetics of expression of 
piL2-CAT plasmids than did EL4.El cells. o activity was 
detected at 5 h even in the presence of 20 U of IL-l per ml. 
Cells had begun to express by 12 h, and CAT activity was 
still rising by 18 h. However. no significant effect. early or 
late, could be attributed to IL-l. These results provide 
evidence that surface expression of a canonical IL-lR is a 
prerequisite for the IL-l effects that we have described. It is 
thus unlikely that the effects seen in EL4.El cells are due to 
the type of phosphatidylcholine hydrolysis reported to occur 
in J urkat cells (34). 
(ii) cAMP. It has been shown that IL-l can utilize cAMP as 
an intracellular second messenger in a number of non-T-cell 
lines (42) . Our results argue against a simple cAMP elevation 
mechanism as the pathway for IL-l costimulation in EL4.El 
cells. First. IL-l costimulation had minimal effects on cAMP 
levels in these cells (Table 2). Second . the effects of20 U of 
IL-l per ml and 10 i.J.M forskolin were clearly different (Table 
3). Expression of pRSV -CAT was enhanced at 18 h with 
forskolin but inhibited with the concentration of IL-l used 
here. Whereas expression of p!L2(-321) was depressed at 
18 h by both IL-l and forskolin. the 5-h results clearly 
demonstrated the dissimilarity of these two stimuli . Forsko-
TABLE 3. Distinct effects of IL-l a nd forskolin on expression of 
pRSV-CAT a nd piL2(-321) in EL4.El cells 
Stimulation CAT activity !'f of controll" 
Con,truct time + IL-l + 10 ~M (h) 
!20 Ulmll forskolin• 
pRSV-CAT 18 68 ::!: 0.5 427 ::!: 99 
piL2!-321 ) 5 169 :::: 22 28 ::!: 4 
18 43 ::!: 6 51 ::!: 17 
" Cells were stimulated for the indicated lengths of time with TPA flO ngiml l 
+ A23187 (37 ng~ml) in the presence or absence of IL-l or forskolin CAT 
ac tivlly per 106 cell equivalents was determined. and the value for the 
drug-treated samples was normalized with re>pect to that of the drug-free 
control. Results are presented as means = standard errors of the mean or as 
means = ranges (in the cases with two experiments) of two to four experi-
ments each. 
b Results are presented in more detail elsewhere (Novak and Rothenberg. in 
press). 
lin was even more suppressive at 5 h than at 18 h, whereas 
IL-l was stimulatory at this time point (Table 3: see also Fig. 
lB, lanes 1 to 4. and Fig. 2A). We have also shown that 
elevation of cAMP by a variety of other agents can depress 
IL-2 gene expression in a dose-dependent fashion (Novak 
and Rothenberg, in press), supporting the conclusion that 
elevation of cAMP levels per se has a net negative effect on 
IL-2 gene promoter function. While these results do not rule 
out cAMP-responsive signaling molecules as participants in 
the IL-l enhancement pathway. they do show that the 
stimulatory effect of IL-l is unlikely to be a result of any 
sustained increase in cAMP concentration. 
IL-2 gene promoter sequences upstream of -321 ar e not 
required for IL-l costimulation. Our previous work on the 
upstream region of the mouse IL-2 gene indicated the 
presence of several positive and negative regulatory ele-
ments between -321 and -2800, any of which might be 
involved in IL-l-mediated effects. However. the data pre-
sented in Fig. 2A make it unlikely that far-upstream se-
quences are required . 
When normalized for maximal levels of CAT activity, the 
kinetics of IL-l costimulation for piL2(-321), plL2( -1890) , 
and piL2( -2800) were virtually superimposable (Fig. 2A). 
Thus. the degrees of both the 5-h enhancement and the 18-h 
suppression were unaffected by IL-2 5' -flanking sequences 
extending upstream of -321. It should be noted , however, 
that the absolute amount of CAT activity per cell at each 
time point was higher with piL2( -1890) and plL2(- 2800) 
than with piL2(-321), in accord with our previously re-
ported results (30). 
Further truncation of the IL-2 gene promoter region led to 
severe loss of inducibility , such that any IL-l-dependent 
enhancement was difficult to detect. We evaluated the re-
sponses of two plasmids with deletions in the region from 
-321 to -261. One, piL2(-232), failed to give significant 
expression with or without IL-l at any time point. Expres-
sion of the other, piL2( -1890; ~NFAT-1) . which bears a 
deletion from -261 to -321 (30), was also undetectable at 5 
h of stimulation, when IL-l would be expected to exert a 
positive effect (P. M. White. T. J. Novak. and E. V. 
Rothenberg, unpublished results: 30). Thus, retention of 
sequences between - 261 and -321 appeared to be essential 
for expression a nd IL-l costimulation. 
Effect of IL-l costimulation on sequence-specific DNA-
binding factors. The sequences from -50 to -300 in the 
human IL-2 gene include binding sites for several DNA-
binding proteins of different specificities which have been 
implicated in regulation (4. 10). One factor. binding se-
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FIG. 3. Specificities of complexes with binding activity for IL-~ regulatory sequences. (A) Homologous and heterologous competition for 
the complex binding the NFAT-1 oligonucleotide. Competition gel shift assays were carried out as described in Materials and :"vtethods with 
a labeled NFAT-1 oligonucleotide. Unlabeled competitor oligonucleotides were added as indicated. to 50- to 200-fold molar excesses. The 
arrow indicates the specific NFAT-1 complex. (P) and (D) represent the AP-1p and AP-1 0 oligonucleotides. respectively. Lane 1. No specific 
competitor. Each lane contained 2.5 f.lg of nuclear extract from cells stimulated with TPA + A23187 + IL-l with 2.3 f.lg of poly(dA . dT) as 
nonspecific competitor. (B) As panel A. using labeled NF-KB oligonucleotide with the indicated competitors at the molar excesses shown. 
Lane 1. No specific competitor. ( -148/- 217) is a restriction fragment from the natural IL-2 gene promoter that contains the NF-KB site. Its 
greater potency as a competitor in pan reflects a general effect of length (F. J . Calzone and E. H. Davidson. personal communication). Each 
lane contained 5 f.Lg of extract from TPA - A23187-stimulated cells and 0.5 1'-g of poly(dl . dC). (C) Cross-competition of complexes binding 
the AP-1p and AP-1 0 oligonucleotides. Lanes: 1 to 7, AP-1p probe with the indicated competitors (lane 7. no specific competitor): 8 to 14, 
AP-1 0 probe with the indicated competitors (lane 8. no specific competitor). (A) denotes a commercial consensus AP-1 22-mer (Stratagene), 
used at 50-fold molar excess; (NJ denotes the NF-KB oligonucleotide used at 200-fold molar excess. Arrows indicate the mobilities of the main 
AP-1p complex (left) and the AP-1 0 complex (right ). Each lane contained 5 1'-g of extract as in panel A. with 0.125 1'-g of poly(dl · dC). Both 
extracts used in this figure were made by the method of Dignam et al. (6). 
quences from -66 to -90. is the constitutive Oct-1 protein. 
which also appears to bind sequences between -240 and 
-250 (10). Factors whose binding activity is known to be 
dependent on cellular activation bind at -264 to - 284 
( FAT-1) and -196 to -205 (NF-KB or a close relative) (5 . 
17. 39). In addition , there are two potential sites for the 
binding of the canonical TPA-response factor AP-1 (2). 
although neither contains a perfect consensus sequence. 
One. from -186 to -195 (AP-1 0 ), has been proposed as a 
critical site for IL-l effects in another cell line (26). The 
other. from -145 to -153 (AP-lp). has been shown to bind 
a purified AP-1 factor (37). 
To dissect the mechanism of IL-l costimulation ofEL4. El 
cells. we focused on the four sites for potentially inducible 
factors: NFAT-1. F-KB. AP-10 • and AP-1p. Synthetic 
double-stranded oligonucleotides containing these sites as 
fou nd in the murine IL-2 gene were used in gel retardation 
assays to detect ON A-binding proteins in nuclear extracts 
from EL4. El cell after different types of stimulation. Typ-
ical results. representative of four to seven independent 
analyses . are presented in Fig. 3 and 4. A summary is 
provided in Table 4. 
Four distinct binding specificities. Confirmation of the 
distinct specificities of these factor i presented in Fig. 3. 
The binding of NF AT -1 was highly sensitive to competition 
with its homologous target sequence and impervious to 
competition with the other oligonucleotides used (Fig. 3A). 
Figure 3B similarly confirms the specificity of the NF-KB 
complexes and their ability to be competed for by a longer 
IL-2 DNA fragment ( -148 to - 217) that contains this site 
We routinely observed a doublet of complexes binding th< 
NF-KB site. both of which appear specific by competitior 
analysis. Only the upper band was strongly induction depen 
dent. however. and in the text that follows we will us 
··NF-KB" to refer only to this slower-migrating species. 
The factors that bind to the two AP-1 sites are nc 
identical, although their target sites are of related sequence 
This conclusion was confirmed by the cross-competitic 
analysis shown in Fig. 3C. First. the two complexes h< 
different mobilities (compare lanes 7 and 8). Second. it 
clear that they had different binding preferences. Both we 
legitimately capable of binding a commercial consens 
AP-1 oligonucleotide (Fig. 3C. lanes 5 and 13). and neith 
wa detectably competed for by the F-KB site oligonuc 
otide (lanes 6 and 14). However. while the AP-lp oligor 
cleotide competed for the complex binding its homologc 
sequence Oanes 1 and :!}. it did not compete for the AP· 
complex (lanes 9 and 10). Correspondingly. the AP 
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FIG. 4. Differential activation of IL-2 DNA-binding factors under different conditions of stimulation. In each panel. the indicated probes 
were used for gel shift analysis, each lane containing 5 ~g of extract from EL4.El cells that were stimulated for 3.5 h under the indicated 
conditions: U . unstimulated : T. TPA alone: I, IL-l alone : T IA . TPA plus A23187: TIA + l. TPA plus A23187 plus IL-l ; T/A + F. TPA plus 
A23187 plus 10 ~M forskol in. In panel A only. NFAT-1 complexes from EL4.El cells (lanes 3 to 9) are compared with complexes formed 
by nuclear extracts from Jurkat cells . either unstimulated (U) or stimula ted with TPA plus A23187 ($ ). (A) NFAT-1 factor. The arrow 
indicates the FAT-1 complex . which is inducible in Jurkat cells (lanes 1 and 2) but constitutive in EL4.El cells (lanes 4 to 9). Lane 3 contains 
a duplicate of the extract used in lane 6 with a lower a mount of nonspecific competitor, to demonstrate that the lower band seen in the Jurkat 
sample (lane 1) is nonspecific. (B) NF-KB factors. The arrow indicates the upper complex. which is more strictly dependent on induction than 
the lower complex and which is the subject of discussion in the text. Each lane contained 0 .5 fl.g of poly(dl-dC). (C) AP-10 factor. The 
increased band intensity seen in lane 4 was highly irreproducible (see Table 4), in contrast to the differences seen in panel B. In pa nels C and 
D. 0.25 ..,.g of po ly(dl · dC) was used as nonspecific competitor. Arrows indicate the specific complexes . (D) AP·lp factor. analysis as for panel 
c. 
oligonucleotide showed homologous compettlton (lanes 11 
and 12) but did not compete for the AP-1p complex (lanes 3 
and 4). The quantitative reciprocity of these effects , as 
measured at 100- and 200-fold molar excess. rules out the 
trivial explanation that the two factors had identical speci-
ficities but were present at different concentrations in the 
nuclear extract. These results show that the two AP-1 
factors are distinct both in size and in specificity. As 
discussed below, they are also distinct in regulation. 
Constitutive factors. Two of the factors detected by these 
assays appeared to be expressed constitutively in the 
EL4.E1 th ymoma cells. One. unexpectedly, was NFAT-1. A 
complex of the expected mobility (indicated by an arrow in 
Fig. 4A) was highly inducible in Jurkat cells (Fig. 4A, lanes 
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condit ions of culture. 
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1 and 2). However. the corresponding complex was present 
at indistingui hable levels in nuclear extracts from our 
subline of EL4.El cells, whether or not they were stimulated 
and regardless of the <;timulation condition~ used (Fig. 4A. 
Janes 4 to 9). This complex appeared unlikely to represent a 
spurious DNA-binding act ivity. since it was specific by the 
competition assays in Fig. 3 but quantitatively unaffected by 
increasing the concentration of nonspecific competitor (Fig. 
4A. Janes 3 and 6). Thus. although the F AT-1 site appeared 
essential for expression. on the basis of our deletion studies. 
the presence of its binding factor was not sufficient to 
support IL-2 expression. 
The other factor present at unchanged levels was the 
complex of well-defined mobility binding the AP-1 0 site (Fig. 
4C). This factor exhibited slight fluctuations in concentration 
in different samples. but no reproducible increase was ob-
served upon stimulation under any conditions (Table 4). In 
fact. in some experiments there wa a n indication that its 
concentration diminished in stimulated cells. The possibility 
that it might exert a negative regulatory effect is under 
further study. 
Inducible factors. Only two of the candidate inducible 
factors showed increased DNA binding in response to induc-
tion. These were F-KB (Fig. 48) and the factor binding the 
AP-lp site (Fig. 4D). In agreement with the abi lity of EL4.El 
cells to make IL-2 in response to TPA alone (Table 1). both 
were activated in cells stimulated with TPA alone (Fig. 48 
and D. lanes 2). The further addition of A23187 up regulated 
both binding activities in most experiments. in accord with 
its effect on IL-2 production (Table 1). although the extents 
of up regulation did not match precisely (Fig. 48 and D: 
compare Janes 2 and 4). The binding activities of both 
factors, however, were reproducibly enhanced further by 
addition of IL-l , which consistently yielded the highest 
levels observed of both complexes (Fig. 48 and D. Janes 5). 
This result was not due to additive activation of these factors 
by IL-l and by TPA + A23187. for in most experiments IL- l 
alone induced little or no binding activity of either type 
(compare Janes 3 in Fig. 48 and D). Thus. while IL-l was 
only marginally and irreproducibly capable of activating 
either binding factor alone. it was a potent enhancer of the 
stimulating capacity of A23187 and TPA. 
Summary. The results of multiple analyses of these four 
factors are collated in Table 4. Overall, these data agree 
plausibly with the IL-2 titers reported in Table 1. if it is 
assumed that all four factors are required for optimal pro-
moter activity. The surprising, constitutive expression of 
NFAT-1 in this subline of cells. and possibly that of the 
AP-1 0 binding factor as well, may simply provide the 
biochemical explanation for the unique ability of EL4.El 
cells to express IL-2 in response to TPA alone. everthe-
less. this set of factors may not be sufficient to account for all 
regulatory modulation of IL-2 gene expression in EL4.El 
cells. As shown previously ( ovak and Rothenberg. in 
press: Tables 1 and 3). 10- 5 M forsko li n inhibits IL-2 
induction by two- to threefold under these conditions. It is 
therefore surprising that forskolin, when added to TPA and 
A23187. induced effects on these D A-binding proteins that 
were very similar to those of IL-l (Fig. 4A. lane 9: Fig. 48 to 
D. Janes 6). While in several experiments the addition of 
forskol in appeared to decrease NF-KB expression selec-
tively (data not shown). this effect was often modest (e.g .. 
Fig. 48). It is thus possible that the ratio of AP-lp to NF-KB 
affects expression. However. it seems more likely that the 
activity of the four putative positive regu lators can be 
influenced by other regulatory proteins not examined here . 
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Preliminary results uggest that the net inhibitory effects of 
elevated cAMP depend on the pre~ence of additional di -
crete equences in the IL-2 regulatory region (P. M. White 
and E. V. Rothenberg. unpublished results). 
DISCUSSION 
IL-l has a long history as a costimulator of T-cell re-
sponses (9. 13. 25. 44). In recent years. it has become clear 
that this cytokine carries out different essential functions, 
depending on the cell type being stimulated. Most effects of 
IL-l on mature T cells. however. can be substituted for by 
the addition of phorbol esters . presumably via stimulation of 
protein kinase C. Biochemical evidence does not upport the 
conclusion that IL-l acts directly via protein kinase C (1). 
but in most cases activation of this kinase can obscure the 
effects of IL-l itself on T cells. In this study we took 
advantage of the unusual properties of EL4.El cells. which 
respond to IL-l as a costimulus even with optimal levels of 
TPA. to investigate the molecular mediators by which IL-l 
can cooperate with the phosphoinositide pathway. Our re-
sults show that IL-l costimulates IL-2 gene expression by 
enhancing the activity of the lL-2 gene promoter. correlated 
with augmented levels of an NF-KB-like factor and one of 
two distinct AP-1-like factors that bind to IL-2 regulatory 
sequences. 
Recent work by Shirakawa and colleagues has hown that 
IL-l can utilize cAMP as an intracellular second messenger 
for the induction of K immunoglobulin light-chain synthesis 
in the mouse pre-B-cell line 70ZJ3 (42). In these cells. 
IL-l-mediated induction coincides with the activation of a 
protein that can bind to the NF-KB consensus site in the 
5' -flanking region of the K-chain genes (40). NF-KB is not the 
only transcription factor implicated in IL-l effects. however. 
IL-l can also induce transcription of the c-jun proto-onco-
gene. which encodes a component of AP-1. in the mouse 
IL-l-dependent T-cell line LBRM-331A5 (26). In that cell 
line. expression of a linked reporter gene from the human 
IL-2 promoter required an intact AP-1 site at -185 relati ve 
to the transcriptional start site. However. the deletions 
tested which removed this site also removed the NF-KB site 
centered at -200. Therefore. the resulting Joss of promoter 
function (26) cannot be attributed unequivocally to loss of 
this distal AP-1 site. In fact. deletion analysis of the human 
IL-2 gene promoter has not demonstrated an important role 
for this AP-1 site in vivo (8). Footprint analysis of the mouse 
IL-2 promoter has led to the same conclusion (37). 
In several respects. our results are in agreement with these 
previous reports . Thus. our data support the interpretation 
that one mediator of the IL-l effect may be NF-KB or a 
related factor (31, 40). The addition of IL-l as a costimulus 
invariably augmented NF-KB binding activity over that 
induced by the cocktail of TPA and A23187. and in some 
experiments (e.g .. Fig. 4) we could even detect enhanced 
NF-KB binding after stimulation with IL-l alone. As ex-
pected if IL-l activated F-KB. it also enhanced the induc-
tion of IL-2 receptor a -chain transcripts in the EL4. El cells 
(T. J . ovak and E. V. Rothenberg. unpublished results). 
Even the failure of IL-l to affect IL-2 gene promoter activity 
in Jurkat cells is also con istent with its working through 
F-KB. since in these cells IL-l does not induce appearance 
of this D A-binding protein (31). The resulting implication 
that F-KB may be rate limiting for IL-2 induction is in 
accord with published evidence that mutation of the F-KB 
site depresses IL-2 gene promoter function. relative to wild 
type. in optimally timulated cells (17). 
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In contrast to other cell types (41. 4::! ). however. EL4.El 
cells appear to be able to re~pond to IL-l a a co.,umulus 
without u ing cAMP a~ the principal mediator. As we report 
here and m more detail el ewhere ( ovak and Rothenberg. 
in press). I L-2 gene promoter activit} i significantly inhib-
ited b~ treatment that cau e a su tained elevation of intra-
cellular cAMP. This inhibition is especially sharp at the early 
time~ when IL-l i most potent in it stimulatory activity. 
Thus. the cooperati•e effect of I L-1 with phosphoino:.itide 
pathway stimulation and those of cAMP appear quite dis-
tinct. 
It ~eems paradoxical. then. that both IL-l and cAMP may 
enhance activation of F-KB. Indeed. both abo hyperacti-
vate the binding factor of the proximal AP-1 ite. However. 
'' hile the induced D A-binding activities that '"e have 
~tudied probably participate in the mechanism regulating 
IL-2 gene promoter activity. they may not be the only 
components. or the onl) decisive component . of a combi-
natorial mechani m. The resolution of this paradox is most 
like!) to come. therefore. from more extensive monitoring of 
the ensemble of regulatory proteins that control lL-::! gene 
expression. rather than a focus on any single one. Our 
results with only four uch factors provide compelling evi-
dence for the combinatorial nature of IL-2 gene regulation. 
The FAT-1 factor. the regulation of ''hich may be suffi-
cient to accou nt for the response to TcR ligands in Jurkat 
cells (4. 10) is not rate limiting in EL4.El cells. The 
FAT-1-binding activity is present at maximal levels even in 
cells which cannot ecrete IL-2 and cannot expre s IL-2 
promoter con tructs. Yet the cooperation of this factor 
appear to be required for efficient IL-2 induction. as hoY. n 
by the minimal activity. with or without IL-l. of con tructs 
from which its binding site has been deleted. In this context. 
the shared abilitie of forskolin and IL-l to stimulate the 
AP-lp factor and F-KB imply less that these agents mediate 
the same ignal than that the set of factors we monitor may 
be incomplete. 
How can the co timulatory effects of IL-l on AP-lp a nd 
F-KB activation be explained? There are two general 
possibilities. First, IL-1/IL-lR triggering may directly induce 
activation of these two factors, and possibly others uniquely 
responsive to IL-l. mobilizing pools that are not accessible 
to the calcium ionophore/phorbol ester stimulation pathway. 
The effects of IL-l would then be additive with tho e of the 
pho phoino itide pathway agonists. at the level of the DNA-
protein contacts in chromatin . Another possibility i that the 
ability of A23187ffPA to activate these D A-binding pro-
teins is itself modulated by an intracellular gating function 
that is subject to IL-l regulation. In this case. IL-l need not 
induce any D A-binding protein activities by itself in order 
to be a potent regulator of the efficiency with which the 
major activating pathway mobilize gene expression. While 
too few factors have yet been examined to confirm or rule 
out the fir t mechanism. several of our finding lend plausi-
bility to the econd. Fir t. IL-l alone is strikingly poor at 
effecting any increa e or decrease in the binding activit y of 
any of the factor tudied here. In EL4.El cell . it i far 
more potent as a co timulus than as a timulus ( ee. e.g .. 
Table 4). Second. the factor!> that IL-l coactivates thus far 
appear to be only tho e that are activated in any ca e by 
A23187 and TPA. Third. our survey of IL-l effect on the 
ex pres ion of IL-2 promoter constructs with widely differing 
numbers of positive and negative modulatory ite'> (30) 
Indicates that all expre sible constructs are affected m par-
alle l. Thus. IL-l may act in these cells by enhancing the 
potency of A23187 and TPA as inducing agents. it ignal 
converging with the pho~phoino itide pathway before the 
activation of the specific D A-binding proteins. 
The mechani m of IL-l co timulation may help to illumi-
nate key stage<; in the de' elopment of T-cell functional 
competence. We have pre\ iou ly reported that immature 
thymocytes can activate the IL-2 gene. but only subject to an 
absolute requirement for IL-l costimulation. The locu of 
the I L-1 effect may thu identif) a tage-specific block to the 
exercise of functio n in immature cells which i later over-
come by the complex physiology of positiv.e. election in the 
thymus. Work i~ now under way to explore this possibili ty. 
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At least three stages in the intrathymic development of pre-T cells are demarcated by differences in the 
competence to express the interleukin-2 (IL-2) gene as an acute response to stimulation. IL-2 inducibility 
appears to be acquired relatively early, prior toT-cell receptor (TcR) gene rearrangement. It is then abrogated 
during the stage when cells are subject to positive and negative selection, i.e., the fate determination processes 
that select cells for maturation or death. IL-2 inducibility finally reappears in mature classes ofthymocytes that 
have undergone positive selection. To provide a basis for a molecular explanation of these developmental 
transitions, we have examined the representation in different thymocyte subsets of a set of DNA-binding 
proteins implicated in IL-2 gene regulation. As the 0:'1/A-binding activities of many factors are elicited only by 
inductive stimuli, the cells were cultured in the presence or absence of the calcium ionophore A231S7 and 
phorbol ester. Our results separate these factors into four regulatory classes: (i) constitutive factors, such as 
Oct-1 and probably Spl, that are expressed in thymocytes at all stages; (ii) inducible factors, such as NF-KB 
and complexes binding. to the region of a CD28 response element, that can be activated in all thymocytes, 
including those cells (CD4+ CDS+ TcR10- ) that can undergo selection; (iii) inducible factors, such as NF-AT 
and AP-1, that can be activated in mature (CD4+ cos- TcRhigh) and immature (CD4- cos- TcR-) 
thymocytes alike but not in the transitional stages when the cells (CD4+ cos+ TcR10 - ) are subject to selection; 
and (iv) a factor containing CREB, which can be activated in thymocytes of all developmental stages by culture 
but does not require specific induction. These results verify that inducible transcription factors are targets of 
intra thymic developmental change. They also identify NF-AT and AP-I as factors that are particularly sensitive 
to the mechanism altering thymocyte responses during the stages when thymocytes may undergo positive and 
negative selection. 
T-cell precursors undergo a cascade of developmental 
changes in the thymic microenvironment which ultimately 
endow them with the recognition specificities. s ignaling 
mediators. and capacity for functional responses of mature T 
lymphocytes (reviewed in references 10, 36, and 49). Rec-
ognition specificity is the result of the rearrangement of 
T-cell receptor (TcR) genes and the cell surface expression 
of their products. The TcR complex becomes effective in 
triggering appropriate signaling pathways through the ex-
pression of the coreceptor molecules, CD4 and/or CDS, at 
the cell surface, together with a network of cytoplasmic 
protein kinases (1, 8). The acquisition of functiona l response 
capability, however, is more complex. Mature T-cell func-
tion is exercised only in response to antigen stimulation, 
through the abrupt and transient transcriptional activation of 
specific response genes such as the gene encoding interleu-
kin-2 (IL-2). The competence to express IL-2 upon stimula-
tion is largely, if not exclusively, a property of T lympho-
cytes. Accordingly, one of the changes induced in precursor 
cells by passage through the thymus is acquisition of IL-2 
inducibility (39, 40). 
Analysis of the competence to express IL-2 at various 
stages of intrathymic development has revealed a series of 
transitions distinct from those recognized on the basis of cell 
surface phenotype and TcR expression (reviewed in refer-
ence 36). In particular, immature thymocytes before TcR 
expression exhibit a form of IL-2 inducibility that seems to 
be extinguished in most of their descendants, while a differ-
ent form of IL-2 inducibility is found in the minority of cells 
• Corresponding author. 
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that go on to full maturation (9, 17, 24, 38, 39). Neither the 
early inducibility nor the extinction of inducibility is well 
understood in relation to the generation of mature IL-2 
producers. However, these find ings suggest provocative 
links between responsiveness to activation signals and thy-
mocyte fa te determination, as we have discussed elsewhere 
(36, 39). The lymphostromal interactions respo nsible for the 
changes in IL-2 inducibility may or may not be the same as 
those that trigger quite different effects on TcR expression. 
However, an advantage of using IL-2 inducibility to monitor 
developmental processes is that this property is relatively 
well understood at a molecular level. Thus, it is possible to 
define the impact of each transition, and gain a clue as to its 
mechanism, by analysis of the IL-2 gene-regulatory proteins 
that it affects. 
Therefore, we have taken advantage of an extensive 
literature characterizi ng the minimal enhancer sequence of 
the IL-2 gene and many of the DNA-binding proteins that 
interact with it (reviewed in reference 47). Both inducible 
and constitutively expressed trans-acting factors are in-
volved in initiating IL-2 gene transcription, including NF-KB 
or Tcf-1 (18, 32, 42), AP-1 (20, 27), Oct-1 and other 
octamer-binding proteins (21), and two uncloned factors 
termed NF-AT (41) or Pu-box factor III (5. 33) and CD28RC 
or the CD28 response element (CD28RE)-binding factor (11, 
48). We have used electrophoretic mobility shifts to score for 
the DNA-binding activities of these and other IL-2 DNA-
binding factors in thymocyte nuclear extracts after in vitro 
stimulation. For those factors which do not require activa-
tion to reside in nuclei and bind D A, these assays allow us 
to score the presence of factor proteins. For those which 
require specific signaling events to display DNA-binding 
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activity. these assays further allow us to score cell!> for the 
existence of the signaling pathway that controls the factor 
modification. Our results demonstrate that inducible IL-2-
regulatory factors are expressed noncoordinately in T-cell 
development. We further show that a full panoply of IL-2-
regulatory proteins is present in immature thymocytes. 
Finally, our results show that the transitional CD4 • cos-
TcR10"' cortical thymocytes that are the main targets of 
selection are highly activatable even though functionally 
incompetent, responding to stimulation with intense induc-
tion of a specific but incomplete set of IL-2 D A-binding 
activities. 
MATERIALS AND METHODS 
Reagents. Tetradecanoyl phorbol acetate (TPA) and the 
calcium ionophore A231S7 (both from Sigma) were dissolved 
in dimethyl sulfoxide to the stock concentrations of 10 ~giml 
and 0. 7 mM. respectively. Recombinant human IL-1o: was 
purchased from Genzyme. Antisera against Fos and Jun 
family proteins were kindly provided by Rodrigo Bravo. 
These reagents react specifically with all known members of 
the Fos and Jun families, respectively (23). Antiserum 244, 
against the W39 peptide of CREB, was a generous gift from 
M. R. Montminy (13). It is highly specific for recognition of 
CREB (26). In addition to the published documentation of 
the specificity of these antisera, we carried out controls for 
specificity under the conditions of our assays. Supershifted 
bands were not produced when 1 ~I of a control antibody, 
RL172.4 (anti-CD4 ascites fluid), was added to the reactions. 
Furthermore, anti-CREB, anti-Fos, and anti-Jun did not 
affect the mobility of complexes binding the NF-Kl3 oligonu-
cleotide. We therefore consider the supershifted complexes 
to be specific. 
Cells. Freshly isolated thymocytes from 4- to 6-week-old 
C57BU6 mice were fractionated by complement-dependent 
cytolysis or panning. To isolate immature TcR- CD4- cos-
cells, we used complement-dependent lysis with anti-C04 
(RL172.4), anti-COS (3.155), and anti-COS (CG-15) (39), or 
we used cells taken directly from the thymus of immunode-
ficient C.B-17 scid/scid (SCIO) mutant mice, which are 
naturally arrested at this stage (>9S% TcR- CD4- CDS-) 
(2). Cortical C04 + cos+ TcR1ow thymocytes were either 
enriched by adherence to peanut agglutinin-coated plates or 
isolated by complement-dependent lysis with anti-H-2Kb 
(2S-13-33), taking advantage of their anomalously low class I 
major histocompatibility complex expression (4). By either 
method, the fraction contained over 9271: C04 + cos+ cells. 
Mature thymocytes were either enriched by nonadherence 
to peanut agglutinin-coated plates (at 4°C} or isolated by 
complement-dependent lysis (at 37°C} with anti-COS anti-
body. By the latter method, over 70% C04 + cos- and less 
than 30% CD4- cos- cells were obtained: the fraction 
contained no cortical-type C04+ cos- thymocytes . Flow 
cytometric analysis was used routinely to confirm the phe-
notypes of the fractions. Freshly isolated SCID thymocytes 
were put into culture directly, without prefractionation. All 
cells were grown in RPM! 1640 supplemented with sq. fetal 
bovine serum (HyClone, Logan, Utah), 2 mM L-glutamine, 
50 ~M 2-mercaptoethanol , and antibiotics, with or without 
TPA (17 nM. 10 ng/ml) plus A231S7 (70 to 120 nM). In some 
experiments, the stimulated cells were also supplemented 
with IL-l (20 or 50 U tml). 
IL-2 bioassay. Supernatants were collected from 20-h 
cultures with or without stimulation under the indicated 
conditions. The IL-2 bioassay was performed as described 
previously (39). 
Nuclear eA1racts_ Nuclear extracts were made from cells 
cultured for 2 to 4 h according to the procedure of Stein et al. 
(45) . Briefly. 1 x 10' to 5 x 107 thymocytes were washed 
twice with ice-cold phosphate-buffered saline and resus-
pended in 100 ~I of lysis buffer (10 mM N-2-hydroxyeth-
ylpiperazine-N' -2-ethanesulfonic acid [HE PES; pH 7.9], 10 
mM Tris. 60 mM KCI, 1 mM EDT A, 0.5t:C Nonidet P-40. 1 
mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride), 
and then the nuclei were pelleted at 1,200 x g for 5 min at 
4oC. The nuclei were washed with lysis buffer without 
onidet P-40. then re uspended in nuclear resuspension 
buffer (250 mM Tris [pH 7.8], 60 mM KCI, 1 mM dithiothre-
itol, 1 mM phenylmethylsulfonyl fluoride), and disrupted 
with three cycles of freezing and thawing. After clarification 
by C:!ntrifugation at 7,000 x g for 15 min, the supernatant 
was collected. and the nuclear extract was stored at -sooc 
until use. Protein concentrations in the extracts were deter-
mined by the Bradford assay (Bio-Rad protein assay: Bio-
Rad Laboratories, Richmond. Calif.). 
Oligonucleotides. Most double-stranded oligonucleotides 
were synthesized at the Microchemical Facility in our Divi-
sion of Biology. Unless specified, the sequences are found in 
the 5'-flanking region of the mouse IL-2 gene (2S) at dis-
tances from the cap site as shown below: 
Spl consensus 5' GATCGATCGGGGCGGGGCGATC 3' 
Stratagene) 3 ' CTAGCTAGCCCCGCCCCGCTAG 5' 
FICTF (4) 5' ATTTTGGCTTGAAGCCAATATG3' 
(Stratagene) 3 TAAAACCGAACTI'CGGTTATAC 5' 
AP-2 consensus 5" GATCGAACTGACCGCCCCGCGGCCCGT 3" 
(Stratagene) 3" CTAGCTI'GACTGGCGGGGCGCCGGGCA 5" 
AP-I (CREB} 5' AATTCCAGAGAGTCATCAG 3' 
(-16lto -143) 3 ' GGTCTCTCAGTAGTC 5' 
NF-KB 5' AAGAGGGATTI'CACCT 3" 
( -2llto 192) 3' TI'CTCCCTAAAGTGGATTI'A 5' 
NFAT-1 5' AAGAGGAAAATTI'GTTI'CATACAGAAGGCG 3' 
(-289to 260) 3 ' TI'CTCCTTI'TAAACAAAGTATGTCTI'CCGCTI'AA 5' 
Spl 5' gatcTCTCCACCCCAAAGAGGAAAATI' 3' 
( -300 to -278) 3' AGAGGTGGGGTTI'CTCCTTTI'AActag 5' 
CD28RE 5' gatcGGGGGTTI'AAAGAAATI'CC 3" 
(-174 to 156) 3' CCCCCAAATTI'CTTI'AAGGctag 5' 
NF-IL1A 5' gatcTCTITGAAAATATGTGTAATATGTAAAACAT 3 
( -100 to -69 J 3 ' AGAAACTTITATACACA'ITATACATTI'TGTAct.a€ 5. 
Lowercase letters indicate bases not found in the natural 
sequence. Oligonucleotides were annealed with their com-
plements and labeled by polymerization with o:-32P-labeled 
deoxynucleoside triphosphates to fill in the 5' overhanging 
ends. 
Gel mobility shift assay. The gel shift assays were per-
formed as described previously (6), with minor modifica-
tions. uclear e:-.tracts (2.5 to 10 ~g of protein) were 
preincubated with 0.5 to 2 ~g of poly(dl · dC) at 25°C for 15 
min and then incubated with 5 fmol of 32P-end-labeled 
oligonucleotides (2 x 104 to 4 x 104 dpm) for another 15 min 
in the final volume of 10 to 20 ~1. Reaction mixtures were 
electrophoresed in 6C:C acrylamide gels, using 0.5x Tris-
borate-EDT A as running buffer. Gels were dried and ex-
~30 CHEN A]'.;D ROTHEJ'\"BERG 
posed to Kodak XAR-5 film overnight at - 70'C with an 
intensifying screen. For competition or antibody supershift-
ing experiments, the indicated molar excess of specific 
competitor DNA or 0.5 to 1 J.LI of antibody was added at the 
beginning of the preincubation, before addition of the labeled 
oligonucleotide . Under these conditions, the complexes 
scored here (indicated by arrows or brackets in the figures) 
were all sequence specific and able to be competed for by 
homologous oligonucleotides. 
Data analysis. To compare the representation of a given 
DNA-binding protein in different extracts, as in Fig. 3 
through 5, samples containing equal amounts of nuclear 
protein were analyzed in parallel by electrophoretic mobility 
shift assay with the same preparation of labeled oligonucle-
otide probe. The amounts of radioactivity in the shifted 
complexes and, where applicable, in the unbound fraction of 
the probe were determined by analysis with a Molecular 
Dynamics Phosphor Imager. The levels of binding activity in 
the various cell types were compared after being normalized 
to the levels of Oct-1 protein determined in parallel in 
aliquots of the same extracts. Results reported were all 
based on at least three (usually six or more) analyses using at 
least two (usually four or more) independent cell prepara-
tions. 
The introduction of antibodies to identify complexes con-
taining CREB, Jun , and Fos significantly perturbs quantita-
tion. In our hands, the antibody against CREB appears to 
enhance the DNA-binding affinity of the complexes that it 
reacts with, so that the total amount of complex (shifted plus 
supershifted by reaction with antibody) appears greater than 
the amount of complex formed in the absence of antibody. 
Conversely, the antibodies against Jun and Fos individually 
reduce the DNA-binding affinity of the complexes that they 
react with and appear to reduce the overall amount of 
complex formed when they are used together in supershift-
ing experiments (data not shown). We have therefore esti-
mated the relative amounts of AP-1 (Fos/Jun) complexes 
only from the level of complex formed that is not super-
shifted by anti-CREB. 
RESULTS 
Nuclear extracts from cells in defined stages of T-cell 
development. To define the IL-2-regulatory proteins present 
at various stages of thymocyte development, we prepared 
nuclear extracts from isolated subsets of thymocytes repre-
senting the immature (CD4- cos- TcR -), transitional (cor-
tical CD4+ COST TcR10 w), and mature helper-type (CD4T 
cos- TcRhigh) stages of development. The nuclear extracts 
from these populations were then used in electrophoretic 
mobility shift assays to detect factors capable of binding to 
any of a panel of double-stranded synthetic oligodeoxynu-
cleotide probes derived from the murine IL-2 5' flanking 
sequence. The sequences of these probes are listed in 
Materials and Methods. Previous reports and our own pre-
liminary studies had indicated that the appearance of certain 
critical binding activities depended on cellular activation. 
Therefore, we prepared nuclear extracts from thymocyte 
subsets that were cultured for 2 to 4 h with or without 
stimulation with the phorbol ester TPA (17 nM) plus the 
Ca2+ ionophore A231S7 (70 to 120 nM). These stimuli mimic 
the second messengers induced by TcR ligands but do not 
require the presence of the TcR complex and therefore allow 
cells from a broad range of developmental stages to be 
assayed for responsiveness. 
Each population of cells analyzed was prepared by two 
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TABLE 1. IL-2 inducibility in thymocyte subpopulations 
Cell population" 
IL-~ activny (Uiml 5 x 10" cells)h 
Exp I Exp ~ Exp 3 
Total thymus 
Unstim. <4c 
Stirn. 52 33 







TcR- co4- cos-t 
Unst irn. <4 
Stirn. <4 
Stirn.+ IL-l 355 
SCID 
U nstirn. <4 
Stirn. 99 37 
S tirn . + IL-l 1,5Sl 848 
• Cells were prepared as described in I he 1ext and cultured as indicated for 
20 h. Unstim. , unstimulated; S tirn., in the presence of 100 nM A23187 and 17 
nM TPA; Stirn.+ IL·L as for Stirn. plus IL-2 at 20 U:ml for experiment 1 and 
50 U/ml for experiment 2. 
h Measured by bioassay on CTLL·~ cells. Units are defined in a given 
experiment as described in reference 39. Where no value is shown, that 
sample was not included in a particular experiment. Results from experiments 
with 3 independent cell preparations, representative of over 10 independent 
experiments, are given (see also references 24 and 38 to 40). 
c Undetectable. 
d Prepared by cytolysis with anti-COS. This fraction also contained -30% 
CD4- cos- cells. 
' Prepared by cytolysis with anti-H-2Kb This fraction consisted of 92CC 
C04- cos- cells with <5CC each CD4- cos-, CD4- cos-, and C04-
cos- ceUs. 
f Prepared from normal mice. 
different methods to control for any perturbations in cell 
physiology that might be caused by a particular method of 
fractionation (see Materials and Methods). For any given 
thymocyte subset, the different methods of isolation in fact 
yielded essentially indistinguishable profiles of D A-binding 
proteins. Thus, the differences between fractions discussed 
below reflect intrinsic cellular characteristics and not simply 
artifacts of the isolation procedure. 
The immature CD4- cos- TcR- cells, cortical-type 
CD4+ cos+ TcR1ow cells, and mature CD4+ cos- TcRh•gh 
cells differ significantly in the ability to express IL-2 upon 
induction (Table 1). In all cases, IL-2 protein secretion 
(Table 1) agrees well with IL-2 RNA expression, as mea-
sured by in situ hybridization and by quantitative RNase 
protection assays, as described elsewhere (25, 39, 40). The 
CD4 + cos- TcR + cells (initially -10% of total thymus) are 
about 10-fold enriched for the ability to express IL-2 relative 
to unfractionated thymocytes, whereas cells in the CD4-
cos+ TcR1ow fraction (initially SO% of total thymus) are at 
least 20-fold depleted of this ability. The immature cells from 
the SCID thymus produce modest amounts of IL-2 under 
normal stimulatiOn conditions and very high levels if IL-l is 
added. In this intense IL-l-dependent response, they resem-
ble normal immature thymocytes, which have the capacity 
to express high levels of IL-2 but do so only when IL-l is 
present (Table 1). By contrast, addition of IL-l does not 
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T.T. SCID DP CD4 
Stirn. ~~~r:-:;:' 
Oct.1--- ~ _ ... .. ---
12345678 
FIG. l. F-IL2A (Oct-1) binding activity in thymocytes. The 
NF-IL~A oligonucleotide (-100 to :..69) was used as a probe to test 
the binding activity in nuclear extracts from unfractionated thymo-
cytes (total thymocytes [T.T.]; lanes 1 and 2), SCID thymocytes 
Ilanes 3 and 4), CD4+ CDS~ TcR10" cortical thymocytes (double 
positive [DP]: lanes 5 and 6), and a population enriched for mature 
CD4+ cos- TcRh•gh thymocytes (CD4; lanes 7 and S). The cells 
were cultured in the absence (- ) or presence ( +) of A231S7 plus 
TPA (Stirn.) for 4 h prior to lysis. Aliquots estimated to represent 
equal amounts of nuclear protein from each sample were compared; 
in fact, the sample in lane 2 contained less protein than did the other 
samples. The electrophoretic mobility shift assay was performed as 
described in Materials and Methods. 
a T.T. SCID DP CD4 b 
Stirn. 
r-----1 r---1 r----1 ,-, 
- + - + - + - + Competitor 
Molar Excess 
"SP-1 " - - • :s ..... ~ -- "Sp-1 " -
2345678 
reveal any cryptic IL-2 inducibility in the CD4 + CD8-
TcR10" cells (38: data not shown). These re sults agree well 
with previously published data (16. 24, 34, 38, 39} indicating 
that these fractions are functionally and phenotypically 
consistent. 
DNA-binding factors present in developmental thymocyte 
subsets. The results of the electrophoretic mobility shift 
experiments revealed that the factors capable of binding to 
IL-2 gene flanking sequences can be divided into four classes 
on the basis of their developmental regulation. 
(i) Constitutive activities. As shown in Fig. 1, all thymocyte 
fractions possess a nuclear protein with binding activity for 
the NF-IL2A element ( - 100 to -69), with or without 
induction by TPA plus A23187. Its mobility compared with 
those of the NFIL-2A-binding proteins in EL4.E1 cells 
suggests that this protein is Oct-1 (data not shown) . In over 
10 independent experiments, there was no consistent differ-
ence between fractions or between stimulated and unstimu-
lated samples in the amount of this binding factor relative to 
total nuclea r protein. 
Another factor that appeared to be expressed constitu-
tively was one that binds to the oligonucleotide containing a 
sequence upstream of the NF-AT site, namely, the region 
from - 300 to - 278 (Fig. 2a). Despite the lack of any 
conventional Sp1 s ites in the IL-2-regulatory region (29), the 
- 300;' - 278 oligonucleotide includes a sequence, CCAC 
CCC, which is similar to a reported variant Sp1-binding site 
(44). In fact, the -300/ -278-binding factor binds with much 
higher affinity to a consensus Sp1 oligonucleotide than to the 
-300/ -278 oligonucleotide itself, as demonstrated by the 
> 10-fold difference between the molar efficiencies of these 
oligonucleotides as competitors (Fig. 2b). Binding of the 
thymocyte factor could not be significantly competed for by 
CD -300/-278 CD Sp-1 CD NF1 c c c 
0 I 40 80 160 320 I ~ 135 70 140 280 1 ~ 135 70 140 2801 z 




FIG. 2. Analysis of a constitutive DNA-binding activity in thymocytes that interacts specifically with the - 300/- 27S sequence. (a) Protein 
binding study. Nuclear extracts from samples of thymocytes that were cultured with (-) or without (- }stimulation were analyzed as for Fig. 
1to measure proteins binding to the -300/-27S oligonucleotide. Symbols and abbreviations are as defined in the legend to Fig. l. The arrow 
indicate~ the prominent specific complex that may correspond to Spl. (b) Results of a competition experiment suggesting that the major 
complex formed with the -300/-~7S oligonucleotide may be closely related to Spl. The indicated competitor oligonucleotides were added 
to an unfractionated thymocyte extract in the molar excesses over the labeled probe that are indicated above the lanes. The relatively poor 
self-competition by the -3001-27S oligonucleotide and the strong competition by the consensus Sp1 oligonucleotide indicate that the factor 
binds to the -3001-27S site with relatively low affinity. No competition is observed with the unrelated F1 oligonucleotide. 
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FIG. 3. Comparison of inducible NF-t<B site-binding activity in 
different thymocyte subsets. Samples of the extracts analyzed in 
Fig. 1 and 2 were incubated with an oligonucleotide spanning from 
mouse IL-2 positions -211 to - 192 to test for specific NF-KB 
sne-binding activity. The specific inducible NF-t<B-binding complex 
is indicated by the arrow. Abbreviations are as defined in the legend 
to Fig. 1. 
a consensus AP-2 oligonucleotide in excess (data not 
shown), even though in some cases AP-2 is reponed to bind 
similar sequences (35). Thus, it is likely that Sp1 or a relative 
of Sp1 may bind to this site. Our in vivo genomic foot printing 
studies confirm that this candidate Sp1 site does become 
occupied as part of a coordinated protein-DNA binding 
complex during IL-2 induction (12). 
(ii) Inducible factors correlated with developmental progres-
sion. The factors binding to the NF-KB site ( -211 to -192) 
and to the region ( - 174 to -156) associated with a proposed 
CD2SRE differ from the previous two in that their DNA-
binding activities are highly dependent on induction. Both 
their induction dependence and their relative inducibilities in 
different thymocyte subsets define the factors that bind the 
NF-KB (Fig. 3) and CD2SRE (Fig. 4) sites as members of a 
separate regulatory class. 
Inducible factors binding the NF-KB and CD2SRE oligo-
nucleotides were observed in all thymocyte subsets. In the 
case of the F-KB site, two well-defined complexes were 
seen, possibly representing the p65-p50 and p50-p50 forms of 
this transcription factor. As we have noted previously for the 
model IL-2-inducible cell line EL4.El (2S), the appearance 
of the upper complex (putative p65-p50 form or T-cell-
specific TCF; indicated by the arrow in Fig. 3) was more 
stringently induction dependent. We provisionally refer to 
this factor as NF-KB in the text that follows. The factors 
binding the CD2SRE oligonucleotide formed multiple re-
tarded complexes that were distinctively enhanced upon 
induction (bracket in Fig. 4). The specific type of complex 
reported to be induced in human Jurkat cells by CD2S 
engagement (11) may correspond to one of these bands but 
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FIG. 4. Comparison of CD28RE-binding ac11v1ty in different 
thymocyte subsets. The oligonucleotide spanning from JL-2 posi-
tions -174 to -156 was used in a binding assay with the panel of 
extracts analyzed in Fig. 1 through 3. The bracketed bands indicate 
inducible specific complexes. The complexity of this pattern. rela-
tive to that reported previously (11). may be due to the inclusion in 
our CD28RE oligonucleotide of five G residues that are omitted in 
the oligonucleotide used by Fraser et al. (11). Abbreviations are as 
defined in the legend to Fig. l. 
was not definitively identified in this study (see the legend to 
Fig. 4). However, in the aggregate, these complexes be-
haved as a cluster of inducible D A-binding proteins whose 
activation, like that of NF-KB. could be seen as the outcome 
of a successful signal transduction cascade. 
Although the CD4 + CDS+ TcR'ow conical thymocytes 
could make no IL-2, we found that they activate both the 
NF-KB upper complex and CD2SRE-binding factors to levels 
at least as high, relative to Oct-1 or total nuclear protein 
levels, as in most preparations of SCID thymocytes (Fig. 3 
and 4; compare lanes 4 and 6). The lower complex, which 
may represent a p50-p50 homodimer, has been associated 
with repression of IL-2 expression (22). Although it appears 
to be expressed in a high ratio relative to the upper complex 
in the CD4 + CDS+ cells illustrated in Fig. 3 (lane 6), more 
commonly the ratio of lower to upper complex in these cells 
was the same as in the o ther subsets of thymocytes. 
(ill ) Inducible factors correlated with IL-2 inducibility. 
Factors capable of binding to the NF-AT and AP-lp sites 
defined a third class of factors. The binding activities asso-
ciated with these factors were highly induction dependent, 
like the factors in the second group. However, in contrast to 
the second group, the NF-AT and AP-1 (see below) factors 
appeared to be inducible mai nly or exclusively in cells 
competent to express IL-2, and in both mature cells and 
immature thymocytes alike. 
Figure 5 shows the results of assaying thymocyte extracts 
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FIG. 5. Comparison of NF-AT-binding activity in different thy-
mocyte fractions. The figure shows a typical result when the 
oligonucleotide from mouse IL-2 positions -289 to -260 was used 
in the binding assay with the panel of extracts used for Fig. 1 
through 4. The inducible NF-AT complex is indicated by an arrow. 
Abbreviations are as defined in the legend to Fig. l. 
for NF-AT activity. NF-AT binding was highly inducible in 
mature C04 + cells but low or undetectable in unfractionated 
and CD4~ cos+ cortical thymocytes (Fig. 5, lanes 2, 6, and 
S). These results are in full agreement with the report by 
Riegel et al. (34). The inducibility of NF-AT-binding activity 
was not restricted to cells in the final stage of T-cell 
differentiation and maturation , however. SCIO thymocytes 
(as well as CD51ow CD4- cos- TcR- thymocytes isolated 
from normal mice: data not shown) were able to mobilize 
NF-AT-binding activity to levels ~ite comparable with 
those of mature C04+ cos- TcRh•s cells. A comparative 
titration of nuclear extracts from stimulated C0 510 w CD4-
cos- TcR- immature cells from normal mice and stimu-
lated CD4+ CDS+ TcR1ow cortical cells showed that the 
immature cells contained at least 10 times more NF-AT 
DNA-binding activity than do the conical cells (data not 
shown). Thus, NF -AT inducibility appears to be acquired at 
an early developmental stage. 
(iv) Developmentally distinct factors binding to the AP-I 
site. Our results indicate that the major AP-1 site at -161 to 
-143 in the IL-2 5' flanking region (AP-1 P) can be engaged 
by at least two differentially regulated factors. one conven-
tionally inducible factor consisting entirely of Fos and Jun 
family members (AP-1 complex) and one which includes at 
least one CREB subunit (CREB complex). The two com-
plexes were similar in electrophoretic mobility and could be 
resolved only by use of antibodies. 
All thymocyte subsets contained factors capable of bind-
ing to the putative AP-1 site, and surprisingly, most did so 
with or without in vitro stimulation (Fig. 6a). In total 
thymocytes overall and in isolated CD4 + CDS+ TcR10 "' cells, 
essentially all of the AP-1P site-binding activity was attrib-
utable to the CREB complex, whether or not the cells were 
stimulated (Fig. 6b, lane 2: Fig. 6c. lanes 1, 2, 7. and S). 
CREB complexes were pre~ent in unstimulated cells of all 
subsets (Fig. 6c, lanes 1. 3. 7, and 9). Levels of the CREB 
complex appeared to be increased by exposure of the 
thymocytcs to culture at 37°C (data not shown) but were not 
enhanced by TPA plus A231S7. In CD4+ Cos- TcRhish and 
SCID thymocytcs specifically. however, activation with 
TPA plus A231S71ed to strong induction of an AP-1 complex 
(Fig. 6c. lanes 3, 4, 9, and 10). Thus, we conclude that (i) all 
thymocytes can activate a leucine zipper family factor in-
cluding at least one CREB subunit simply in response to 
stimuli such as a temperature shifi and (ii) immature and 
mature thymocyte subsets alike can activate a canonical 
AP-1 factor in response to Ca2+ ionophore and protein 
kinase C stimulation, but (iii) cortical CD4 + CDS+ TcR10 "' 
thymocytes are specifically disabled in their activation of the 
inducible AP-1 factor despite their ability to activate other 
factors such as the C02SRE-binding complexes and F-KB. 
DISCUSSIO:'II 
Summary of developmental changes in IL-2 DNA-binding 
factors. The pattern of inducibility of the DNA-binding 
proteins studied here is summarized qualitatively in Fig. 7 _ 
As a framework for the following discussion, the data are 
presented as a hypothetical developmental progression, in 
which the average cell types in each of the fractions studied 
here are assumed to be linked in a precursor-product con-
tinuum. The discontinuities in the inducibility of AP-1 (Fos/ 
Jun) and NF-AT. both at the immature-to-cortical transition 
and, presumably, at the cortical-to-mature transition (see 
below) contrast sharply with the gradual, monotonic in-
creases in the inducibility of NF-KB and at least the majority 
of the complexes that bind to the CD2SRE oligonucleotide. 
Each thymocyte subset has its own characteristic profile of 
these factors. The combinatorial requirement for these fac-
tors in assembling IL-2 transcription complexes accounts for 
the ability of immature thymocytes and the inability of their 
cortical thymocyte descendants to express the IL-2 genes. 
The most interesting aspect of these results. however, is the 
light that they shed on the kinds of physiological changes 
imposed on developing thymocytes during intrathymic pro-
cessing. 
Reverse maturation of function in the immature-to-cortical 
thymocyte transition. The results presented here show that 
cells in the immature population can already deploy a set of 
transcription factors that includes all those known to be 
needed for IL-2 expression in mature cells. Even NF-AT, 
initially described as a mature T-cell-specific factor. is al-
ready highly inducible in these cells. Any developmental 
changes needed to turn on N F-AT expression must therefore 
already have occurred at this stage, before TcR gene rear-
rangement. Furthermore, the signaling pathways needed to 
activate NF-AT and other regulatory factors already appear 
to be effectively indistinguishable in immature cells from 
those in mature T cells. Both normal CD4 - cos- TcR-
populations (data not shown) and SCID thymocytes could 
activate F-AT, the AP-1 complex, and other regulatory 
factors comparably to mature cells in response to A231S7 
plus TPA. Surprisingly, costimulation with IL-l did not 
appear to be required for induction of any of these activities. 
The only difference in D A-binding protein activation ob-
served in the immature cell samples (normal or SCID) when 
IL-l was added was a modest enhancement of the induction 
of the NF-KB binding activity (data not shown). The basis for 
the strong ob.,erved effect of IL-l on IL-2 R A and protein 
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FIG .. 6. AP-1/CREB proteins of thymocytes. (a) Comparison of AP-1P site-binding act ivity in different thymocyte fractions. Nuclear 
extracts from the indicated thymocyte samples were analyzed for complex formation with the AP-1P oligonucleotide. Abbreviations for 
th)'m ocyte samples and culture conditions are as given in the legend to Fig. 1. (b) Reactivity of AP-1P site-binding factors in cortical 
thymocytes with different antibodies. An extract from stimulated CD4~ Cos- TcR10w thymocytes was used for electrophoretic mobility shift 
assays with the AP-1P oligonucleotide, with the following antibodies (Ab) added: lane 1, none; lane 2, anti-CREB; lane 3, anti-Fos and anti-Jun 
family: lane 4, all three antibodies. Anti-CREB shifts a much larger fraction of the initial. unperturbed binding activity than does anti-Jun plus 
anti-Fos. The material reactive with anti-CREB defines the CREB complex .. (c ) Differential expression in thymocyte subsets of Fos{Jun and 
CREB complexes with binding activity for the AP-1P site. Extracts from the thymocyte samples shown in panel a were analyzed for binding 
to the AP-1P oligonucleotide in the presence of the following antibodies: anti-CREB (C). anti-Fos family plus anti-Jun family (FJ), and a 
cocktail of all three antibodies (FJC). As CREB-like factors are present in all samples, all C lanes contain supershifted (antibody-bound) 
complexes. The Fos/Jun or AP-1 complex referred to in the text is the material in the lanes treated with anti-CREB that remains in the 
antibody-unbound position. Lanes 6 and 12 verify that all this material is in fact reactive with anti-Jun and/or anti-Fos. 
expression (9, 17, 39) must therefore reside elsewhere and 
remains under investigation. However, the results presented 
here clearly show that the molecular prerequisites for IL-2 
producer function that we can score have already been 
achieved through extremely early events in T-cell develop-
ment, in a process completely independent of T-cell recog-
nition specificiry. 
In this context, the transition to C04 + cos+ TcR1ow 
conical thymocyte status is confirmed as a loss of response 
function .. However, the loss is surprisingly specific .. Previous 
work had shown that murine C04 + cos+ TcR1o w thymo-
cytes fail to express known response genes, like the IL-2 and 
IL-2 receptor alpha-chain genes, even when the TcR is 
bypassed with strong pharmacological stimuli (4, S, 9, 16, 
24). A priori, the cells might have been fou nd to lack basic 
molecular transducers of signals such as calmodulin or 
appropriate isoforms of protein kinase C. Instead, the results 
described here show that these cells are capable of strong 
though selective transcription factor activation. For exam-
ple , the inducibiliry of NF-KB in these cells makes it likely 
that a fully operational protein kinase C-dependent pathway 
is present.. Thus, the dissociation of one ubiquitous phorbol 
ester-inducible response from another. in the selective loss 
of AP-1 induction while NF-KB induction is preserved, 
implies a precise. factor-specific mechanism rather than a 
cataclysmic, global change in cell physiology. There are two 
tmplications of these results . First, the reverse maturation 
process in which AP-1 and NF-AT inducibiliry are lost 
defines a novel transition in thymocyte development. Its 
possible timing and s ignificance are discussed further below. 
Second, the cells in this functionally incompetent population 
remain highly responsive, with an ability, in principle, to 
integrate signals from protein kinase C, cyclic AMP/protein 
kinase A (50), and possibly also C02S (14, 46) fo r transcrip-
tion factor mobilization .. Their potential to carry out effi-
cient, if specialized, patterns of gene expression is further 
supported by our recent evidence that they can serve as 
preferential targets for transient expression of certain exog-
enous ONAs in transfection experiments (30). Thus, the 
cortical thymocytes need not be beyond rescue; in fact , the 
repertoire of inducible transcription factors that they pre-
serve might participate in the poorly understood processes 
of positive and negative selection. 
Selection and the selectable state. A most interesting pos-
sibiliry raised by these results is that changes in F-AT and 
AP-1 inducibiliry may contribute to the mechanisms that (i) 
make thymocytes subject to selection and (ii) transform 
them into mature thymocytes via positive selection. Figure 7 
indicates a possible temporal correlation between these 
important developmental transi tions and the discontinuities 
in the use of F-AT and AP-1. At present , this hypothesis is 
speculative, because it is not yet known whether the " typi-
cal" subset members depicted in Fig. 7 are truly related in a 
precursor-product continuum .. However, the striking simi-
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FIG. 7. IL-2 DNA-binding factors in thymocytes: a proposed developmental progressio n. This summary figure juxtaposes the results from 
Fig. l through 6 on the abundance of various IL-2 D A-binding factors in three broad stages of thymocyte differentiation. The data are 
arranged along a horizo ntal axis that represents the differentiative progress of thymocytes toward maturity, with the key event s that mark 
transitions and states of interest indicated. While the characteristics of the three stages are established by our results. the proposed 
connections between them are hypothetical. as discussed in the text. The vertical axis represents relative levels of DNA-binding activi ties of 
various factors , expressed on an a rbitrary scale, with the results for different classes of factors offset. As the true copy number of different 
factors are not known, the values along the vertical axis in this figure cannot be used to compare one factor with another. (i), (ii), (iii), and 
(iv) refer to the four regulatory classes of factors distinguished in the text. - - - - , true constitutive factors. ---. CREB, the binding activity 
of which is increased by culture but i not dependent on Ca~-/protein kinase C activation: --, factors whose D A-binding activity is 
detectable only after Ca~+ /protein kinase C activation. 
larities between the IL-2 DNA-binding activities available in 
immature and mature thymocytes suggest two possible kinds 
of linkages between transcription factor regulation and thy-
mocyte fate determination. One, an alternative to the 
scheme shown in Fig. 7, is that the downregulation of 
NF-AT and AP-1 may occur only in cells that have failed 
positive selection and are committed to die. In this case, 
cortical thymocytes that remain susceptible to positive se-
lection could be identified as a subset specifically protected 
from NF-AT and AP-1 downregulation, bypassing the typi-
cal cortical cell state. The other possibility, illustrated in Fig. 
7. is that a relatively simple, reversible molecular switch 
may shut off AP-1 and NF-AT inducibility prior to any 
selection and restore it as a consequence of selection. In this 
case, the mechanism controlling NF-AT and AP-1 inducibil-
ity would define one of the molecular targets of the positive 
selection process. The choice between these alternative 
interpretations depends on the precise timing of NF-AT and 
AP-1 downregulation relative to TcR gene rearrangement 
and surface expression. As of this writing, the possibility 
depicted in Fig. 7 is favored by two kinds of evidence. We 
and others have already shown that thymocytes lose a 
variety of inducible gene expression responses at a stage 
well before their acquisition of a selectable TcR (3, 9, 37, 51). 
Also, our own preliminary results (7) indicate that NF-AT 
and AP-1 inducibility has already been lost by cortical 
thymocytes that are still act ively in cycle, a population that 
clearly includes cells with full precursor activity that may yet 
be positively selected (15, 19, 31, 43). Thus, no evidence yet 
available suggests loss of activatability as a late event. If 
further investigation confirms the early timing of NF-AT and 
AP-1 downregulation , then this process must be reversible, 
as a direct or indirect consequence of positive selection. 
Work to define the biochemjcal basis of the changes in AP-1 
and F-AT availability is now under way. 
In summary, the data from this study identify NF-AT and 
the AP-1 complex described here as potentially valuable 
probes to define the mechanisms regulating the varying 
responses of thymocytes to activation in the course of their 
development. A full understanding of their changes in activ-
ity must awajt the cloning of the genes encoding NF-AT 
components and the identification of AP-1 family members 
that actually participate in IL-2 regulatory complexes. How-
ever, the inducibility of these factors is at least correlated 
with the abrupt changes in cellular responses to signaling 
that define both onset of and rescue from the selectable 
state. Furthermore, their pleiotropic roles in response gene 
regulation can explain the functional effects of the regulatory 
changes. Whether or not their function is also implicated in 
the fate determination events per se, they provide likely 
molecular targets of the switch mechanism that transforms 
cell physiology to convert simple activation signals into the 
arbiters of irreversible developmental choice. 
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Characterization of AP-1 Induction in Developing Thymocytes: 
Differential Activation of fos Genes 
93 
Abstract 
Thymocytes lose their interleukin-2 gene inducibility upon transition from CD4-
CD8-TCR- stage into the CD4+CD8+TCRI0 stage. This inducibility is restored once the 
double positive cells are positively selected to become mature T cells. Our previous studies 
showed that nuclear extracts from the stimulated CD4+CD8+TCRlo cortical thymocytes 
have decreased AP-1-and NF-AT-binding activities in comparison to the immature CD4-
CD8-TCR- precursor cells and postively selected mature CD4+TCRhi cells. To investigate 
whether the reduced nuclear factor binding activity is due to an absolute reduction of AP-1 
components at the transcriptional level, we analyzed jun and fos mRNA accumulation upon 
stimulation in thymocytes representing different stages of development. The appearance of 
all three jun mRNAs is stimulation-dependent and there is no consistent variation in the 
levels of their expressions across development. However, the accumulation of c-fos, fosB 
and fra-2 mRNAs are significantly lower in stimulated cortical cells than in stimulated 
mature cells. Although immature CD4-CD8-TCR- cells also have similar low levels of 
c-fos expression, they can transcribe high levels of fosB and fra-2 mRNAs which are 
equivalent to those of mature thymocytes. There is no detectable fra-1 expression in any 
population of thymocytes 1 hr after stimulation. These results strongly suggest that the 
lack of AP-I and NF-AT binding activities in cortical thymocytes is due to a deficiency of 
Fos proteins. 
Introduction 
The AP-1 transcription factor is composed of two families of leucine zipper 
proteins, the Jun family and the Fos family (Vogt and Bos, 1990; Angel and Karin, 1991). 
Proteins within each family share a high degree of homology at the amino acid level. 
Genes encoding them are categorized as immediate-early genes, since they are readily 
induced by growth or differentiation signals and are independent of protein synthesis. In 
addition to the control at transcriptional level, they are also controlled post-translationally. 
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As a trans-acting factor, AP-1 in combination with other trans-acting factors regulates a 
number of genes including c-jun through binding to the AP-1 site (TGAC/GTCA) at the 
regulatory sequence. Dimerization via the leucine zipper motif is required for DNA binding 
(Sassone-Corsi et al., 1988). The Jun family proteins can form either Jun-Jun intrafamily 
dimers or Jun-Fos heterodimers with Fos family proteins, while the latter can only 
heterodimerize with the Jun family. The dimer complex formed by different combinations 
of Jun-Jun and Jun-Fos may have similar binding specificities but different affinities and 
different trans-activation activities (Ryder and Bravo, 1991; Halazonetis et al., 1988). For 
a given Jun-Jun or Jun-Fos dimer, both DNA-binding acivities and trans-activation 
activities are subject to regulations by post-translational modification (Hunter and Karin, 
1992; Smeal et al., 1991). Differential regulation of AP-1 proteins has been shown during 
different stages of the cell cycle (Kovary and Bravo, 1991 and 1992). 
The interleukin-2 gene is one of the target genes which are subjected to AP-1 
regulation along with other trans-activators. AP-1 activation is a target of perturbation not 
only in developing CD4+CD8+TcRlo thymocytes, but also in glucocorticoid-treated T cells, 
in anergized T cells, and in IL-l treated T cells (Northrop et al., 1992; Vacca et al., 1992; 
Kang et al., 1992; Chapters 1 and 2). The 300 bp IL-2 gene 5' regulatory sequence 
contains at least four sites which interact with AP-1 factor, which are one AP-1 site, the 
two NF-AT sites and the octamer/OAP40 site. The attempt to identify which dimer 
combination of Jun and Fos proteins binds to each site has not been satisfactory. It has 
reported that c-Jun, c-Fos, FosB, Fra-1, and Fra-2 are able to bind the AP-1 site in the 
IL-2 promoter (Jain et al., 1992; 1994). For the NF-AT site, c-Jun, JunD, JunB, c-Fos, 
and Fra-1 have shown to be able to form complexes with this site in vitro. With the 
exception of JunB, they have all been shown to enhance NF-AT site driven transcription 
and to eliminate the TP A stimulation requirement in in vivo cotransfection experiments 
(Northrop et al., 1993; Jain et al., 1992; Hentsch et al., 1992; Boise et al. , 1993). JunD 
and c-Jun form complexes with the octamer protein to bind Oct/OAP40 site. In addition, 
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JunO, c-Jun, and c-Fos, but not JunB, can contribute to the enhancer activity of a 
concatamerized Oct/OAP40 site when cells are stimulated with ionomycin alone without 
PMA (Ullman et al., 1992 and 1993). Therefore, all members have been implicated in 
binding to one site or another or to all of them, suggesting a possible functional 
redundancy. 
In chapter 2, we reported the finding that CD4+CD8+TcRlo cortical thymocytes 
have decreased inducible AP-1 and NF-AT binding activities. It is not known which Jun 
or Fos proteins are physically or functionally deficient in these cells. As an initial approach 
to address this problem, we examined the AP-1 mRNA accumulation upon stimulation in 
these IL-2-noninducible cortical cells as compared with the IL-2-inducible immature 
RAG2-/- thymocytes or SCID thymocytes and mature CD4+TcR+ and CD8+TcR+ 
thymocytes. Similar to other types of cells, expression of jun and fos genes is induction 
dependent in all fractions of thymocytes. Uninduced thymocytes express no or very low 
levels of jun or fos mRNA. In this study, we showed that mRNA of jun family members 
are equally inducible in either IL-2 inducible and non-inducible thymocytes, but that three 
of the fos genes, c-fos, fra-2, and fosB, are differentially regulated. c-fos mRNA is poorly 
inducible in both immature and cortical cells, but it is significantly more inducible in mature 
thymocytes. More interestingly, the fosB and fra-2 mRNA are much more highly inducible 
in both immature and mature IL-2-producing thymocytes than in IL-2-nonproducing 
cortical cells. Therefore, the decreased AP-1 and NF-AT binding activities could be a 
result of the low fos gene activation. 
Materials and Methods 
Cells. Thymocytes were prepared mostly from 3 to 5-week old mice, except 
RAG2-/- mice which were 2-month old. Immature CD4-CD8-TCR- thymocytes were 
prepared from either RAG2-/- mice (From F. W. Alt) or Balb/C or C57BU6 SCID mice. 
Unfractionated thymocytes were prepared from C57BU6 mice. Mature TCRhi thymocytes 
96 
were prepared from C57BL/6 mice two days after 2.5 mg hydrocortisone i.p. treatment. 
Cells in suspension were then cultured in RPMI1640 with 6% fetal bovine serum with 
supplements and antibiotics, with or without TPA and A23187 as stimuli for 1 hr. 
RNA analyses. Total cellular RNA samples were prepared by guanidinium 
isothiocyanate/phenol-chlorofonn extraction methods (Chomczynski and Sacchi, 1987) and 
2 !lg of RNA was used for RNAse probe protection analyses as described before (McGuire 
and Rothenberg 1987; Miner and Wold 1991). For Northern analysis 10 !lg of RNA was 
denatured with glyoxal and DMSO and was electrophoresed in NaH2P04 buffered agarose 
gel. The RNA was blotted onto nylon membranes (Nytran; Schleicher and Schuell) with 
7.5 mM NaOH and was fixed to the membrane by baking at 80°C for 60 min. 
Hybridizations were performed as described in chapter 1 (Novak et al. , 1990). The c-jun 
and junD templates were generated by Pvull and Apalll digestion, respectively, of the 
appropriate eDNA constructs (from ATCC). The junB template was made by subcloning a 
5'-end EcoRI and Smai fragment of junB eDNA (ATCC) into the corresponding sites of 
pSP73 (Promega). This was linearized with EcoRI. The fosB template was prepared by 
subcloning a PvuiJ/Pstl fragment of fosB eDNA (a gift from Scholthal) into the same sites 
of pSP72 (Promega), and linearizing with Xhol. All jun family and fosB templates were 
transcribed with T7 polymerase to make antisense probes. The fra-1 , the c-fos and 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) probes were generated and 
described by Sean Tavitigian. (Tavtigian, 1992). The fra-2 probe was an EcoRI human 
fra-2 eDNA fragment (a gift from Scholthal) and was labeled with random priming for 
Northern blot analysis. 
Reagents. Both tetradecanoyl phorbol acetate (TP A) and the calcium ionophore 
A23187 are from Sigma (St. Louis, MO). They were used at concentrations of lOng/ml 
and 200nM respectively. Interleukin-1 (Genzyme) was used at 50ufmL and added to the 
culture simutanously with TPA and A23187. Forskolin (Sigma) was used at 10 Jlg/mL and 
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added 15 to 30 min prior to the addition of TPA and A23187. Cortisone acetate (Merck 
Sharp Co.) (25mg/ml) was administered at 2.5mg/mouse, by i.p. injection. 
Results 
To test the possibility that the lack of inducible AP-1 binding activities in cortical 
CD4+CD8+TcRl0 thymocytes is regulated at the transcriptional level of AP-1 components, 
we decided to examine the fos and jun mRNA accumulation in different populations of 
thymocytes. Our previous experiments indicated that both immature and mature 
thymocytes can be induced to express high levels of IL-2 in vitro. The intermediate cortical 
thymocytes, on the other hand, cannot be induced to do so. Therefore, RNA was prepared 
from the following samples: thymocytes from RAG2-/- or SCID mice, representing 
immature thymocytes, from C57BU6 mice representing cortical thymocytes, and from 
hydrocortisone treated C57BU6 mice, respresenting mature single positive CD3hi cells. 
Unfractionated normal thymocytes could be used to approximate the behavior of cortical 
cells because cortical type thymocytes represent the majority ( -85%) and dominate the 
behavior of the unfractionated population (Chapter 2). These cells were collected and 
cultured, with or without TPA and ionomycin A23187 treatment. Most AP-1 mRNA peaks 
around 30 min to 2 hr (Reed et al., 1986), so we used 1 hr stimulation for our analyses. 
Total RNA was extracted from the cultured thymocytes treated with or without 
TPA/A23187 for 1 hr. RNase probe protection analyses and Northern blot analysis were 
used to detect the expression of jun and fos mRNA. 
Similar experiments were also done with RNA extracted from thymocytes 
stimulated with TPA/A23187 in the presence of IL- l or forskolin. As shown in the 
previous two chapters, IL-2 expression is subjected to the regulation of various signals, 
including cytokines like interleukin-1 and pharmacological agents like cAMP-elevating 
agent forskolin. IL-l in particular is a stage-specific enhancer of IL-2 expression for 
immature cells, and has been shown to induce c-jun expression in a T -cell line (Mueggge et 
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al., 1989). It is possible that the synergistic effect of IL-l with signals mediated through 
TCR to augment the IL-2 expression can be attributed to the increase in both NF-KB and 
AP-1 DNA-binding activities. The cAMP-elevating agent forskolin, on the other hand, 
exerts an antagonistic effect on signals activating IL-2 gene. Although the DNA-binding 
activity of AP-1 is not changed in the presence of forskolin, junB expression is increased, 
while the expression of c-jun and junD is reduced in EL4 cells. It is possible that the 
unchanged AP-1-DNA complex varies its AP-1 components by activating cAMP-dependent 
protein kinases. It has been shown in cotransfection experiments that junB failed to replace 
the TPA signal requirement to induce NF-AT or OAP40/0CT enhancer activities (Northrop 
et al., 1993; Ullman et al., 1992; 1993). Therefore, it is important to see whether 
increasing intracellular cAMP in thymocytes would have a similar effect as seen in EL4 
cells or some other T -cell lines. The results are summarized below. 
Levels of different jun mRNA induction are similar in all subsets of thymocytes. 
First, junD mRNA is equally inducible in all thymocytes. As shown in figure lC, two 
specific bands, possibly due to incomplete digestion, are seen after probing with a 3' 
eDNA fragment . There are no significant variations in the level of mRNA accumulation 
among different fractions of cells (Fig. lC, compare lanes 2, 5, and 8), nor is there any 
increase or decrease of induced junD expression upon stimulation in the presence of IL-l 
(Fig. lC, compare lanes 2 and 3, 5 and 6, and 7 and 8). Similarly, junB expression is also 
inducible in all fractions of thymocytes (Fig. lB). However, stimulation in the presence of 
forskolin can further enhance junB induction in all the fractions tested (data not shown). 
The accumulation of c-jun mRNA is also observed in immature, cortical, and mature 
thymocytes after 1 hr of stimulation (Fig. lA). Costimulation in the presence of IL-l 
superinduces c-jun mRNA accumulation, which is more obvious in RAG2-/- and cortical 
thymocytes (Fig. lA, compare lanes 2 and 3, 8 and 9). Interestingly, the RAG2-/-
thymocytes express relatively higher levels of c-jun mRNA in comparsion to other 
populations. Such IL-l induced higher expression of c-jun, however, is not observed in 
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SCID thymocytes, another preparation of immature thymocytes. Since c-jun mRNA is 
least abundant and is roughly 10 to 20-fold less than that of junD and junB mRNA, if c-jun 
is differentially regulated, it might likely be regulated by post-transcription modification 
(Smeal et al., 1991). 
Differential regulation of fos family mRNA in thymocytes during development. 
Upon examination of c-fos mRNA accumulation, we observed highly inducible c-fos 
mRNA induction in mature single positive TCRhi cells and only barely detectable c-fos 
induction in either RAG2-/- (data not shown), SCID or unfractionated total thymocytes 
(Fig. 2A). The difference is about 2 to 4-fold. Addition of either ll...-1 or forskolin does 
not change the level of c-fos expression in mature cells, but they slighly decrease c-fos in 
SCID cells and in one sample of unfractionated thymocytes (Fig. 2A, compare lanes 2 and 
3, 8 and 9, 11 and 12). Thus, c-fos appears to be mature cell-specific. Induction of fosB 
mRNA is seen in all fractions of thymocytes, and is not affected by forskolin addition (Fig. 
2A and data not shown). However, there are some differences among different 
populations of cells when comparing the level of fosB expression. The unfractionated total 
thymocytes have a barely detectable basal level of fosB expression, while both immature 
RAG2-I- or SCID thymocytes and mature thymocytes have a relatively high basal level 
expression of fosB (Fig. 2A, compare lanes 1 and 10 with 4 and 7, and data not shown). 
Upon induction, immature and mature cells express roughly 3 times more fosB mRNA 
than total cells (Fig. 2A. compare lanes 2, 5, 8, and 11). Addition of IL-l to the 
stimulation does not change fosB accumulation in most populations examined except for 
one preparation of unfractionated thymocytes in which decreased c-fos expression is 
observed (Fig. 2A, compare lanes 8 and 9). Since mature cells have consistently lower 
levels of GAPDH expression compared to other fractions (2.5-fold less), c-fos and fosB 
expression in mature cells was normalized with the average level of GAPDH in immature 
and unfractionated thymocytes, and similar normalization was done for fra-2 expression. 
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Bar graphs accompaning each fos protection analysis is used to show the relative fold of 
induction. 
Fra-2 has been reported to be one of the immediate early genes which may be 
involved in IL-2 gene activation (Jain et al., 1992 and 1994). The murine fra-2 gene has 
not been cloned, but there is a high degree of homology between human and chicken fra-2 
eDNA (Matsui et al., 1989; Nishina et al., 1990). To analyze its induction in murine 
thymocytes, a human fra-2 eDNA was used as the probe for Northern analysis. As shown 
in figure 2B, the 6 kb species represents the mouse fra-2 mRNA. The expression pattern is 
similar to fosB, with both immature and mature cells able to express relatively high levels 
of fra-2 1 hr after stimulation, while unfractionated thymocytes can only express very low 
levels of fra-2 (Fig. 2B, compare lanes 2, 4, and 5). Data from two independent 
experiments showed that there is between 3 to 8-fold higher fra-2 expression in immature 
thymocytes than in unfractionated thymocytes. There is no change in fra-2 induction with 
or without IL-l addition (data not shown). 
We also examined fra-1 mRNA expression in these cells. Unlike other AP-1 
mRNA which can be induced by TPA/A23187 treatment, there is no inducible fra-1 mRNA 
accumulation even after 6 hr stimulation (data not shown). 
Discussion 
In current studies, three populations of thymocytes were prepared to represent T 
cells at three intrathymic developmental stages. Thymocytes from either SCID or RAG2-/-
mice were used to represent immature CD4-CD8-TCR- thymocytes. Phenotypic analyses 
have shown that T cell arrest point in SCID mice is not beyond the immature stage of 
normal thymocyte development. Cells from RAG2-/- mice have also been shown to arrest 
at similar point (Rothenberg et al., 1993; Shinkai et al., 1992; SA Diamond & K Makabi, 
unpublished data). Functional analyses further confirmed that SCID cells and immature 
cells from normal mice are indistinguishable. Both populations can be induced to express 
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IL-2 in the presence of IL-l (Rothenberg et al., 1993). In chapter two, we also showed 
equivalent DNA-binding activities of a set of transcription factors in both SCID and normal 
immature cells. Thus, we expect that normal immature cells would behave similarly to cells 
from SCID and RAG2-/- mice. Unfractionated thymocytes from C57BU6 mice were used 
to represent cortical cells. It has been shown many times that these cells contain over 85% 
of cortical CD4+Co8+TCR10 cells. Besides, experiments in chapter two clearly showed 
that the ability to mobilize a set of transcription factors are very comparable in both induced 
and non-induced states. Nonetheless, the 10 to 15% non-cortical cell contamination in 
unfractionated total thymocytes might affect the intepretation of the result. Especially in 
cases where we see decreases in particular transcripts, contaminated immature or mature 
cells might actually account for the residue mRNA detected. In fact, if we have used 
enriched cortical cells for the RNA analysis, the difference seen in the expression of certain 
fos genes might be even bigger. Finally, for mature T cells we used cells from mice treated 
with cortisone, which selectively induces the apoptosis of cortical cells. FACS analysis 
clearly demonstrated that over 90% of cells are either CD4+TCRhi or CD8+TCRhi (data not 
shown). We did not use anti-CD8 antibody plus complement to eliminate CD4+cos+ 
cortical cells, because cells obtained in this way still contain small percentage of immature 
cells. However, by injecting hydrocortisone we may inadvertantly vary the responsiveness 
of these cells to induction. But circumstantial evidence supports the validity of the results. 
This is because although glycocorticoid induced apoptosis in cortical cells has been shown 
in rat thymocytes to be accompanied by increased c-jun and c-fos induction, the response is 
very rapid and transient (Grassilli et al., 1992). Our cortisone treatment lasted two days, 
and if there is any residual induction effect left on AP-1 it would be likely seen in cells 
freshly isolated in the absence of further activation. However, cells in that condition do not 
have higher levels of either jun family gene expression when compare to other populations. 
In addition, these cells do not have higher levels of inducible jun family gene expression 
either. The higher basal levels of some fos genes in these cells are also seen in immature 
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cells which were not treated with cortisone. Therefore, cells from cortisone treated mice 
can be used to represent mature cells. Ideally, a direct comparison of mature thymocytes 
obtained by different methods should be done to verify the data. 
So far three jun family genes and four fos family genes have been found in human, 
murine, and chicken systems. In the current study we examined the mRNA accumulation 
of these AP-1 components at different stages of developing thymocytes. The results 
showed that three jun mRNAs are similarly inducible in thymocyte populations 
representing different developmental stages, but that c-fos, fosB and fra-2 are differentially 
inducible in various populations of thymocytes as summarized in Table 1. It is unlikely 
that the reduced accumulation of fos mRNA might be due to its different induction kinetics 
in certain populations of thymocytes, because most of these genes are protein synthesis 
independent immediate early genes whose accumulations peak around 30 min to 1 hr after 
induction (Reed et al., 1986). The 1 hr time point we chose is a proper time to examine 
most of them except fra-1 which takes 6 h to induce. If the mRNA accumulation reflects 
the level of AP-1 proteins, the possible Jun/Fos heterodimer combinations would contain 
all three Jun proteins with FosB and Fra-2 in immature cells and three Jun proteins with 
c-Fos, FosB and Fra-2 in mature thymocytes. However, for cortical thymocytes, the low 
level of inducible c-fos, fosB and fra-2 mRNA may indicate the deficiency for those Fos 
proteins as well. Thus, it leaves only c-Jun, JunB, and JunD to form homodimers or 
interfamily heterodimers, which have been shown to have a lower DNA binding affinity 
than Jun/Fos heterodimers (Ryseck and Bravo. 1991; Halazonetis et al., 1988). The 
current data clearly show that the reduced AP-1 and possibly NF-AT DNA-binding 
activities in nuclear extracts from stimulated cortical cells can be attributed to their inability 
to transcribe high levels of fos mRNA upon induction. The subsequent deficiency in Fos 
protein production predicted from these data would result in the lack of Jun/Fos 
heterodimer formation, and any resulting Jun-Jun homodimers may not be sufficient to 
bind nor to activate the IL-2 gene. In this study we did not rule out the possibility that 
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AP-1 could also be regulated at the level of transcription and/or post-translational 
modifications. However, our findings provide a strong indication that Fos protein levels 
might be reduced in cortical cells. The fact that c-jun's trans-activation activity depends on 
the phosphorylation of serine residues indicates that further characterization of AP-1 
proteins themselves is necessary. 
The ability of c-fos to participate in IL-2 gene activation was actually demonstrated 
in H-2Kh-c-fos transgenic mice, in which T cells express constitutively high level of c-fos 
mRNA. Upon stimulation with anti-CD3 antibody, those T cells showed increased AP-1 
site binding acitivity and produced higher level of IL-2 both at RNA and protein level than 
T cells from non-transgenic littermates (Ochi et al., 1994). Overexpressing Fos in 
cotransfection studies not only enhances the NF-AT-dependent transcription but also 
eliminates the dependency on TPA stimulation (Northrop et al., 1993). In our experiment, 
even though immature cells also lack of c-fos expression, the relative higher level of fosB 
and Fra-2 expressions might compensate the c-fos deficiency, and this compensation 
cannot be achieved in cortical cells. It is also possible that fra-2 or fosB is the actual AP-1 
component which is used in both immature and mature thymocytes to activate IL-2 gene. 
Recent experiments on c-fos knockout mice confmned the ability of these products to drive 
IL-2 expression in the absence of c-fos. Spleen T cells from c-fos deficient mice are able to 
make IL-2 in a level similar toT cells from wild-type mice. Biochemical analyses revealed 
that activation of these T cells can induce AP-1 binding, which contains FosB and Fra-2; 
while the induced AP-1 binding complex from wild-type T cells contains c-Fos, FosB and 
Fra-2 (Jain et al., 1994). Another experiment showed that c-jun is not necessary and is 
dispensible forT-cell development and activation. The chimeric mice generated from 
RAG2-/- blastocytes injected with c-jun mutant ES cells have normal thymocyte 
development and normal IL-2 production in response to stimulation (Chen & Alt, personal 
communication). This need not be abnormal, because it is likely that these Jun and Fos 
proteins have redundant functions and are interchangable, especially in the context of 
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lymphocyte development. The redundancy of myoD family proteins has been shown in 
muscle development (Rudnicki et al., 1993). As of yet there has not been an experiment to 
address the outcome of disrupting more than one fos or jun member. The multiple defects 
with osteogenesis, gametogenesis, and neurological responses seen in c-fos knockout mice 
and the lethality in c-jun knockout mice should not hinder the investigation, because the 
manipulation of blastocysts from RAG2-/- mice has proven to be an excellent method to 
analyzing genes responsible for lymphocyte development (Johnson et al., 1992; 1993; 
Wang et al., 1992; Chen et al., 1993). To study whether reduced levels of Fos protein in 
cortical cells alone causes the lost IL-2 gene inducibility, a complementation experiment can 
be performed by either transfecting fos genes driven by a strong promoter into cortical cells 
or by directly examining those cells in H-2K-c-fos transgenic animals. 
How is the change in AP-1 inducibility achieved? Detailed dissection of the thymic 
developmental stages further subdivides immature CD4-CD8-TcR- thymocytes into 
different populations according to their surface expression of CD44, IL-2Ra., and HSA. 
Roughly, the progression proceeds from CD44+JL-2Ra.- to CD44+JL-2Ra.+ to CD44-
IL2Ra.+ to CD44-!IL-2Ra.-. Functional analyses actually showed that the loss of IL-2 gene 
inducibility occurs at the transition from CD44-IL-2Ra.+ to CD44-IL-2Ra.- (Godfrey and 
Zlotnik, 1993; Rothenberg et al., 1993; Rothenberg & Diamond, 1994). TcR 13 chain gene 
rearrangement occurs at the CD44+JL-2Ra.+/CD44-IL-2Ra.+ stages prior to loss of IL-2 
gene inducibility. It is certain that successfull3 chain rearrangement is required for the 
immature to cortical transition, since the thymocytes from both SCID and RAG-1-/- or 
RAG-2-/- mice which are unable to rearrange their TCR or lg genes are arrested at immature 
stage (Rothenberg et al., 1993; Mombaerts et al., 1992; Shinkai et al., 1992). As the loss 
of IL-2 gene inducibility is correlated with the TcR 13 rearrangement, the possibility remains 
that TcRI3fgp33 surface expression not only signals the cell to stop 13 gene and start a. gene 
rearrangement (Groettrup et al., 1993), but also induces other changes including reduced 
fosB and fra-2 expression in response to activation signals. The positive selection signal, 
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however, may reverse the fosB and fra-2levels and restore the AP-1 binding activity in 
mature T cells. Correlation of lineage differentiation with differential AP-1 expression has 
been observed in hematopoietic cell differentiation. In human promeylocytic HL-60 cells, 
differentiation toward macrophages by addition of TP A is accompanied by upregulation, 
while differentiation toward granulocytes by treatment of DMSO is accompanied by 
downregulation of AP-1 expression and its DNA-binding activity (Mollinedo et al., 1993). 
It has been shown that tyrosine kinase lck is the downstream signalling molecule of 
TCR ~chain during early thymocyte development. Increasing dosage of a dominant-
negative lck transgene results in decreased differentiation of immature triple negative 
thymocytes to cortical double positive thymocytes (Anderson et al., 1992 and 1993; Levin 
et al., 1993). By crossing a TCR ~chain transgenic mouse with a dominant-positive lck 
transgenic mouse, animals could be generated in which the otherwise immature CD4-CD8-
TCR- cells would prematurely express TCR ~and have high levels of lck activity. If the 
activation of fos genes in these immature cells is downregulated when compared to the cells 
from single transgenic mice, a direct correlation between signals mediated by TCR ~-lck 
and the inducibility of fos genes can be established. Meanwhile, in vitro systems which 
allow double positive thymocytes bearing transgenic TCR to be positively selected in 
response to the target antigen and antigen-presenting cells can be used to study whether and 
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Immature Cortical Mature 
IL-2 inducibility + + 
AP-1 binding ++ +1- ++ 
c-fos induction + + +++ 
fosB induction +++ + +++ 
fra-2 induction +++ + +++ 
c-jun induction ++I+ + + 
junB induction ++ ++ ++ 
junO induction ++ ++ ++ 
Table 1. Summary of fos and jun RNA induction in different populations of 
thymocytes in correlation with their IL-2 gene inducibility and the 
AP-1 binding activity in their nuclear extracts. Number of II+ II is 
determined by amounts of corresponding RNA or DNA-binding 
acitvity relative to each population of thymocytes. 
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Figure legends: 
Figure 1. RNase protection analysis of jun transcripts in RNA from different 
populations of thymocytes. A. Thymocyte RNA from RAG2-/- (lanes 1-3), from SCID 
(lanes 7-9), from different preps of normal C57BL/6 mice (lanes 4-6, 10-12, 13-15), and 
from hydrocortisone treated C57BU6 mice (lanes 16-18) were hybridized with the c-jun 
and GAPDH probes. Each lane represents RNA from cells cultured without stimulation 
(-), with TPNA23187 stimulation (+),or with TPNA23187 and IL-l stimulation (1). 
Lane 19 is a negative control sample with 30 Jlg oftRNA. B. and C. Similar RNA samples 
hybridized with junB and junO probes respectively. Two specific bands resolved with 
junO protection may be caused by incomplete digestion. 
Figure 2. A. RNase protection analysis of c-fos and fosB mRNA in different 
populations of thymocytes. B. Northern blot analysis of fra-2 mRNA with a human fra-2 
eDNA probe. A 6 kb species as indicated in the figure represents the murine fra-2 RNA. 
Each lane is similarly labelled as in figure 1. Bar graphs on the side show the quantitiative 
results from phosphoimager scanning. In the fra-2 graph, another set of SCID and U.T. 
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Interle11kin-2 (IL-2) transcription is developmentally restricted to T cells and physiologically dependent on 
specific stimuli such as antigen recognition. Prior studies have shown that this stringent two-tiered regulation 
is mediated through a transcriptional promoter/enhancer DNA segment which is composed of diverse 
recognition elements. Factors binding to some of these elements are present constitutively in many cell types, 
while others are signal dependent, T cell specific, or both. This raises several questions about the molecular 
mechanism by which IL-2 expression is regulated. Is the developmental commitment of T cells reflected 
molecularly by stable interaction between available factors and the IL-2 enhancer prior to signal-dependent 
induction? At which level, factor binding to DNA or factor activity once bound, are individual regulatory 
elements within the native enhancer regulated? By what mechanism is developmental and physiological 
specificity enforced, given the participation of many relatively nonspecific elements? To answer these questions, 
we have used in vivo footprinting to determine and compare patterns of protein-DNA interactions at the native 
IL-2locus in cell environments, including EIA T-lymphoma cells and 32D clone 5 premast cells, which express 
differing subsets of IL-2 DNA-binding factors. We also used the immunosuppressant cyclosporin A as a 
pharmacological agent to further dissect the roles played by cyclosporin A-sensitive factors in the assembly and 
maintenance of protein-DNA complexes. Occupancy of all site types was observed exclusively in T cells and 
then only upon excitation of signal transduction pathways. This was true even though partially overlapping 
subsets of IL-2-binding activities were shown to be present in 32D clone 5 premast cells. This observation was 
especially striking in 32D cells because, upon signal stimulation, they mobilized a substantial set of IL-2 
DNA-binding activities, as measured by in vitro assays using nuclear extracts. We conclude that binding 
activities of all classes fail to stably occupy their cognate sites in IL-2, except following activation ofT cells, and 
that specificity of IL-2 transcription is enforced at the level of chromosomal occupancy, which appears to be 
an aU-or-nothing phenomenon. 
lnterleukin-2 (IL-2) is an important cytokine that acts on 
both T cells and B cells. Its synthesis is developmentally 
restricted to a subset of T-helper cells; in these cells, IL-2 is 
exclusively expressed as a transient response to stimulation. In 
vivo , the appropriate combination of signals to elicit IL-2 
expression is usually triggered by antigen recognition (re-
viewed in references 36 and 49). Because much of the regula-
tion of IL-2 is transcriptional (3, 22), the IL-2 gene has been 
extensively studied to learn how multiple signal transduction 
pathways are integrated to evoke a specific transcriptional 
response (45). In this study, we have focused on the mecha-
nisms that control cell type restriction and signal dependence 
of IL-2 transcription. 
In vivo interactions between sequence-specific DNA-binding 
proteins and their cognate DNA regulatory elements have 
been described for only a small number of genes. Even within 
this limited data pool, substantially different strategies are used 
for different genes. At one extreme, a protein-enhancer com-
plex can be preassembled on · the DNA but be inactive until 
receipt of an appropriate stimulatory signal or signals. This 
describes the activation of c-fos transcription in fibroblasts 
upon epidermal growth factor treatment (16). At the other 
extreme are cases like the myocyte-specific enhancer of the 
• Corresponding author. Mailing address: Division of Biology, 156-
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muscle creatine kinase gene, which is not occupied by any of 
the DNA-binding factors present in the nonexpressing myo-
blast precursors (29). Only when differentiation is triggered by 
decreasing levels of growth factors such as fibroblast growth 
factor or transforming growth factor beta do multiple regula-
tory factors bind to the enhancer to activate muscle creatine 
kinase transcription. Similar diversity can be imagined for the 
mechanisms controlling transcription in a cell-type-specific 
manner, although in the cases studied so far, including the 
immunoglobulin heavy-chain enhancer (9), no protein-DNA 
interactions have been detected in nonexpressing cell types. 
Since IL-2 expression is governed by both lineage restrictions 
that confer cell type competence and transient mechanisms 
that depend on activation signals, this gene might employ 
either mechanism or elements of both. 
The 300 bp immediately upstream of the IL-2 transcriptional 
start site contains a minimal promoter/enhancer region which, 
as a whole, can drive expression in a stimulation-dependent, 
T-cell-restricted fashion ( 45). It is composed of multiple 
individual regulatory elements which, when assayed on their 
own, have strikingly different behaviors. The NF-AT recogni-
tion element binds a complex factor assembled in the nucleus 
only in activated T cells (38). When multimerized, this element 
drives expression that is largely restricted to T cells and is 
activation dependent (47). The NF-KB and AP-1 elements also 
drive expression in stimulated but not unstimulated T cells (1); 
however, these elements are also active and signal responsive 
in other cell types (15). Two CACCC motifs likely act as 
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constitutive, general elements (5). Finally, the IL-2 regulatory 
region contains a site, octamer (0Cf)/OAP40, which binds the 
relatively ubiquitous octamer family proteins (15, 18), adjacent 
to the more restricted, stimulation-dependent OAP40 protein 
(44). The 0Cf/OAP40 unit functions as aT-cell-specific and 
stimulation-dependent activator site, though the octarner fac-
tor component is capable of binding to DNA constitutively (1, 
18, 44). We and others have previously shown that different 
subsets of these factors are mobilized in T cells as a function of 
the use of different combinations of stimuli or in T -lineage cells 
of different developmental states (5, 8, 14, 19, 23, 30, 33). In 
general, conditions that permit activation of only a subset of 
factors do not allow IL-2 expression. The importance of 
interactions between multiple sites to create the IL-2 transcrip-
tional pattern is also evident from mutational studies. For 
example, disrupting individual cis elements, such as the NF-
AT, AP-1, or 0Cf/OAP40 site, !eads to 4- to 20-fold decreases 
in expression (7, 17, 32). These data suggest extensive func-
tional collaboration between regulatory elements of diverse 
character, but the mechanism of their collaboration is not 
known. This functional collaboration could be at the level of 
enhancer occupancy by these factors or at the level of factor 
activity or a combination of the two. 
In this work, we investigate the mechanistic basis of IL-2 
regulation by determining the pattern of protein-DNA inter-
actions at the IL-2 locus in living cells. For simplicity, we have 
focused on a few well-defined cellular environments in which 
the presence of distinct but overlapping spectra of IL-2 DNA-
binding activities are associated with dramatic all-or-none 
effects on IL-2 expression. Three different cell types were 
compared: lineally related cells which can or cannot be induced 
to transcribe IL-2 as well as an unrelated cell type which does 
not make IL-2. We also make use of cyclosporin A (CsA) to 
test how specific factors affect both establishment and mainte-
nance of an active transcriptional complex. The results indicate 
that diverse DNA-binding activities that participate in control-
ling IL-2 expression collaborate at the level of stable occu-
pancy of IL-2 regulatory sequences. 
MATERIALS AND METHODS 
Cell culture. EL4.El.F4 (EL4) thymoma cells and 320 clone 
5 (320) premast cells were grown as described in reference 31, 
and L cells were grown as described in reference 12. EL4 cells 
and 320 cells were induced with 10 ng of 12-0-tetradecanoyl-
phorbol-13-acetate (TPA) per ml and 180 nM A23187. When 
inductions were performed in the presence of CsA, CsA was 
used at a concentration of 0.5 f.Lg/ml. 
RNA preparation and measurements. Total RNA was pre-
pared by the guanidinium isothiocyanate-organic extraction 
method of Chomczynski and Sacchi (6), and RNase protection 
analysis was performed as previously described (24, 26). RNA 
probes were as previously described for IL-2 (24), metallothio-
nein I (MT-I) (28), and glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) (41). Five micrograms of total RNA was 
used in the IL-2 analysis, 1 f.Lg was used in the MT-I analysis, 
and 1 f.Lg was used in the GAPDH analysis. 
In vivo and in vitro OMS-piperidine treatment of DNA. 
Adherent L cells were treated as described in reference 28. 
EL4 and 320 suspension cells in medium (107 to 108 in 50 ml) 
were pelleted at 500 X g for 5 min at ··room temperature. 
Sufficient medium was left behind to allow resuspension of the 
cell pellet in a final volume of 1 mi. Cells were transferred to 
a 1.5-ml microcentrifuge tube and placed in a 37°C water bath; 
10 f.LI of a freshly made 10% dimethyl sulfate (DMS)-90% 
ethanol solution was added, and the sample was mixed by 
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gentle inversion. After incubation at 37"C for 1 min, cells were 
transferred to a tube containing 49 ml of ice-cold phosphate-
buffered saline (PBS) and centrifuged at 500 X g for 5 min at 
4•c. The cell pellet was resuspended by gentle pipetting in 1 ml 
of ice-cold PBS, 49 ml of additional ice-cold PBS was added, 
and the sample was centrifuged at 500 X g for 5 min at 4•c. 
The cell pellet was resuspended in 0.3 ml of ice-cold PBS and 
then added to 2.7 ml of lysis solution (300 mM sodium 
chloride, 50 mM Tris (pH 8.0), 25 mM EDTA (pH 8.0), 200 f.Lg 
of proteinase K per ml, 0.2% sodium dodecyl sulfate). DNA 
was prepared as previously described (27). Naked DNA prep-
aration and in vitro OMS treatment were done as described in 
reference 28 except that 0.125% OMS for 2 min at room 
temperature was used. Subsequent piperidine cleavage was 
performed as previously described (27). 
LMPCR visualization of genomic footprints. Ligation-medi-
ated PCR (LMPCR)-aided OMS in vivo footprinting was 
carried out as detailed previously (12). Note that the activity of 
each unit of Vent polymerase as provided by the manufacturer 
(New England Biolabs) has increased in the time since the 
experiments in reference 12 were done, and thus 0.5 U of Vent 
polymerase is now used in the first-strand synthesis, 1.0 U is 
used in the PCR amplification step, and 1.0 U is used in 
labeling step. Oligonucleotides used in LMPCR to detect 
interactions on the noncoding strand of IL-2 were primer 1 
(CfATCfCCfCTTGCGTTT-GTCCACC), primer 2 (TGTC 
CACCACAACAGGCTGCTTACAGGT), and primer 3 (CA 
CCACAACAGGCTGCTTACAGGTTCAGGATG). Coding-
strand IL-2 oligonucleotides were primer 1 (GGACTTGAGG 
TCACfGTGAGGAGTG), primer 2 (CAAGGGTGATAGG 
CAGCfCTTCAGCATG), and primer 3 (CAAGGGTGATA 
GGCAGCfCTTCAGCATGGGAG). LMPCR hybridization 
temperatures for both primer sets were as follows: primer 1, 
6o•c; primer 2, 69•c; and primer 3, n•c. The coding-strand 
MT-1 oligonucleotides were primer 1 (CGGAGTAAGTG 
AGCAGAAGGTACTC), primer 2 (GGAGAAGGTACTC 
AGGACGTTGAAG), and primer 3 (GAAGGTACTCAGG 
ACGTTGAAGTCGTGG). LMPCR hybridization tempera-
tures were as follows: primer 1, 6o•c; primer 2, 66•c; and 
primer 3, 69•c. 
Quantitation of band intensity was performed by using an 
LKB UltroScan XL laser densitometer and recording peak 
heights. Fixed and dried gels were exposed to XAR-5 film 
without an intensifying screen. Multiple exposures of two 
independent in vivo footprint experiments were quantitated, 
using three scans per lane. Protections and hypersensitivities 
indicated in Fig. 4 ranged in intensity from 25 to 65% 
protection and from 25% to twofold hypersensitivity in the 
induced EL4 cell samples compared with both naked DNA 
samples and uninduced EL4 cell samples; these were all 
observed in both experiments. Comparison of band intensities 
among in vivo samples from nonexpressing cells indicated that 
all were within 7%. Not marked in Fig. 4 are several G residues 
on the coding strand near -100 and - 200 which were 
between 20 and 25% hyperreactive in all in vivo samples from 
nonexpressing cells compared with naked DNA (see text). 
Electrophoretic mobility shift assays. Nuclear extracts were 
prepared as described previously ( 40) from the same cell 
populations as used in the in vivo footprinting experiments. 
The mobility shift assay was performed as described previously 
(5), using 5 f.Lg of nuclear extract, 0.5 f.Lg of poly(dl-dC) , and 
approximately 5 .fmol of the appropriate 3 2P-labeled oligonu-
oleotide. Antibody supershift experiments were performed as 
described previously (5) with anti-CREB serum provided by 
Marc Montminy and anti-Fos family and anti-Jun family sera 
provided by Rodrigo Bravo. As preimmune serum controls 
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FIG. 1. RNasc protection analys is of IL-2, MT-1, and GAPDH 
transcripts in RNA from the cell populations used in Fig. 2, 3, 4, and 
7. RNA from unstimulated EL4 cells (lane 1). EL4 cells stimu lated 
with TPA and A23187 for 7 h (lane 2), EL4 cells stimulated for 7 h in 
the presence of CsA (lane 3), unstimulated 320 cells (lane 4 ), and 320 
cells stimulated with TPA and A23187 for 2 h (lane 5) was used. IL-2 
RNA was also easily detected in EL4 cells stimulated for 2 h (data not 
shown). Lane 6 contained only 30 f.Lg of tRNA. 
were not provided, we verified the specificity of these reage nts 
by their lack of reaction with NF-KB and CACCC site-binding 
complexes. Oligonucleotides were labeled by end filling with 
Klenow po lymerase. The sequence of one strand is given for 
each oligonucleotide used (bases not present in the IL-2 gene 
a re in lowercase): distal CACCC ( - 300 to - 278), 
gatcTCTCCACCCCAAAGAGGAAAA TTgatc; proximal CA 
CCC ( - 72 to -52), gatcACATCGTGACACCCCCAT A TTg 
a te; octamer ( -100 to - 69), gatcTCTTTGAAAATATGTGT 
AATATGTAAAACATgatc; AP-1 (-161 to -143), AATT 
CCAGAGAG T CATCAG; TGGGC ( - 237 to -218), ga tcC 
ACCT AAGTGTGGGCT AACgatc; NF-KB ( - 211 to - 192), 
AAAGAGGGA TTTCACCT AAA T ; distal NF-AT ( - 289 to 
- 260), AAGAGGAAAA TTTGTTTCATACAGAAGGCG 
AAT; and proximal NF-AT ( - 147 to - 120), gATCAGAAG 
AGGAAAAACAAAGGT AA TGCgatc. 
RESULTS 
To examine the mechanisms used to activate IL-2 transcrip-
tion in T cells as well as mechanisms that may be used to keep 
CACCC 
distal prox OCT AP-1 
TPAIA23 -++ -++ -++ -++ 
CsA --+ --+ --+ --+ 
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IL-2 IN VIVO FOOTPRI NT 211i1 
it inactivated in no ncxpressing cells, we determined the pattern 
of protein-DNA interactions at the lL-2 locus in three different 
types of cells. EL4 thymoma ce lls were used as a model IL-2 
producer cell type, as 70 to 80% of these cells can be induced 
to express IL-2 synchronously (24). Upon stimula tion wi th the 
phorhol este r TPA and the calcium io nophore A23187, which 
mimic many of the physiologica l effects of antige n stimulation, 
EL4 cells show many of the same gene induction events as 
antigen-activated T-helper cells do. As in normal T cells. IL-2 
transcriptional inductio n in EL4 cells is sensitive to CsA 
trea tment (33) . To examine why the IL-2 gene is not expressed 
in othe r hematopoietic cell types, 32D premast cells were 
chosen because they respond to TPA and ionophore stimula-
tio n with some o f the same gene inductio n responses as E L4 
cells but fa il to induce IL-2 (3 1, 32). F ina lly, L-cell fi broblasts 
were studied to examine mechanisms that may be used to keep 
the IL-2 gene inactivated in nonhematopoietic cells (da ta no t 
shown). R Nasc protectio n analysis was performed to confirm 
the expression pattern of IL-2 in the va rious ce ll populations 
with and witho ut stimula tion (Fig. 1), using the same cell 
prepara tions analyzed in the in vitro DNA binding and in vivo 
footprinting expe riments described below. 
Multiple factors that bind sites in the IL-2 promoter/ 
enhancer in vitro are present in the nuclei of cells that do and 
cells that do not express IL-2. The presence of nuclear facto rs 
that can bind to the IL-2 promoter/enhancer is a prerequisite 
for the assembly of a transcription complex on the IL-2 gene in 
vivo. Previo us studies using in vitro DNA footprinting have 
a lready established that large regions of t he IL-2 enhancer can 
be bound by nuclear factors from cells that cannot make IL-2, 
such as He La cells (4, 37). The identity, abundance, and 
re levance to IL-2 expression of the factors responsible for such 
binding are unknown. To establish the availability of specific 
factors implicated in the control of IL-2 expression, nuclear 
extracts were prepared from the same E L4 T cells and 32D 
premast cell populations examined above. These nuclear ex-
tracts we re then tested to monito r and identify the factors 
capable of binding sites in the IL-2 promoter/enhancer in vitro 
by using gel mobility shift assays. The binding activities de-
tected in EL4 T cells (Fig. 2) can be placed into three 
categories: co nstitutive, stimulation dependent (inducible), 
and stimulation dependent but CsA sensitive. Oligonucleotides 
NF-AT 
TGGGC NF-kB distal prox 
-++ -++ -++ -++ 
--+ --+ --+ --+ 
[ s ~ • • :.,1-·:1-: 
131415 161718 19 20 21 2223 24 
FIG. 2. Characterization of nuclear factors present in EL4 T-lymphoma cells by electrophoretic mobility shift assay. Nuclear extracts were 
prepared from the same populations used in the RNase protection and in vivo footprinting experiments. The 32P-Iabeled oligonucleotide used in 
each experiment is indicated at the top. Arrowheads and brackets mark the major binding activities, as discussed in the text. The major complex 
for either CACCC motif can be competed for by the oligonucleotide containing the other CACCC motif or, even more efficiently, by a consensus 
SPl oligonucleotide (5) (data not shown). The unmarked, inducible lower complex in lane 2 can be competed for hy the distal NF-AT 
oligonucleotide and represents binding of factors to the portion o f the distal NF-AT site present in th~ distal CACCC oligonucleotide (data not 
shown). Additional, faster-migrating complexes were detected 111 lanes 4 to 6. None were CsA scns1t1vc, and the most prevalent spec1es was 
constitutively expressed. In lanes 7 to 9. OAP40-binding activity could not be detected in these expedments, probably beca~se of the abundance 
of octamer-binding species in EL4 cell extracts. In lanes 16 to 18, a faster-~1gratm¥, mmor NF-KB sl!e-bmdmg ~pec1e~ wh1ch was mduc1ble and 
partially CsA sensitive like the major species was detected. In lanes 19 to 24, m add1t1on to the well-charactcnzcd, mduc1blc, CsA-scm1t1vc NF-AT 
complex (filled arrowheads), a faster-migrati ~g ~pecieswith similar regulatory characteristics (open arrowheads) was observed for hoth NF-AT 
sites. Additional, constitutive NF-A T mollf-btndmg ac11v1t1es were also detected m these EL4 cells. prox, prox1mal. 
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spanning the CACCC sites in the IL-2 promoter bound nuclear 
factors in extracts from all cell preparations (Fig. 2, lanes 1 to 
6). The most prominent CACCC activities were ne ithe r stim-
ulation dependent nor CsA sensitive. Similarly, the octamer 
(NF-IL2A)-binding activities in these cells were neither stim-
ulation dependent nor CsA sensitive (lanes 7 to 9). The 
proximal AP-1 site was bound by factors which were inducible 
but were no t CsA sensitive (lanes 10 to 12). By contrast, both 
the distal and proximal NF-A T-binding sites, as seen previ-
ously by others (8, 33), showed stimula tion-dependent binding 
activity tha t was highly CsA sensitive (lanes 19 to 24 ). The 
NF-KB site bound inducible factors whose binding activities, 
under our conditions, were also much reduced by CsA (lanes 
16 to 18). Finally, a newly identified TGGGC element (see 
below) bound inducible activities with partia l CsA sensitivi ty 
(lanes 13 to 15). Thus, multiple factors capable of binding 
regulatory elements in IL-2 DNA are present in the nuclei of 
unstimulated, stimula ted, and CsA-trcatcd stimulated EL4 T 
cells. 
Simila r assays were done to determine whether factors 
recognizing TL-2 regula tory elements were present in the 320 
premast cells before or afte r excitation of signal transduction 
pathways (Fig. 3). 320 ce ll nuclear extracts contained consti-
tutive activities capable of binding the CACCC and octamer 
motifs at levels simila r to those in EL4 cells (Fig. 3A, lanes l to 
9; sec be low). Both constitutive and signal-respo nsive factors 
in 320 cell extracts bound to the NF-KB and TGGGC sites 
(lanes 10 to 15). At both sites, the most promine nt of the 
inducible complexes were at least as prevalent as those in EL4 
cell extracts. 320 cells also contained diverse constitutive and 
inducible AP-1-binding activities (Fig. 3B; see be low). Thus, 
320 cell nuclei contain multiple, sequence-specific factors, 
some of which are inducible, that bind elements within the IL-2 
regula tory region in vitro. 
Although many sites have binding activities in both cell types 
examined here, previous studies have shown qualitative dis-
tinctions among pro tein complexes at some individual IL-2 
regulatory elements. Moreover, expression of IL-2 has been 
correlated with the rela tive prevalences of these different 
activities (5, 19). Here, comparison of 320 cell factors with 
EL4 cell factors revealed such differences in the complexes 
binding a t four sites. First, the two more rapidly migrating 
octamer-binding activities found in EL4 cells, apparently cor-
responding to the Oct-2 species observed in other cell types 
(18), were not observed in 320 cells (Fig. 3A, lanes 7 to 9). 
However, this may not be very significant for IL-2 transcrip-
tion, as these species are also absent from subsets of thymo-
cytes which are competent to transcribe IL-2 (5). A second and 
potentia lly more interesting qualitative difference was at the 
AP-1 site (Fig. 3B and C). We have previously noted that 
although several distinct factors can bind this site, all yield 
complexes with similar migration characteristics in band shift 
assays (5). These factors can, however, be distinguished by the 
use of specific immune reagents. In Fig. 3B and C, antibodies 
against CREB (13), Fos fami ly, and Jun family (21) prote ins 
were used to characterize the complexes binding a t this site. As 
in thymocytes, the majority of activity in uninduced 320 cells is 
immunologically rela ted to the cyclic AMP-responsive CREB 
factor (Fig. 3B, lanes 1 and 2, and da ta not shown). Upon 320 
cell stimula tion, an activity that reacted with Fos and Jun 
family-specific antisera was induced (Fig. 3B, lanes 3 to 6). By 
contrast, extracts from stimulated EL4 cells contained rela-
tively little of the CREB-related factor (Fig. 3C, lane 2) and 
higher levels of Fos and Jun family activities (Fig. 3B, lane 9; 
Fig. 3C, lanes 3 and 4). NF-KB site-binding activities also 
differed be tween 320 and EL4 cells. In addition to an appar-
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FIG. 3. Characterization of nuclear factors present in 320 prcmast 
cells by electrophoretic mobility shift assay as described in the legend 
to Fig. 2. To facilitate comparisons, nuclear extracts prepared from 
stimulated EL4 cells were examined in parallel with the 320 extracts. 
(A) Comparison of factors in unstimulated 320 cell nuclear extracts, 
stimulated 320 cell nuclear extracts, and stimulated EL4 cell nuclear 
extracts. Arrowheads and brackets mark the major binding activities, 
as discussed in the text. prox, proximal. (B and C) Perturbation of 
complexes formed at the AP-1 site with specific antisera. For pertur-
bation of gel shift complexes with antibodies against CREB (C), Fos 
family (F), and Jun family (J) proteins, samples of nuclear extracts 
were pre incubated with the appropriate antibodies (13, 21) exactly as 
described by Chen and Rothenberg (5). Nuclear extracts prepared 
from unstimulated 32D cells (panel B, lanes 1 and 2), stimulated 32D 
cells (panel B, lanes 3 to 8), and stimulated EL4 cells (panel B, lane 9; 
panel C, lanes 1 through 4) were used. Filled arrowheads denote the 
major binding species in extracts not exposed to antisera, and open 
arrowheads denote the major antibody-reactive supershift complexes. 
Neither supershift complexes nor inhibition of binding was obsetved 
when these antibodies were assayed for perturbation of complexes with 
the NF-KB site (data not shown). The prevalent, faster-migrating 
species in panel B, lane 1, was not observed reproducibly. 
ently common major binding species, 320 cells contained 
elevated levels of a more rapidly migrating complex. Its 
migration characteristics suggest that it may correspond to the 
NF-KC activity previously proposed to play a negative role in 
IL-2 transcription (19). Finally, gel mobility shift assays showed 
that the inducible NF-AT activity observed in EL4 cells is 
greatly reduced in 320 cells (Fig. 3A, lanes 16 to 18). 
Taken together, the cell type differences and similarities in 
individual binding activities emphasize several points. First, 
although the difference in NF-AT-binding activity corre lates 
nicely with the demonstrated importance of its sequence 
element for IL-2 transcription, there are numerous other 
quantitative and qualita tive differences in the sets of binding 
factors in 320 cells compared with EL4 cells. Second, these 
differences involve not only regulatory factors thought to act 
positively but also potential negative regulators. Fina lly, the 
multiplicity of factors suggests that only a subset of the factors 
detected in vitro are assembled in the active complex in vivo. 
Moreover, the factors that are relevant in vivo may, at least in 
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FIG. 4. DMS in vivo footprint of the IL-2 regula tory region. DNA from in vivo OMS-treated unstimulated 320 cells (panel A, lane 1; panel 
B, lane 2), stimulated 320 cells (panel A, lane 2; panel B, lane 3), unstimulated EL4 cells (panel A, lane 4; panel B, Jane 5), stimulated EL4 cells 
(panel A, lane 5; panel B, lane 6), EL4 cells stimulated in the presence of CsA (panel A, lane 6; panel B, lane 7), and EL4 cells stimulated for 
2 h prior to the late addition of CsA (panel A , lane 7; pane l B, lane 8) was used. Naked 320 DNA (panel B, lane 1) and naked EL4 DNA (panel 
A, lane 3; panel B, lane 4), each treated with DMS in vitro, were also used. The in vivo footprint patterns of the coding (A) and noncoding (B) 
strands are shown. Location in the sequence ladder with respect to the major start site of IL-2 transcription is indicated at the inside edge of each 
panel. Bands marked with arrows were reproducibly more than 25% protected {plain arrow) or more than 25% hypersensitive (arrow with circle) 
in induced EL4 cells compared with uninduced EL4 cells and naked EL4 DNA. Weak interactions appare nt in the experiment shown but not 
reproducibly observed over the multiple independent experiments performed (e.g., a protection ncar - 100 on the coding strand) are not marked. 
An artifactual band not predicted from the sequence of !L-2 (asterisk) was seen when the noncoding-strand primer set was used. It became 
approximately 10-fold more intense than any other band in the ladder under LMPCR conditions which gave genera lly high background (e.g., with 
usc of excess Vent DNA polymerase; data no t shown). Its intensiry corre lated in no way with the identity of the DNA sample (data not shown). 
some cases, be species other than the quantitatively dominant 
ones observed in vitro. 
Determining the pattern of protein-DNA interactions at the 
IL-2 locus in vivo. To detect in vivo protein-DNA interactions, 
in vivo footprinting was performed by treating intact cells with 
the membrane-permeable alkylating agent OMS (9). OMS 
detects proteins bound to DNA at G residues in the major 
groove. Protein occupancy can protect individual G residues 
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121 
MoL. CELL. BIOL. 
CACCC NF-AT 3 • NF-AT octamer 
-310 TACT'l'TTGTG TWCC L~ ~TTTCA TACA~ ~TTAAAA CTGCCACCTA -231 
ATGAAAACAC AGA T ~CCTTT _AAAGT ATGTC_ G ~TTAATT'M' GACGGTGGAT 
t t 
CACCC TATA-2 TATA-1 
!TAAihGCCT CCCATGCTGA AGAGCTGCCT ATCACCCTTT 
-30 ~CGGA GGGTACGACT TCTCGACGGA TAGTGGGAAA 
FIG. 5. Summary of protein-DNA interactions detected in stimulated EL4 cells. Downward arrows denote protected bases; upward arrows 
denote hypersensitive bases. CD28RE, CD28 response element. 
within its recognition site from reaction with DMS or, occa-
sionally, render additional G residues within that site hyper-
sensitive to DMS. After alkylation with DMS, subsequent 
treatment with piperidine was used to produce DNA cleavage 
at the methylated G's. When appropriately visualized, this 
results in a G-specific sequence ladder. In parallel, unmodified 
DNA was purified from cells and deproteinized, and the naked 
DNA was then treated with DMS. DMS footprints were 
revealed by comparing the patterns of G cleavage (G ladders) 
of DNA treated with DMS within different living cell popula-
tions (in vivo samples) with each other and with the pattern of 
G cleavage of naked DNA samples. The DMS footprints, 
consisting of protected G residues and associated G hypersen-
sitivities, were visualized by LMPCR genomic footprinting (29) 
as described previously (12). 
Stimulation of EIA T cells results in the coordinated 
binding of multiple proteins to the IL-2 promoter/enhancer. 
The pattern of in vivo protein-DNA interactions at the IL-2 
locus was assessed by quantitatively comparing band intensities 
in different in vivo DMS-treated and naked DNA samples (Fig. 
4). First, note that many sites in the IL-2 promoter/enhancer 
showed footprints in EL4 T-lymphoma cells upon induction. 
Comparison of the G ladder generated from IL-2-transcribing, 
induced EL4 T cells (Fig. 4A, lane 5; Fig. 4B, lane 6) with the 
G ladder from the same cells prior to induction (uninduced 
EL4 T cells; Fig. 4A, lane 4; Fig. 4B, lane 5) revealed many 
differences in DMS reactivity. Each interaction, indicated at 
the margins of Fig. 4 and summarized in Fig. 5, involves just a 
few specific G residues, as expected for a DMS footprint. 
These footprints were highly reproducible in multiple indepen-
dent experiments. 
Each interaction corresponds to a sequence-specific binding 
activity that can be detected in vitro in an electrophoretic 
mobility shift assay, with the exception of one site not yet 
tested. In vivo footprints were found at previously identified 
NF-AT (both -280 and -135), AP-1 ( - 150), OCT/OAP40 
(- 70 to - 85), and NF-KB (- 200) recognition sites, all of 
which have been shown to be functionally important by 
cis-element mutagenesis experiments (2, 7, 17, 37, 44). In vivo 
footprinting also confirmed the occupancy of a CACCC site 
(- 294) described elsewhere (5) and revealed interactions at 
two previously unidentified elements, a proximal CACCC 
motif (- 60) and a TGGGC site (- 225). The ability of each of 
these elements to bind sequence-specific factors from nuclear 
extracts in vitro was demonstrated in Fig. 2 and 3. An 
additional interaction was detected at an ATGG site (- 175), 
which has not yet been examined in vitro. Finally, an interac-
tion was seen between the two IL-2 TATA boxes, which may 
reflect the assembly of the basic RNA polymerase II machinery 
in that region. Occupancy of all these sites was detectable after 
1 h of induction and was maximal by 2 h (Fig. 6A and data not 
shown). Representative footprints at the distal NF-AT site, the 
NF-KB site, and the proximal AP-1 site after 2 and 5 h of 
induction are shown in Fig. 6A. Footprints persisted at maxi-
mal levels until at least 11 h after induction, as shown in Fig. 6B 
for the proximal AP-1 site, the proximal NF-AT site, and the 
OCT/OAP40 site. 
Conversely, several other potential regulatory elements were 
not detectably occupied in the major groove in vivo. We failed 
to detect contacts at the G residues in the distal octamer motif 
at -255, the distal AP-1 motif at -180, and the region 3' of 
the distal NF-AT core at - 280 (3' NF-AT site), whose 
counterparts in the human gene, though not perfectly homol-
ogous to the murine elements, have been shown to contribute 
to the function of the human IL-2 gene (17, 18, 42). In these 
cells, no clear evidence was found for the binding of factors to 
the CD28 response element either, although protection was 
seen at the junction of this site with the proximal AP-1 site. 
This is consistent with observations that the CD28 response 
element plays no role in IL-2 induction in response to TPA-
A23187 inductio11 in the human Jurkat T-cellline (11). Though 
in vivo footprints were performed up to 24 h after induction 
(data not shown), no major groove interactions were detected 
at the G residues in the putative negative element at - 105, 
proposed to decrease induced transcription of the human IL-2 
gene by functioning to shut off IL-2 transcription at later time 
poin.ts (50). Thus, for several potential regulatory elements, we 
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FIG. 6. (A) OMS in vivo footprints over representative binding sites at 2 and 5 h of induction. DNA from in vivo OMS-treated uninduccd EL4 
cells (Jane 1 ). EL4 cells induced for 2 h (lane 2), and EL4 cells induced for 5 h (lane 3) was used. Lant! 2 was exposed for 20% longer than lanes 
I and 3 to compensate for underloading of that lane. (B) OMS in vivo footprints over representative binding sites between 4 and 11 h of stimulation. 
DNA from in vivo OMS-treated unstimulated EL4 ce lls (lane 2). EL4 ce lls stimulated for 4, 7, 9, and I I h (lanes 3, 4, 6, and 8), and EL4 cells 
stimulated in the presence of CsA for 7, 9, and 11 h (la nes 5, 7, and 9) was used. Naked E L4 DNA (Jane 1 ), treated with OMS in vitro, was also 
used. The entire set of interactions shown in Fig. 4 was seen in these experiments. All were of equal relative intensity in the induced samples, but 
only a subset are shown here. 
see no in vivo evidence that they play a role in IL-2 transcrip-
tional regulation in mouse EL4 T cells. 
No protein-DNA interactions were detected in unstimulated 
EIA T cells, 32D premast cells, or L cells. In principle, cells 
that are not transcribing IL-2 might have stably bound repres-
sors at the IL-2 locus or partially assembled enhancer com-
plexes. Furthermore, a developmentally committed but as yet 
uninduced IL-2 producer (EL4 T cell) might reveal its com-
mitted status in the form of a pattern of protein-DNA inter-
actions different from that of an IL-2 nonproducer (32D cell or 
L cell). Finally, an activated 32D cell might in principle 
asse mble partial protein-DNA complexes at the IL-2 locus, 
reflecting its partial content of inducible IL-2 DNA-binding 
activities. However, we detected no in vivo protein-DNA 
interactions in any of the nonexprcssing cells examined, includ-
ing unstimulated EL4 T cells, 32D cells, and L cells (data not 
shown), as well as stimulated 32D cells. This conclusion was 
d rawn by comparing the G ladders derived from naked DNA 
samples with those from in vivo samples. The naked DNA 
samples (Fig. 4A, lane 3; Fig. 4B, lanes 1 and 4) were very 
similar to the in vivo samples from cells not actively expressing 
IL-2 (Fig. 4A, lanes l , 2, and 4; Fig. 4B, lanes 2, 3, and 5). The 
only changes in DMS reactivity between naked DNA samples 
and these in vivo OMS-treated samples were observed on the 
coding strand near - 100 and -200, where several G's were 20 
to 25% hyperreactive in all the in vivo samples. However, the 
complete absence of associated protections is not typical of 
most protein-DNA inte ractions, and no interactions of any sort 
were detected at adjacent bases on the noncoding strand. Such 
isolated hypersensitivities have sometimes been encountered 
in comparisons of naked D NA versus in vivo DMS-treated 
DNA for other genes, and the ir significance remains unknown 
(20, 29). More importantly, all e leme nts in the pattern of 
interactions seen in the induced EL4 T cells are entirely absent 
in the nonexpressing cells. For example, the NF-KB site is 
unoccupied even in stimulated 32D cells, though ample levels 
o f NF-KB-binding activities (including putative NF-KC) are 
present in nuclear extracts from these cells. Furthermore, no 
interactions are apparent elsewhere in the IL-2 regulatory 
region in nonexpressing cells. This absence of detectable in 
vivo binding contrasts with the presence of corresponding 
DNA-binding activities in the nuclei of these cells. 
CsA treatment entirely blocks protein-DNA interactions in 
stimulated EIA T cells. IL-2 transcription can be completely 
inhibited by CsA treatment, although individual IL-2 regula-
tory elements show diverse sensitivities to the drug. This could 
result from CsA totally blocking the binding of both CsA-
sensitive and -insensitive factors to the DNA or through the 
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elimination of a subset of DNA-bound activators sufficient to 
prevent transcription. When EL4 T cells were stimulated with 
TPA and A231R7 in the presence of CsA. all footprints 
associated with IL-2 induction were absent (Fig. 4A, lane 7: 
Fig. 4B, lane R; Fig. 6B, lanes 5. 7, and 9). Thus, CsA blocks the 
in vivo binding of all detected factors to the IL-2 regulatory 
region, despite affecting the in vitro binding activities of only a 
few. Therefore, at least one CsA-scnsitive component of the 
EL4 response is required for the coordinated binding of all 
factors. 
The results presented above show that CsA blocks the 
establishment of stable occupancy at the IL-2 regulatory 
region. We next addressed whether CsA has an effect on the 
maintenance of stable occupancy after it has been established. 
Addition of CsA to preactivated EL4.E1 cells is known to 
abort IL-2 expression almost immediately (38). This effect 
might be due to the partial or complete loss of hound factors. 
Alternatively, the binding of factors, o nce established, might be 
insensitive to CsA treatment, with delayed CsA treatment 
instead inhibiting the ability of these bound factors to activa te 
transcription. As shown in Fig. 6, maximal levels of regulatory 
region occupancy are obtained after 2 h of TPA-A23187 
stimulation and persist at these levels for at least an additional 
9 h. Thus, CsA was added after 2 h of stimulation ("late" in 
Fig. 4). When prote in-DNA interactions were examined 7 h 
later the delaved CsA treatment had resulted in the elimina-
tion ~f all footprints (Fig. 4A, lane 8; Fig. 4B, lane 9). In the 
absence of CsA, regulatory region occupancy was still maximal 
at this time point. Thus, CsA blocks both the establishment 
and the maintenance of the protein-DNA complex at the IL-2 
promoter/enhancer. 
The absence of in vivo protein-DNA interactions in cells that 
do not express IL-2 is gene specific. The conclusion that 
unstimulate d EL4 T cells, CsA-treated stimulated EL4 T cells, 
and 32D cells show none of the in vivo interactions character-
istic of induced T cells required a positive control to show that 
the absence of IL-2 footprints is gene specific and not a simple 
artifact of toxicity, cell handling, or footprinting manipulations. 
This issue was addressed by using the same DNA preparations 
to footprint another gene, the MT-1 gene, which is expressed in 
all of these cell populations (Fig. 1). The characteristic in vivo 
footprint at the MT-1 locus Spl site was present in all samples 
(Fig. 7 and data not shown). 
DISCUSSION 
Regulation of the IL-2 gene is interesting on several levels. 
First, the stringency of its transcriptional regulation is extreme 
with respect to its developmental specificity and its rapid 
response to specific environmental signals. The well-estab-
lished complexity of IL-2 cis elements and of their cognate 
binding activities demands the integration of many less specific 
activities. How is this integration accomplished, and what 
p revents low-level, leaky expression? To address these issues, 
we have determined the nature of in vivo protcin- IL-2 gene 
complexes and compared them with the sets of nuclear fac~ors 
present in an informative group of cell lines. These cell l!nes 
represented different developmental lineages and were studied 
under different signal transduction states. A central result was 
that the level of regulation which directly correlated with active 
IL-2 transcription was enhancer occupancy by all factor types 
involved. This appeared to be an ali-or-nothing, reversible 
phenomenon. Insults to subsets of the binding activities to~ally 
abolished all interactions by those factors that remamed 
(summarized in Fig. 8). This places the burden of specificity on 
stable chromosomal occupancy. If t he whole protem-enhancer 
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FIG. 7. DMS in vivo footprint of the Spl -bi!lding site in the MT-1 
gene. DNA from in vivo OMS-treated unstimulated 320 cells (lane 2), 
stimulated 320 cells (lane 3 ). unstimulated EL4 cells (lane 5), stimu-
lated EL4 cells (lane 6). and EL4 cells stimulated in the presence of 
CsA (lane 7) was used. Naked 320 DNA (lane 1) and naked EL4 DNA 
(lane 3), each treated with DMS in vitro. were also used. 
complex must be assembled on the DNA in order to achieve 
stable occupancy by any subset of the factors, stringent limita -
tions are imposed on when and where transcriptional activa-
tio n occurs. We also infer that it is this highly coordinated 
assembly that satisfies the biological requirement that the IL-2 
enhancer/promoter be robust when act ivated yet very sensitive 
to multiple signal inputs. As discussed below, this provides an 
explanation for the previously observed sensitivity of this 
enhancer/promoter to mutagenesis of individual elements. 
Thus, while it remains possible that the transcription-inducing 
activities of some of these factors are also regulated after they 
bind to DNA, regulation of stable occupancy dominates. 
The study of IL-2 transcriptional control also presents the 
potential for separation of developmental restriction from the 
actual induction of expression. In this respect, IL-2 differs from 
several other developmentally restricted genes that have pre-
viously been studied in this way. In those systems, differentia-
IL-2 REGULATORY REGION 
·300 NF-AT TGGGC ' 200 ATGG NF·AT 
·1 00 CACCC 
CACCC AP·1 OAP40/0CT 
IN VIVO PROTEIN: DNA INTERACTIONS TRANSCRIPTION 
Uninduced EL4 T Cells 
No 
Induced EL4 T Cells 
Yes 
Induced, cyclosporin A·treated EL4 T Cells 
• No 
FIG. 8. Summary of the protein-DNA interactions detected in EL4 
T lymphoma cells by in vivo footprint analysis and the presence of 
nuclear factors in these cells as determined by in vitro DNA-binding 
ana lysis. Decreased size of TGGGC- and NF-KB-binding activities in 
stimulated. CsA-trcatcd EL4 ce lls depicts the quantitative decrease in 
in vitro DNA-binding activity in Fig. 2. OAP4U activity could not be 
detected in Fig. 2, bu t its presence in stimulated EL4 ce lls was inferred 
because of the in vivo methylation protection of a G residue adjacent 
to the octamer motif which specifically disrupts OAP40 binding when 
methylated (44). Stimulation-dependent OAP40 binding activity has 
been detected in the human Jurkat T-ccll line, but its CsA sensitivity 
was not examined (44). The ATGG site was not assayed for in vitro 
b inding activity. 
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tion of the cell was temporally and physiologically coupled to 
expression of the gene; for example. muscle creatine kinase is 
expressed upon differentiation of myoblasts into myocytes. 
Because differentiation of T-hclper cells is separated from 
their activation to express IL-2, it seemed possible that in this 
system. there might be factor-DNA interaction at the IL-2 
locus in T cells prior to act ivation that would distinguish them 
from non-T cells. thereby setting the stage fo r the induction 
event. Alternatively, such developmental marking might take 
the form of specific repressing interactions present in non-T 
lineages a nd then removed in T cells. We tested these possi-
bilities by comparing in vivo prote in-DNA interactions in T 
cells with those in other hematopoie tic and nonhcmatopoictic 
cells prior to induction. No evidence was found fo r stable, 
lineage-dependent molecular commitment at the IL-2 locus. 
Thus, the cell-specific competence of the IL-2 locus to be 
induced could not be detected a t the level of protein-DNA 
contacts in the majo r groove. In addition, even a potent 
act ivation cascade could not trigger any protein-DNA contacts 
in the nonpermissive developmental environment of the 32D 
cells. It is important to recognize that these observations do 
not rule out the possibility of repressive o r permissive interac-
tions to which DMS was insensitive, such as binding of proteins 
in the minor groove or to recognition sites devoid of G 
residues. Thus, the possible involvement of factors such as 
TCF-1 and TCF-la/LEF-1 (43, 46, 48) remains to be investi-
gated. However, the compelling result is that there was no 
evidence, in any nonexpressing cell examined, of in vivo 
occupancy of those sites that ultimately do become occupied in 
IL-2-expressing T cells. This finding argues strongly against 
straightforward competition between activator and repressor 
proteins for binding site contacts in the major groove as a way 
of enforcing cell-type- and signal-dependent restriction of IL-2 
in these cells. 
CsA was used as a pharmacological tool to probe separately 
the sensitivity of complex establishment and complex mainte-
nance to the presence of CsA-sensitive factors. One or more 
CsA-sensitive factors were required for the stable binding of all 
factors, a finding consistent with the functional requirement 
fo r CsA-sensitive regulatory elements such as NF-AT deter-
mined by cis-element mutagenesis studies (7, 32, 42). But such 
mutational analyses cannot separate a transient need for an 
activity from a sustained requirement for it. The possibility that 
establishment of an active enhancer-protein complex can be 
functionally separated from its ongoing maintenance has prece-
dent. For example, a "hit-and-run" -style mechanism has been 
proposed for the tyrosine aminotransferase gene whereby 
interaction of the glucocorticoid receptor is appare ntly tran-
sient, being needed only to initiate hormonally responsive 
expression, with other e lements driving ongoing maintenance 
and activity of the complex (34). By analogy, CsA, which has 
been shown to block initial translocation of NF-AT compo-
nents to the nucleus (10), could act on the initiation of 
occupancy but not interfere with its maintenance. However, 
CsA treatment of cells containing preassembled complexes 
clearly showed that these complexes are not stable over the 
time course tested. Thus, one or more CsA-sensitive factors 
are required for the persistence of stable binding by all other 
factors. Furthermore, unless an unknown effect of CsA is the 
active disassembly of protein-DNA complexes, the complexes 
that we observe in footprints are not static but arc instead in a 
dynamic equ ilibrium with nuclear factors. Mechanistically, the 
loss of in vivo binding shows that either a CsA-scnsitive 
factor(s) functions through cooperative binding inte ractions 
with CsA-insensitive factors or, alternatively, if CsA-sensitive 
factors regu late the region's accessibility, this opening is 
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readily reversible and depends on the CsA-sensitive factors for 
its persistence. 
Within the IL-2 enhancer. we identified new TGGGC and 
proximal CACCC elements whose functions can be addressed 
in par·t by reexamining previously published de letion mutant 
studies. A nested series of 5' deletion constructs o f the mouse 
I L-2 gene displayed a fivefold drop in inducibility in EL4 T 
cells when 36 bp including the TGGGC motif was eliminated 
(37). T his region contains no other clement which showed an 
in vivo interaction in our analysis (Fig. 4). An internal deletion 
across the proximal CACCC motif in the human IL-2 gene 
decreased activity of the otherwise intact enha ncer fivefold, 
though thi s deletion includes the distal TAT A box, and 
alterations in spacing could have contributed to the effect (7). 
Thus the protein-DNA contacts at the newly identified ele-
ments, like those at the previously described clements, appear 
to contribute to IL-2 expression. 
Either of two models, which are not mutually exclusive, 
could explain the coordinated binding observed at the IL-2 
locus: cooperative binding or limited site accessibili ty. Coop-
erative binding interactions between the multiple DNA-bind-
ing proteins that can interact with individu al cis clements, 
pe rhaps anchored by a few key factors, would stabilize the 
binding of each member of the complex. Such cooperativity 
could operate through direct interactions of the DNA-binding 
factors with each other as well as through additional, as yet 
unidentified proteins which would act through protein-protein 
interact ions with the DNA-binding factors. At a minimum, 
inducible, T-cell-spccific, CsA-sensitive factors would be lim-
iting for stable complex assembly, but other factors, not 
limiting in any case studied here, could be equally essential. 
O ne coopera tive interaction has been already documented 
for the IL-2 regulatory region at the OCT/OAP40 element, 
where co-occupancy by OAP40 and Oct-1 stabilizes the bind-
ing of Oct-! (44). Additional evidence also suggests that the 
binding of factors to the IL-2 NF-KB element is stabilized when 
the adjacent AP-1 site is included in the target DNA sequence 
(31). It will now be important to look fo r such interactions 
more broadly between the multiple clements in IL-2. Evidence 
consistent with cooperativity as a substantial component of 
IL-2 transcriptional control a lso comes from cis-element mu-
tational analysis, in which individual a lteration of any of a 
number of different sites strongly decreases overall promoter/ 
enhancer activity (7, 17, 18, 37, 42, 44). However, those 
experiments did not address whether the collaborative cfl'ect 
was at the level of DNA binding or at the level of transcrip-
tional activation. An addi tional feature of the IL-2 regulatory 
region that may especially favor dependence on cooperative 
interactions is that, as noted by Hcntsch et al. (15), the 
multiple si tes in IL-2 for general factors, such as NF-KB and 
AP-1, deviate significantly from their respective consensus 
sequences. These changes decrease the binding affinity of the 
major species detected in gel shifts and may render them 
especially dependent on interactions with nearby factors to 
bind in vivo. 
By contrast, regulated site accessibility is envisioned to 
involve the masking of potential binding sites near IL-2 in a 
repressed chromatin configuration. In this case, the act ion of 
inducible factors could serve to open the region, thus allowing 
a ll of the proteins to interact with their binding sites. These two 
models differ in the roles that they ascribe to activation-
dependent, T-cell-specific, CsA-sensitive factors like NF-A T. 
In one case, they are needed as architectural elements that act 
strictly in concert with the other factors; in the other case, t hey 
have a unique role which all other interactions depend on and 
follow. The disappearance of existing complexes upon the 
216!1 GARRITY ET AL. 
de layed addition of CsA is consistent with either model. 
However, it does require that if chromatin accessibili ty a lone is 
used to regulate prote in -DNA contacts at IL-2, the increase in 
accessibility must be fully reversible. Further examination of 
the relative contributions of binding cooperat ivity and si te 
accessibi lity should reveal the mo lecu lar detail s of the ob-
served coordinated assembly controlling !L-2 t ranscription. 
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Summary 
Elevation of cAMP can cause gene-specific inhibition of interleukin 2 (IL-2) expression. To investigate 
the mechanism of this effect, we have combined electrophoretic mobility shift assays and in vivo 
genomic footprinting to assess both the availability of putative IL-2 transcription factors in forskolin-
treated cells and the functional capacity of these factors to engage their sites in vivo. All observed 
effects of forskolin depended upon protein kinase A, for they were blocked by introduction of 
a dominant negative mutant subunit of protein kinase A. In the EL4.E1 cell line, we report 
specific inhibitory effects of cAMP elevation both on NF-KB/ Rel family factors binding at -200 
bp, and on a novel, biochemically distinct "TGGGC" factor binding at - 225 bp with respect 
to the IL-2 transcriptional start site. Neither NF-AT nor AP-1 binding activities are detectably 
inhibited in gel mobility shift assays. Elevation of cAMP inhibits NF-KB activity with delayed 
kinetics in association with a delayed inhibition of IL-2 RNA accumulation. Activation of cells 
in the presence of forskolin prevents the maintenance of stable protein-DNA interactions in vivo, 
not only at the NF-KB and TGGGC sites of the IL-2 enhancer, but also at the NF-AT, AP-1, 
and other sites. This result, and similar results in cyclosporin A-treated cells, imply that individual 
IL-2 transcription factors cannot stably bind their target sequences in vivo without coengagement 
of all other distinct factors at neighboring sites. It is proposed that nonhierarchical, cooperative 
enhancement of binding is a structural basis of combinatorial transcription factor action at the 
IL-2 locus. 
Activation ofT helper cells results in secretion of diverse 
.fl. lymphokines. The precise combination oflymphokines 
produced is variable, depending on the circumstances of the 
activation process. Different effector mechanisms are triggered 
by different lymphokines. Locally and systemically, the rela-
tive levels of different lymphokines with respect to one an-
other strongly affect in vivo outcomes. Thus, the type of im-
mune response that is mobilized ultimately depends on the 
differential transcriptional regulation of lymphokine genes. 
The major stimulatory signal for lymphokine production is 
delivered by engagement of the TCR with antigen in the 
context of MHC on APCs. However, engagement of acces-
sory molecules on the T cell with additional ligands, either 
on APCs or in the microenvironment, may also deliver other 
kinds of signals that affect lymphokine gene expression 
differentially. Expression of the T cell growth factor, IL-2, 
is particularly susceptible to this kind of modulation. Glucocor-
ticoids inhibit IL-2 induction preferentially (1-3), and con-
tact of aT cell with antigen in the absence of a CD28 ligand 
can drive the T cell into an anergic state in which IFN-')' 
can be expressed, but not IL-2 (4, 5). Agonists that elevate 
cAMP levels, such as prostaglandin E1 and Ez, give especially 
clear evidence for selective inhibition of IL-2 expression (6, 
7), as they can inhibit IL-2 expression in cases where there 
is no inhibition of IL-4 expression at all (8-10). The effects 
of cAMP on T cells can be exerted at both cell- and gene-
specific levels, depending on the cells and stimuli used . In 
certain IL-2-producing cells, cAMP elevation can uncouple 
the TCR/ CD3 complex from its downstream signaling medi-
ators, preventing the generation of Ca2+ and protein kinase 
C signals (11- 13). On the other hand, even when Ca2 + and 
protein kinase C signals are provided pharmacologically, cAMP 
elevation can still interfere selectively with induction of IL-2 
gene expression, yet allowing other responses to proceed. It 
is the mechanism of this second, gene-specific effect that we 
investigate here. 
The IL-2 gene regulatory region consists of compact, 
clustered binding sites for an assortment of transcription factors 
that are disparately regulated (14). In most or all cases studied, 
IL-2 expression is induced only when all the known factors 
are present, and the IL-2 promoter only works at maximal 
efficiency w hen all the major binding sites for these factors 
are intact . H owever, in physiological situations, data seem 
to indicate that certain factors play more critical roles than 
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others. Two of them, AP-1 and NF-AT, appear repeatedly 
to be rate limiting for IL-2 expression. When selective down-
regulation of IL-2 production is caused by exposing T cells 
to glucocorticoids, the possible mechanisms are a protein-pro-
tein interaction that sequesters AP-1 by dimerization of AP-1 
components with the glucocorticoid receptor (2), or a specific 
inhibition of interaction between AP-1 and NF-AT (3). When 
IL-2-producing cells have been anergized and become un-
able to express IL-2, their failure appears to be due to either 
a general block ofNF-AT, NF-KB, and AP-1 activation (15), 
or a selective inability to activate AP-1 (16). The potent 
immune-suppressive drugs cyclosporin A (CsA)1 and FK 506 
completely block IL-2 transcription by blocking the nuclear 
translocation of one component ofNF-AT (17). Whereas this 
is an example of strictly pharmacological inhibition, defects 
in both NF-AT and AP-1 mobilization also appear to be 
responsible for a normal developmental block in the ability 
to express IL-2, namely in cortical thymocytes (18) . A similar 
phenotype is observed in a pre-mast cell line that can express 
IL-4 but not IL-2 (19). Thus, an important question is whether 
all physiological regulation of IL-2 expression is exerted 
through effects on AP-1 or NF-AT, or whether cAMP-
elevating agonists might inhibit IL-2 expression through effects 
on different factors. 
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To address these questions, we have chosen EL4.E1 thy-
moma cells as a model T cell system, and the Ca2 + iono-
phore A23187 and the phorbol ester PMA (TPA) as stimulants 
that can bypass any effects of cAMP on signal generation at 
the cell membrane. Using this system previously, we showed 
that cAMP could inhibit IL-2 transcription (9). We also ob-
tained initial indications that elevation of cAMP caused a slight 
decrease in the binding activity of NF-KB, but did not in-
hibit NF-AT or AP-1 site binding activities (20). In our present 
studies, we have clearly defined two specific effects of cAMP 
on factor-binding activities and examined the resulting pro-
tein-DNA interactions at the IL-2locus in vivo. Our results 
confirm that cAMP, acting via activation of protein kinase 
A (PKA), selectively affects the in vitro DNA binding ac-
tivities of NF-KB and a newly described TGGGC binding 
factor, and that it does so with novel and distinctively delayed 
kinetics. No evidence was found for any negative effect on 
NF-AT or AP-1 binding. However, cells stimulated in the 
presence of forskolin failed to sustain stable protein-DNA con-
tacts at a broad array of sites spanning the entire IL-2 en-
hancer region. T he lack of occupancy may be evidence for 
a new role for NF-KB and TGGGC binding activities, as re-
quired partners in transcription complex assembly. 
Materials and Methods 
Cells. EL4.E1 cells (EL4) were grown in RPMI-1640 in the 
presence of2 mM L-glutamine, 50 mM /3-ME, antibiotics, and 6% 
1 Abbreviatiotls used in tlris paper: CsA, cyclosporin A; DMS, dimethyl 
sulfate; EMSA, electrophoretic mobility shift assay; PKA, protein kinase 
A; TPA, 12-0 -tetradecanoyl phorbol 13-acetate (PMA). 
fetal bovine serum (Hyclone, Logan, UT). Cells were cultured to 
confluence before stimulation and were stimulated at 1-2 x 106 
cells/ml using 17 nM TPA and 120 nM A23187 in the presence 
or absence of 10 /LM of forskolin (Sigma Chemical Co., St. Louis, 
MO), which raises the cAMP level by directly activating adenylate 
cyclase. Recombinant human IL-1a (Genzyme Corp., Cambridge, 
MA) was used at SO U/ml. 
IL2 Analysis. RNase probe protection analysis to quantitate 
IL-2 RNA was performed as previously described (19, 21). For each 
sample, 10 /Lg of RNA was used to hybridize with the IL-2 probe 
(22), and 1 /Lg RNA was used to hybridize with either an actin 
or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe (23). 
Cyclic AMP Assay. Levels of cAMP were measured in EL4 cells 
as described previously using an Amersham dual-range cAMP kit 
(9), except that nonacetylated standards and samples were used. 
Gel Mobility Shift Assays. Nuclear extracts of EL4 cells were 
prepared as before (18). Double-stranded oligonucleotide corre-
sponding to portions of the mouse IL-2 gene regulatory region were 
labeled by end filling with a-[32P]deoxynucleoside triphosphates. 
The detailed sequences and corresponding sites relative to the tran-
scription start site were described elsewhere (18-20). Oligonucleo-
tides used for this experiment were synthesized in the California 
Institute of Technology Biology Microchemical Facility. The binding 
reaction and gel electrophoresis procedures were exactly as reported 
before (18). Note that these conditions for detection of NF-AT site 
binding activity differ from those we used in initial studies (20), 
as poly (di-dC) is used as a nonspecific competitor in place of poly 
(dA-dT) . In our hands, this substitution yields a spectrum of gel-
shift complexes more consistent with NF-AT complexes described 
elsewhere, and less dominated by highly protease-sensitive com-
plexes. However, the insensitivity of NF-AT site binding factors 
to forskolin reported in our earlier study (20) is confirmed here. 
In vivo Footprinting Analysis. The genomic footprinting anal-
ysis was done as before with the same set of IL-2 gene primers pre-
viously reported (19). Briefly, 3 x 107 cells were concentrated into 
1 ml medium, and treated with 0.1 o/o of dimethylsulfate at 37°C 
for 1 min. The reaction was stopped by transferring the cells to 
a tube containing 49 ml of ice-cold PBS, and the cells were pelleted 
and washed once more with 50 ml PBS. The cell pellet was then 
resuspended in 3 ml of lysis buffer (300 mM NaCl, SO mM Tris, 
pH 8.0, 2S mM EDTA, pH 8.0, 200 /Lg/ ml proteinase K, and 0.2% 
SDS), and incubated at 37°C overnight. Nucleic acids were obtained 
by phenol/chloroform extraction and isopropanol precipitation, then 
subjected to piperidine cleavage and subsequent ligation-mediated 
PCR (24). The final labeled PCR products were separated on a 
6% polyacrylamide sequencing gel. 
Transfection and Selection. 10 /Lg of linearized HL-REV ABpKOneo 
(designated p~PKA in the text) (a gift from G. S. McKnight, 
University of Washington, Seattle, WA) was electroporated at 960 
ILF and 320 V into 107 EL4.E1 cells in 1 ml of serum-free RPMI-
1640 medium with supplements and 14.4 mM /3-ME. The cells 
were then diluted into 50 ml of medium and plated in two 24-well 
plates (1 mllwell). 2 dafter plating, G418 (GIBCO BRL, Gaithers-
burg, MD) was added to the wells at 400 /Lg/ml. Positive wells 
were identified 7- 10 dafter selection and the cells were expanded 
in 200 /Lg/ml G418 for further analysis. The plasmid DNAs, pBR322 
and pSV2neo (2S), were used in transfection as negative and posi-
tive controls. Integration of the mutant PKA construct in estab-
lished transfectant lines was confirmed by Southern blot analysis 
and its expression was further confirmed by Northern blot anal-
ysis. One mutant PKA transfectant line, IIA4, and two pSV2neo 
control lines were used in the subsequent experiments. 
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Results 
Forskolin Affects DNA-binding Activities of a Specific Subset 
of Factors. To investigate the effects of cAMP on IL-2 tran-
scriptional control, EL4 cells were stimulated with TPA+ 
A23187 in the presence or absence of 10 J.tM of forskolin, 
and the IL-2 mRN A level in the cells was examined 5 h after 
induction (Fig. 1 A). Addition of forskolin to the 
TPA+A23187 stimuli significantly decreased the level of iL-2 
mRNA (Fig. 1 A, lane 3). In previous work (9), we reported 
that forskolin could also inhibit inducible expression of a 
reporter gene under the control of the minimal 321-bp IL-2 
promoter/enhancer. This indicated that at least part of the 
effect of forskolin was mediated through the 5' regulatory 
sequence of the IL-2 gene, presumably at the level of tran-
scriptional initiation, and that the "-'300 bp minimal pro-
moter/enhancer sequence was sufficient to produce this re-
sponse. Therefore, to determine the mechanism of the forskolin 
A ~ 
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GAPDH ------.. ; . -1 2 3 4 
B NF-ICB TGGGC 
+ F + F 
• 
- .. M -
1 2 3 4 5 6 
c NF-ATd NF-ATp AP-1 
+ F + F + F 
- -.. -
f -
1 2 3 4 5 6 7 8 9 
933 Chen and Rothenberg 
130 
inhibition effect, we focused on protein-DNA interactions 
in this 300-bp region. 
To ascertain whether forskolin inhibits the binding of par-
ticular factors to the IL-2 regulatory region, we compared 
the levels of most DNA binding activities known to be cor-
related with IL-2 gene activation in nuclear extracts from 
stimulated cells and from cells stimulated in the presence of 
forskolin. Nuclear extracts were prepared from EL4 cells in-
cubated under different conditions for 4-5 h, and these ex-
tracts were analyzed for sequence-specific binding activities 
by electrophoretic mobility shift assays (EMSAs) (Fig. 1, B 
and C). Double stranded oligonucleotide probes were chosen 
to span all the major sites of protein-DNA contact in IL-
2-producing EL4 cells, as previously identified by in vivo foot-
printing (19). As shown in Fig. 1 C, the DNA binding ac-
tivities of factors that are constitutively present, such as the 
Figure 1. IL-2 expression and nuclear DNA-binding activities in EL4 
cells after stimulation in the presence or absence of forskolin. (A) RNase 
protection analysis of IL-2 RNA expression. Total cytoplasmic RNA (10 
ttg) from unstimulated cells (lane 1 ), from cells stimulated for 5 h (lane 
2) with TPA+A23187, or from cells stimulated for 5 h with TPA+A23187 
in the presence of forskolin (lane 3), or 30 ttg of yeast tRNA (lane 4) 
were hybridized with IL-2 probe or a control GAPDH probe and quanti-
tated by ribonuclease protection assay. (B) EMSAs of NF-KB and TGGGC 
DNA-binding activities. Corresponding nuclear extracts from the same 
populations of EL4 cells used in A were tested for NF-KB (lanes 1- 3) and 
TGGGC (lanes 4-6) site binding activities. (C) EMSAs of other factors. 
Nuclear extracts corresponding to the same three populations (unstimu-
lated, lanes 1, 4, 7, 10, 13, and 16; stimulated, lanes 2, 5, 8, 11, 14, and 
17; and stimulated for 5 h in the presence of forskolin for 5 h, lanes 3, 
6 , 9, 12, 15, and 17) were compared for binding activities to the distal 
NF-ATd site (lanes 1-3), the proximal NF-ATp site (lanes 4-6), the AP-1 
site (7-9), the distal CACCCd site (lanes 10-12), the proximal CACCCp 
site (lanes 13- 15), and proximal octamer (16-18) sites. Large arrowheads 
in B and C indicate the major complexes at each site. At the Oct site, 
the complexes are likely to represent Oct-1, Oct-2B, and Oct-2A. Minor 
complexes at the CACCC site (small arrowheads) are discussed in the text. 
(-) Unstimulated; ( +) stimulated; and (F) stimulated in the presence of 
forskolin. 
CACCCd CACCCp Oct 
+ F + F + F .... _ - ---_ ... _ 
10 11 12 13 14 15 16 17 18 
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major binding factors for the CACCC sites (18, 19), and the 
proximal octamer site, were not affected by forskolin (Fig. 
1 C, lanes 10-18, large arrowheads). Similarly, some induction· 
dependent activities, such as the major inducible complexes 
binding the NF-AT and AP-1 sites, were unaffected or even 
slightly enhanced by stimulation in the presence of forskolin 
(Fig. 1 C, lanes 1-9, large arrowheads). These results are in 
agreement with our previous conclusions from more limited 
studies (20) . However, as shown in Fig. 1 B, binding activi-
ties of several other inducible factors were significantly re-
duced in nuclear extracts from cells that were activated in 
the presence of forskolin. Most prominent among these were 
the upper complexes binding to the NF-KB and TGGGC sites 
(Fig. 1 B, lanes 2, 3 and 5, 6). In addition, we noted effects 
of forskolin on minor complexes binding the two CACCC 
sites, which in both cases were of faster mobility than the 
major CACCC complex (Fig. 1 C, lanes 11, 12, and 14, 15, 
small arrowheads). The identities of the lower inducible com· 
plexes bound to the CACCC sites are not known. They could 
not be competed by a consensus Sp-1 oligonucleotide as could 
the major CACCC binding complexes (18, and data not 
shown). The nature of the TGGGC binding factor is also 
not known. As it appeared to show a similar electrophoretic 
mobility to that of the upper NF-KB complex, it was sub-
jected to some further characterization. 
Although both NF-KB and TGGGC binding activities were 
coinhibited by forskolin, the protein components involved 
were clearly different . This was confirmed by the demon-
stration, (a), that the TGGGC and NF-KB binding sites could 
not cross-compete in mobility shift assays, and (b), by anti-
body supershift experiments in which anti-p65, anti-e-re!, 
and anti-pSO antibodies that could supershift or inhibit the 
NF-KB complexes were all completely unable to affect the 
TGGGC complexes (data not shown). Furthermore, whereas 
TNF-a could "rescue" NF-KB binding activity in cells stimu-
lated in the presence of forskolin, there was no rescue of the 
TGGGC factor (data not shown). These results, and data 
presented below, show that the regulation of activation of 
these two binding activities was different. 




The presence of forskolin during stimulation appeared to 
result in a reduction in the total amount of NF-KB complexes 
per cell, not simply a sequestration of NF-KB activity (26). 
This was shown both by Western blotting of nuclear and 
cytoplasmic extracts with antibodies against p65, pSO, and 
e-re!, and by using deoxycholate to dissociate NF-KBI IKB com-
plexes, thus revealing previously masked NF-KB binding ac-
tivities (27). Stimulation for 4 h led to a sharp increase of 
p65 / p50 and c-rel/pSO complexes in the nucleus, and this 
increase was profoundly antagonized by the presence of for-
skolin. However, there was no compensatory increase in NF-KB 
components or binding activities in the cytoplasm (data not 
shown). Thus, forskolin may inhibit NF-KB synthesis or pro-
mote NF-KB degradation. 
Delayed Inhibition of IL-2 Expression Via Delayed Inhibition 
of NF-KB. The effects of forskolin on NF-KB appear to be 
paradoxical, for it has been reported that PKA can activate 
NF-KB, and our own earlier study (20) did not show consis-
tent reduction of NF-KB binding at 2 h of forskolin treat-
ment. To clarify this contradiction, we did kinetic studies 
to see whether the reduction we observed here is an early 
event or a possible secondary effect. First, we examined the 
kinetics of cAMP elevation after forskolin treatment. A 
significant increase in cAMP levels could be seen 15 minutes 
after administration of forskolin, reaching a maximum within 
an hour. High levels of cAMP were then retained for up 
to 6 h of forskolin treatment (Fig. 2 A). The addition of 
TPA+A23187 did not affect the initial elevation or the later 
accumulation of cAMP (Fig. 2 B). Pretreatment of cells for 
2 h with TPA+A23187 before addition of forskolin also did 
not significantly affect the subsequent elevation of cAMP (Fig. 
2 C). The high levels of cAMP sustained for many hours made 
it possible that cAMP-dependent mechanisms could exert 
effects at late time points, not just immediately after stimu-
lation. 
In fact, the effects of forskolin on NF-KB and TGGGC 
binding factor induction showed strikingly different time 
courses. When cells were activated in the presence of for-
skolin, mobilization of the factors binding to the TGGGC 
C. Fonkolin chase 
• 
10'o L -'---'z- ..L..--'-4_......_--':6 10' o'---....L..--'2- ..L..--'-4--'-_..,6 101 o~....L..--'~~--'-4--':----';6 
Figure 2. Sustained elevation of cAMP as a func· 
tion of duration of forskolin treatment. The figure 
shows cAMP levels in EL4 cells that were cultured 
in the presence of forskolin alone (solid and dotted 
curve, A; solid curve, Band C); with TPA+A23187+ 
forskolin added simultaneously (dots, B); or with 
forskolin added (time 0) after 2 h of pretreatment 
with TPA+A23187 (dots, C). Levels of cAMP are 
also shown for IIA4 transfectants (see Fig. 4) that 
were cultured with forskolin alone (triangles, A). 
The incubation was stopped at different time points 
and cAMP was measured in aliquots of 105 cells. 
As a reference for the data in A-C, the data from 
EL4 cells treated with forskolin alone (A) were used 
hours 
to calculate the solid curve shown in all three panels. Individual data points were plotted as triangles or dots to compare with the solid curve. This 
comparison emphasizes the similarity in the kinetics of cAMP accumulations with or without stimulation. The experimental data for forskolin-treated 
EL4 cells (solid curve) are well-represented by the equation C(,) = K/ Kd - (K,/Kd - Co)exp( - K.It), where C(r) is the amount (fmol) of cAMP/ 106 
cells at time t (h). Co ( = 568 fmol/106 cells) is the amount of cAMP at t ime 0, K, ( = 1.6 x 104 fn10l1106 cells h) is the calculated cAMP synthesis 
rate constant in the presence of forskolin. Kd ( = 1.14 h- 1) is the cAMP decay rate constant, from which we compute t112 = 0. 79 h. 
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site was inhibited both at 2 and at 4 h of treatment (Fig. 
3 A, compare lanes 9 and 11, 12, and 14), indicating that 
this inhibition is an early event. However, when analyzed 
after 2 h of stimulation, NF-KB binding activities appeared 
to be induced equally well whether forskolin was present or 
not (Fig. 3 A, compare lanes 2 and 4). Only after at least 
4 h of stimulation in the presence of forskolin did we see 
the characteristic decrease of the NF-KB site binding activity 
(Fig. 3 A, compare lanes 5 and 7). These findings indicated 
that elevation of cAMP does not inhibit the initial dissocia-
tion of NF-KB from lKB or its subsequent nuclear localiza-
935 Chen and Rothenberg 
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Figure 3. Delayed inhibition of lL-2 RNA accumulation 
correlated with delayed inhibition of NF-KB binding activity. 
(A) NF-KB and TGGGC site binding activities were measured 
at different intervals of stimulation ([2]), in the presence 
(c::J), or absence of forskolin, as indicated in the bar graph 
over each lane. Note that it took 4 h of forskolin treatment 
to reduce N F-KB binding activity, whether forskolin addi-
tion was delayed or not (lanes 6 and 7), but only 2 h to reduce 
TGGGC binding activity significantly (lanes 10 and 11). (B) 
II.-2 mRNA levels at various times of stimulation were mea-
sured by RNase protection analysis. Data were collected from 
two independent experiments. (LLft) Cells stimulated for the 
indicated lengths of time in the absence (El) or presence ( + ) 
of forskolin from time 0. (Right) Forskolin and CsA chase 
experiments. All samples were stimulated from time 0. For-
B skolin ( + ) or CsA (0) was added to the culture 2 h after 
initiating the stimulation with TPA+A23187. 
tion. They also suggested either that the effects of forskolin 
on NF-KB were intrinsically subject to delay, or that NF-KB 
proteins only became susceptible to forskolin-dependent in-
hibition at some point at least 2 h after initial exposure to 
TPA+A23187. To test these possibilities, we first stimulated 
the cells with TPA and A23187 for 2 h, to make all the neces-
sary trans-acting factors available and initiate transcription of 
IL-2 RNA, then we introduced 10 JLM forskolin to the cul-
ture and continued the culture for another 2 or 4 h. As shown 
in Fig. 3 A (lanes 3 and 6), forskolin "chasing" for 2 h still 
had little effect on NF-KB binding, but chasing for 4 h greatly 
reduced the binding. These results suggested that PKA acti-
vation had an intrinsically delayed effect on NF-KB binding 
activity. 
The delayed and asynchronous effects of cAMP elevation 
on the NF-KB and TGGGC site binding factors were associated 
with delayed inhibition of IL-2 mRNA expression, as shown 
in Fig. 3 B. IL-2 mRNA accumulation in the stimulated con-
trol cells followed biphasic kinetics with a relatively low rate 
of accumulation in the first 2 h, which then shifted to a higher 
rate that was sustained for the next 4 h. When forskolin was 
present at the start of stimulation, IL-2 mRNA initially ac-
cumulated almost as fast as in the control cells without for-
skolin, but then declined to baseline between 2 and 4 h of 
stimulation (Fig. 3 B, left). When the addition of forskolin 
was delayed until after 2 h of stimulation, the rate of IL-2 
mRNA accumulation was significantly reduced as compared 
with the control samples without forskolin, and inhibitory 
effects were evident within the first 2 h of forskolin chasing 
(Fig. 3 B, right). However, this inhibition was slow as com-
pared with the immediate shut-off of IL-2 mRNA accumu-
lation when CsA, instead of forskolin, was added after 2 h 
of stimulation (Fig. 3 B, right) . Thus, some early effects of 
forskolin which inhibit IL-2 activation may be exerted be-
fore its effects on NF-KB, suggesting that a lack of factors 
other than NF-KB, including the TGGGC binding factor, 
may be sufficient to hinder the transcription but not to block 
it fully. The reduced NF-KB binding activity seen at rela-
tively later time points would then be associated with the 
complete arrest of IL-2 mRNA accumulation. 
Effects of Forskolin Are Mediated by PKA. Forskolin ele-
vates intracellular cAMP by directly activating adenylate cy-
clase, and cAMP in turn activates cAMP-dependent protein 
kinases (PKA). To ascertain whether all the effects of for-
skolin depend on the activation of PKA, we introduced a 
dominant negative mutant PKA regulatory subunit eDNA 
construct, driven by the Harvey sarcoma virus LTR, into EL4 
cells (28). The product encoded by this construct has two 
point mutations at cAMP-binding sites which block its binding 
to cAMP but still allow it to associate with the catalytic 
subunits in competition with endogenous regulatory subunits. 
Once bound, the mutant regulatory subunit will not dis-
sociate from the catalytic subunit in response to cAMP and 
therefore acts as a dominant negative regulator of PKA ac-
tivity. One stable transfectant line showing high expression 
of the mutant subunit, IIA4, and two pSV2neo transfectant 
control lines, were tested to compare their forskolin responses. 
As shown in Fig. 2 A (triangles), the introduction of the mu-
tant subunit had no effect on the ability of the cells to elevate 
their cAMP levels in response to forskolin. However, the mu-
tant subunit completely protected the induction of IL-2 
mRNA from forskolin inhibition in the IIA4 line, in con-
trast to the significant inhibition of IL-2 expression by for-
skolin in control lines as measured 4 h after stimulation (Fig. 
4 A). In agreement with its effects on IL-2 mRNA expres-
sion, expression of the dominant negative mutant PKA also 
relieved the inhibitory effects of forskolin on NF-KB and 
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Figure 4. Dominant negative mutant PKA transfected cells are resis· 
tant to the forskolin inhibitory effect. (A) Levels of 11-2 mRNA induced 
in two control lines of pSV2neo transfectants, IB2 and IB6, and in one 
line of mutant PKA transfectants, IIA4, were compared by RNase protec· 
tion analysis with 10 J.t.g of RNA from uninduced cells (- ), or cells after 
4-h stimulations ( +) in the absence or presence (F) of forskolin. 1 J.t.g of 
RNA from each sample was hybridized with actin probe to verify com· 
parability and integrity of the RNA. (B) Nuclear extracts from IIA4 cells 
were tested for NF-KB and TGGGC binding activities. All stimulations 
were for 4 h. (-) Uninduced; ( +) induced with TPA and A23187; (F) 
induced with TPA and A23187 in the presence of forskolin; (I) induced 
with TPA and A23187 in the presence of 50 U/ ml 11-1. 
binding complexes, and the two lower inducible CACCC 
binding complexes, were fully inducible in the mutant PKA-
containing cell line IIA4 whether forskolin was added or not 
(compare Figs. 4 Band 1 B; and data not shown). The binding 
activities of other factors in forskolin-treated IIA4 cells re-
mained the same as in cells stimulated without forskolin (data 
not shown). The mutant cells were not simply refractory to 
modulation of NF-KB activity, for they remained capable of 
upregulating their NF-KB site b inding activity upon stimu-
iation in the presence of 50 U I ml IL-1 (Fig. 4 B, lane 4) 
(20). Therefore, it is clear that PKA is a mediator of the in-
hibitory effects of forskolin on DNA-binding activities. 
Forskolin Inhibits Stable In Vivo Assembly of the IL-2 DNA-
Protein Complex. The highly selective effects of forskolin on 
particular DNA-binding activities raised the question of 
whether the binding activities that remain are capable of 
forming stable contacts with IL-2 regulatory DNA in the 
nuclei of forskolin-treated, stimulated cells. To resolve this 
issue, living cells were treated with dimethyl sulfate (DMS), 
which methylates G residues (met-G) in the major groove. 
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tect them from methylation or make them hypersensitive to 
methylation. The subsequent piperidine cleavage of the ex-
tracted DNA at met-Gs followed by ligation-mediated PCR 
amplification generates a G-specific sequence ladder. In fact , 
this technique has revealed specific major groove contacts at 
most or all of the sites known to be required for IL-2 expres-
sion (19). In agreement with the results we have shown pre-
viously (19), there is no obvious difference in the G ladder 
pattern between the DNA from DMS-treated, uninduced cells 
and naked control DNA which was DMS treated after 
purification (Fig. 5 A, lanes 1, 2, and 5). However, multiple 
footprints spanning almost the entire 300-bp upstream se-
quence were found in DNA from cells stimulated for 4 h 
with TPA+A23187 in the absence of forskolin, which cor-
responded to the well-characterized cis elements noted previ-
ously (Fig. 5, compare lanes 2 and 3 in A and lanes 1 and 
2 in B). Whereas these DMS footprinting results do not rule 
out some form of protein-DNA associations at the IL-2locus 
in uninduced cells, such associations clearly do not include 
the diagnostic, specific contacts that are formed at regula-
tory sites in induced cells. As noted above, these specific sites 
of occupancy define the oligonucleotide probes used in Fig. 
1. Each site was revealed in vivo by protection ( 0~). hyper-
sensitivity ( ..,.. ), or a characteristic pattern of both; ex-
amples are shown in Fig. 5 C. As previously discussed (19), 
G residues in the footprint are never completely protected 
from cleavage, and this effect is exacerbated by the asynchrony 
of IL-2 transcription in the stimulated population, in contrast 
with the more complete protection seen in the regulatory 
sequence of a constitutively expressed gene such as metal-
lothionein-1 (19, and data not shown). However, the pattern 
of protections and hypersensitivities at the IL-2locus in stimu-
lated cells was still highly reproducible. 
When examining the DNA from cells induced for 4 h in 
the presence of forskolin, pronounced differences from the 
characteristic induced pattern were noted. First, at almost 
every cis element, signs of occupancy were absent (Fig. 5, 
A, lane 4 and B, lane 3). Not only were the NF-KB and 
TGGGC sites empty, but the two NF-AT sites (Fig. 5 C), 
the AP-1 site and the proximal CACCC site also remained 
unoccupied, even though the factors binding these latter sites 
were present in the nucleus and were able to bind to their 
sites individually as shown by in vitro mobility shift studies 
(see above, Fig. 1). The global blockade of stable footprint 
formation is reminiscent of the CsA effect, which tightly 
shuts off IL-2 transcription and completely eliminates all evi-
dence for protein-DNA interaction in footprinting analysis 
(19 and see below). Only one sign of protein- DNA interac-
tion was consistently seen in the cells stimulated in the pres-
ence of forskolin: a persistent hypersensitivity at the 5'-most 
G in the distal CACCC element. The significance of this 
isolated feature, at the border of the known IL-2 enhancer, 
is unknown. 
The elimination of protein-DNA contacts in cells that had 
been stimulated in the presence of forskolin was dependent 
on PKA activity, as shown with DNA samples from mutant 
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PKA transfectants. Like the parental cells, IIA4 cells estab-
lished a full range of protein-DNA contacts in response to 
TPA+A23187 (Fig. 5, A, lane 6; B, lane 5). In contrast to 
the wild-type parental EL4 cells, treatment of IIA4 cells with 
forskolin did not affect any of the TPA+A23187-induced pro-
tections and hypersensitivities on the DNA sequence ladder 
(Fig. 5, compare lanes 4 and 7 in A and lanes 3 and 6 in 
B). Thus the disruption of protein-DNA contacts at the IL-2 
locus was a specific effect of PKA activation. 
The effect of cAMP elevation on protein-DNA contacts 
differed from that of CsA, described previously (19), in that 
the initial establishment of footprints proceeded normally in 
the presence ofTPA+A23187+forskolin, for example as mea-
sured after 2 h of stimulation (data not shown). The absence 
of footprints at the later time points thus reflected the net 
disassembly of preexisting complexes. To confirm the ability 
of forskolin treatment to block continuation of occupancy, 
we examined DNA samples from two independent forskolin 
chasing experiments (Fig. 6). In agreement with the binding 
studies and RNA analysis, the results showed that 2 h of 
forskolin chasing after 2 h of stimulation did not change the 
preexisting footprints formed after 2-h stimulation (Fig. 6, 
lane 3). By contrast, the same 2-h chase with CsA completely 
reversed the stimulated footprint pattern to an "uninduced" 
one (Fig. 6, lane 4). When forskolin chasing was extended 
to 4 h, however, a gradual weakening of protein-DNA in-
teractions was seen (Fig. 6, lane 9). Notably, footprints 
weakened at all sites concomitantly, with the unstimulated 
pattern reemerging as quickly at the NF-AT site as at the 
NF-KB site. Thus, even preformed IL-2 DNA-protein com-
plexes are not stable in vivo in activated cells without the 
continued contribution of forskolin-sensitive components. 
Discussion 
Agonists that elevate intracellular cAMP are likely modu-
lators of immune responses in vivo (6-10). We and others 
have previously shown that they selectively interfere with IL-2 
expression. Here we also report that the inhibition can follow 
a distinctively delayed time course, allowing an initial limited 
burst of IL-2 expression before transcription ceases. These 
qualitative and kinetic effects on cytokine gene expression 
resulting from the elevation of cAMP could be used in vivo 
to play a role in the shaping of a Th2 vs. Th1 response. 
In this work, we present molecular evidence for the way 
elevation of cAMP downregulates expression of the IL-2 gene 
in a model cell line. At least two transcription factors associated 
with IL-2 activation, including NF-KB and the newly de-
scribed TGGGC-binding factor, were specifically reduced in 
nuclear extracts from cells that were activated in the presence 
of forskolin. This pattern of transcription factor inhibition 
differed markedly from the patterns of inhibition by CsA treat-
ment or anergy induction, in that neither NF-AT nor AP-1 
binding activities were detectably reduced. With a closer look 
at protein-DNA interactions by in vivo footprinting, we dis-
covered that the loss of the NF-KB and TGGGC binding ac-
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tein-DNA contacts at virtually all detectable sites in the IL-2 
enhancer. Thus, cAMP-sensitive transcription factors appear 
to be as necessary as the CsA-sensitive factors described pre-
viously (19) for the maintenance of transcription factor com-
plexes at the IL-2 locus. 
Mechanism of Forskolin Effects on NF-KB. All the inhibi-
tory effects of forskolin treatment studied here were executed 
by cAMP-dependent protein kinases, since cells expressing 
a dominant negative PKA mutant were completely resistant 
to forskolin effects. These cells preserved a high level of IL-2 
mRNA accumulation, full NF-KB and TGGGC binding ac-
tivities in their nuclear extracts, and persistent high affinity 
protein-DNA interactions at the IL-2locus even in the pres-
ence of forskolin. In some cellular contexts, NF-KB can be 
activated by PKA (26, 29-31), but in stimulated EL4 cells, 
the net role of PKA is to inhibit NF-KB availability. Because 
it was not a complete failure of NF-KB induction but rather 
an inability to sustain NF-KB activation that was observed, 
it remains possible that early PKA activation might initially 
synergize with PKC to activate NF-KB through immediate 
IKB phosphorylation (27, 29-31). However, recent work has 
described additional pathways for PKA that provide a basis 
for delayed .effects. It was reported that it takes 30 min for 
the catalytic subunit of PKA to translocate to the nucleus, 
and phosphorylation of the cAMP response factor CREB and 
CREB-dependent gene activation occur only afterwards (32). 
Thus a delayed effect of cAMP elevation on NF-KB levels would 
be expected if the inhibition were dependent on de novo tran-
scription of some target gene. Preliminary experiments did 
not reveal qualitative differences between the types of NF-
KB/c-Rel complexes induced at 2 h, at 4 h, and at 2 h in 
the presence of forskolin (data not shown). However, any 
sustained NF-KB activation, as observed in stimulated EL4 
cells, requires both new synthesis and ongoing nuclear trans-
location of NF-KB molecules (33). Forskolin could interfere 
with this by (a) causing direct cAMP-dependent repression 
of ongoing NF-KB subunit transcription; (b) causing cAMP-
dependent overexpression of an appropriate form of IKB; or 
(c) directly or indirectly stimulating NF-KB proteolysis. The 
degree to which each of these mechanisms contributes to the 
lagged inhibition of NF-KB binding activity remains to be 
determined. 
How Are Reduced NF-KB and TGGGC Binding A ctivities 
Related to the Inhibition of IL-2 Gene Expression? In our 
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Figure 5. Forskolin affects the formation of specific 
DNA binding complexes at multiple sites of the 
IL-2 promoter/enhancer region. In vivo genomic foot-
printing on IL-2 300-bp promoter/enhancer regions 
was performed with DNA samples from EL4 (lanes 
2-4, A and lanes 1- 3 , B) and IIA4 cells (lanes 5-7, 
A and lanes 4-6, B) cultured under different condi-
tions. Resulting ladders for the coding strand are shown 
in A, and for the noncoding strand in B. (C) A close 
view of the effects of forskolin treatment on footprints 
at the distal and proximal NF-AT sites. (A and B) 
Specific sites and the distance relative to the transcrip-
tion start site are as indicated. (N) Naked DNA sample 
from EL4 cells; ( - ) unstimulated cells; ( + ) induced 
with TPA+A23187 for 4 h ; (F) induced with 
TPA+A23187 + forskolin for 4 h. Comparing lanes be-
tween the uninduced and induced samples, multiple 
footprints throughout the whole 300-bp region are 
clearly observed, consisting of reproducible partial pro-
tections ( 0._ ) and hypersensitivities ( .,.. ). In the 
forskolin-treated EL4 lane, the sequence ladder gener-
ally resembles the uninduced one, with the exception 
of the hypersensitive G in the distal CACCC site (non-
sense strand), as noted in the text. However, as seen 
in lanes 5-7 for both strands, forskolin did not affect 
the footprint formation in IIA4 cells. This subline ex-
hibited relatively weak footprints in general, but there 
was no significant difference between the footprints 
in induced samples of the mutant cells w hether for-
skolin was present or not. 
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previous studies (19), we described three extreme situatioJ:.ls: 
when the IL-2 gene was silent, fully activated, or suppressed 
by CsA. Each condition was associated with the availability 
of a different spectrum of IL-2 DNA binding proteins as as-
sayed in nuclear extracts. However, in vivo footprints revealed 
a simpler dichotomy, with either no detectable occupancy 
or a fully occupied footprinting pattern (Fig. 7). This indi-
cated that in vivo, transcription factors interact with IL-2 
regulatory DNA in a highly coordinated, ali-or-none fashion. 
The effects of forskolin treatment on in vivo footprints at 
the IL-2 locus enhance the previous conclusion in three ways. 
First, the key finding is that exposure to forskolin during 
stimulation blocks the formation of stable footprints at vir-
tually all the sites of protein-DNA contact that we detect 
in the IL-2 enhancer. In nuclear extracts from forskolin-treated 
cells, almost all the major binding activities for these sites 
appeared to be available at normal levels; only two major com-
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plexes, the upper NF-KB and TGGGC complexes, were 
affected. Yet in the nuclei of living, forskolin-treated cells, 
none of the binding activities could in fact engage their target 
sites in the context of the full IL-2 enhancer (Fig. 7). In vivo, 
the binding of forskolin-insensitive factors like NF-AT was 
therefore contingent upon the binding of forskolin-sensitive 
factors like NF-KB. This finding parallels the effect of CsA 
on the establishment of stable contacts (19, and Fig. 6). How-
ever, as summarized in Fig. 7, a different subset of factors 
is prominently affected by each inhibitor. The effect of CsA 
treatment, considered alone, made it possible to speculate that 
a single CsA-sensitive factor, lik-e NF-AT, might play a unique 
role in opening the IL-2 chromatin structure for transcrip-
tion. However, considered in light of the similar effects of 
forskolin treatment, such a model is much less likely. A prob-
able inference from the results summarized in Fig. 7 is that 
the assembly of stable transcription factor complexes at the 
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Figure 6. Forskolin has delayed effects on the stability of preformed 
protein-DNA complexes. In vivo footprints at three regions of the IL2 
regulatory sequence (sense strand) are shown. The data in lanes 1-4 and 
in lanes 5-9 are from two independent experiments. Lanes 1 and 5 contain 
DNA from uninduced cells. Lanes 2 and 6 contain DNA from cells in-
duced with TPA+A23187 for 2 h . In lanes 3 and 4, cells were stimulated 
for 2 h, and then forskolin (lane 3) or CsA (lane 4) were added for another 
2 h. In lane 3, the inducible footprints seen in lane 2 remain identifiable. 
However, in lane 4, those inducible. footprints seen in lanes 2 and 3 disap-
pear and the overall sequence ladder approaches the uninduced state seen 
in lane 1. In lane 7, cells were stimulated for 4 h without inhibitor. In 
lane 8, cells were stimulated for 4 h with forskolin added from time 0. 
In lane 9, cells were prestimulated for 2 h, then incubated with forskolin 
for another 4 h. Stimulated samples without inhibitors (lanes 2, 6, and 
7) are indicated with asterisks. 
IL-2 locus requires multivalent protein- protein interactions 
as well as the protein-DNA interactions at the individual 
sites. Thus, a major component of the combinatorial action 
of these transcription factors may be the cooperativity required 
for their binding. 
Second, a further clue to support the need for cooperative 
binding in IL-2 regulation may be provided by the persis-
tence of a sole residual site of activation-associated pro-
tein- DNA contact in nuclei of forskolin-treated cells, long 
after other footprints have disappeared. The transcription factor 
or nucleosomal structure responsible for this feature is un-
known. The isolated DMS hypersensitivity at the distal 
CACCC site is a structure that is not only distinguished from 
the resting state and the fully activated state of the IL-2locus, 
but also distinguished from the state of the IL-2 locus in cells 






treated pattern with the resting (uninduced) pattern had not 
allowed us to distinguish whether limited chromatin accessi-
bility or a requirement for cooperative binding actually re-
stricted occupancy. However, it is less likely that "accessi-
bility" is limiting after PKA activation, since residual CACCC 
occupancy is still permitted in forskolin-treated cells. 
Finally, the effect of forskolin differs from that of CsA (19) 
in that the presence of forskolin does not block transcription 
factor binding initially. In fact, the time course of its effect 
on in vivo protein- DNA contacts is delayed in parallel with 
the effect on NF-KB availability. This indicates that a key role 
is played by NF-KB or by a factor(s) inhibited with a similar 
time course. The transient assembly and disassembly of com-
plexes in forskolin-treated cells suggests that "stable" com-
plex formation could be a misnomer in general. Instead, the 
accessibility of the IL-2 gene to sharply discontinuous regu-
lation may result from rapid cycling of transcription factors 
between disassembled and reassembled states. The rate of tran-
scriptional initiation, by this model, would depend on the 
rate with which the most limiting component could be en-
gaged. Such a model would explain how forskolin could first 
inhibit IL-2 expression to a modest degree, through reduc-
tion in the TGGGC factor, and then more severely as NF-KB 
complexes also became rare. Further support for this interpre-
tation is provided by the results of the experiments in which 
cells were stimulated normally, then subjected to a inhibitor 
chase. Forskolin and CsA work through completely different 
mechanisms, resulting in blocking the availability of different 
subsets of factors, yet both can shift the equilibrium to dis-
sociation of active IL-2 transcription complexes. 
This study adds a third set of transcription factors to those 
already known to be critical for physiological regulation of 
IL-2. As discussed in the introduction, inhibition of NF-AT 
and inhibition of AP-1 separately can block IL-2 expression. 
Neither of these factors is detectably inhibited by forskolin. 
Our results suggest a similar need for NF-KB, the TGGGC 
factors, and/or other factors that are sensitive to PKA activa-
tion. In vivo footprinting data are not yet available for any 
of the cases where AP-1 is selectively inhibited. However, 
generalizing from the effects of forskolin and the effects of 
CsA, we could predict that selective AP-1 inactivation would 
also destabilize the whole protein- DNA assembly at the IL-2 
enhancer. This would confirm a nonhierarchical requirement 
for the various IL-2 regulatory factors. Such a mechanism 
vividly illustrates how, as a cell-specific and activation-
dependent response, IL-2 expression is rendered vulnerable 
to multiple signaling events. 
Figure 7. Summary of the availability and in vivo binding 
to the IL2 enhancer of different transcription factors, as mea-
sured by gel mobility shift assays and in vivo footprinting 
in EL4 cells under different stimulation conditions. (Stirn.) 
TPA+A23187; (+CsA) TPA+A23187+CsA; (+FKL) 
TPA+A23187+forskolin. The pattern shown represents results 
obtained when stimulation, in the presence or absence of the 
indicated agents, is carried out for at least 4 h. 
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The ultimate goal forT helper cells during an immune response is to be activated to 
secrete lymphokines to boost the functions of T killer cells and B cells. The regulation of 
lymphokine secretion is under the control of multiple different kinds of signals. T cells 
normally keep cytokine genes silent as much as possible and, if the stimulation is 
inappropriate, the cells simply become anergized. Only when the T cell receptor matches 
antigen/ APC and the appropriate accessory signals are present can T cells be activated. In 
the present study, we selected IL-2 as an example of a set of lymphokines specific toT 
cells to investigate the molecular mechanisms of developmentally controlled IL-2 gene 
inducibility, specifically the mechanisms of how different signals affect IL-2 expression at 
the level of protein-DNA interaction. 
First, we showed that one reason that T cells at a critical developmental stage, i.e., 
CD4+CD8+TCR1°, transiently lose the ability to make IL-2 is due to the fact that they 
cannot activate fos genes, which results in a significant reduction in AP-1 binding activity 
in the nuclei. Furthermore, we showed that these cells in parallel with a reduction of AP-1 
binding activity, also have a reduced NF-AT binding activity. Both may be attributable to 
the lack of fos proteins, although it is also possible that there is a blocking of NF-ATc 
nuclear localization. Another developmental stage dependent control of the IL-2 gene is in 
the immature CD4-CD8-TCR- cells. In addition to 'TCR'-like activation signals, they also 
require IL-l to make IL-2. Stimulation of immature cells in the absence of IL-l only 
activates limited amount of NF-lCB, which is lower than in mature T cells. We showed that 
IL-l can potentiate the NF-lCB binding activity in these nuclei (Rothenberg et al., 1994). 
The compensation of the intrinsic, developmental stage related deficiency of NF-KB in 
activated cells by IL-l could be the reason why immature cells require IL-l to produce 
IL-2. 
Second, upon examing the IL-2 promoter region with in vivo footprinting analysis, 
two forms of the promoter are seen. One shows a complete occupancy of the promoter by 
transcription factors, the other is no occupancy by sequence-specific transcription factor at 
142 
all. The footprinting patterns parallel directly with the activation state of the IL-2 gene. 
Under conditions when all the sites in the promoter region are bound by transcription 
factors, IL-2 gene transcription is detected; while under conditions when there are no 
footprints on the promoter, no IL-2 transcription is observed. These results indicate that 
sequence-specific protein-DNA interaction and subsequent IL-2 gene activation require the 
presence of all the necessary transcription factors. 
Our studies went one step further from previous work toward an understanding of 
both the developmental control and signalling regulation of IL-2 gene expression. We 
especially focused on the point which connects the final targets of signal transduction 
pathways and initiation of transcription activation, and demonstrated how trans-acting 
factors connects these two processes. The results not only help us understand gene 
regulation at a new level but also shed light on the issue ofT-cell development. 
Implications of gene regulation 
Requirement for combinatorial and coordinated protein-DNA interaction. The ali-
or-none footprinting pattern seen in IL-2 producing T cells and IL-2 non-producing cells at 
the IL-2 proximal promoter region means that both in T cells in the resting state and in non-
T cells, the induction independent transcription factors, such as octamer and the factor for 
the CACCC site, are unable to bind their cognate sites. Yet in T cells in the stimulated 
state, the induction independent and dependent factors assemble a protein-DNA complex. 
In several cases where stimulated T cells are unable to express the IL-2 gene, a limited 
number of transcription factors has been implicated as the cause. For example, CsA 
treatment results in decreased NF-KB and especially NF-AT binding activities, anergized T 
cells are specifically unable to activate the AP-1 factor, glucocorticoid stimulation 
sequesters the AP-1 factor by dimerizing it with GR, and in CD4+CD8+'fCRlo thymocytes 
both NF-AT and AP-1 binding activities are reduced. All these cases seem to imply that 
either NF-AT or AP-1 or both may be the key factor which may either be involved in 
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loosening up the chromatin structure or initializing the coordinated binding. However, we 
showed that NF-AT and AP-1 are not the only factors which are required for the 
coordinated binding. Forskolin treatment, which reduced the TGGGC and NF-lCB 
bindings but not NF-AT nor AP-1, also led to no protein-DNA interaction. Thus, the 
maintenance of the protein-DNA complex may not be an ordered process as is the assembly 
process in which NF-AT is presumbly the pre-requisite, rather it is an interdependent 
process requiring the presence of every activator protein. 
The coordinated assembly and maintanence of the protein-DNA complex may have 
two purposes. First, it may intiate a high affinity cooperative binding to form a stable 
nucleoprotein-DNA structure. Because some of the binding sites for inducible factors like 
AP-1 and NF-lCB, are not 100% homologous to the consensus sequences, the individual 
binding affinities may be many fold lower than they are to the concensus site. Second, the 
low affinity binding sites may be required to maintain the cell specificity of the n..-2 gene. 
It has been demonstrated that mutating the NF-lCB site to a higher affmity 1CB site resulted in 
a loss ofT-cell specificity of the concatamerized IL-2 1CB promoter (Briegel et al., 1991). 
Therefore, in addition to providing the inducibility of the gene, the combinatorial and 
coordinated fashion of binding may also contribute to its cell specificity. 
The protein-DNA interaction is dynamic. Once the regulator is bound to its cognate 
site and the footprint is observed, the interaction is not static but dynamic. The 
maintenance of the interaction requires continued protein synthesis or modification. It has 
been demonstrated that blocking protein synthesis with cycloheximide leads to loss of the 
protein-DNA contact in vivo (Weih et al., 1990). In CsA and forskolin chase experiments, 
we showed that the disappearance of footprints correlated proportionately with a decrease 
in n..-2 transcription, indicating that the DNA-binding activity of CsA and forskolin 
sensitive factors are subject to turnover in the nuclei. More importantly, this fmding 
provides strong evidence for a dynamic equilibrium on-and-off interaction of the 
transcription factors with DNA. Addition of forskolin gradually reduced the TGGGC and 
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NF-KB binding activities, which shifts the equilibrium toward the "off' direction. In 
contrast to the relatively slow onset of the forskolin effect, CsA blocking is kinetically more 
efficient than forskolin. This could be related to its immediate inactivation of the Ca2+ 
signalling pathway, which is required for the nuclear localization of the cytoplasmic 
component of NF-AT and the trans-activation activity of the octamer factor. The 
coordinated binding basically demands the presence of all the binding factors. Decreasing 
nuclear concentrations of certain factors in tum shifts the equilibrium towards dissociation. 
The equilibruim reaction could also shift toward the "on" direction by increasing the nuclear 
concentration of certain factors. This is best illustrated in activated T cells in the presence 
of IL-l. With the rapid increase in AP-1 and NF-KB factor binding activities, the initial 
increase in association rate shifts the onset and peak of IL-2 transcription earlier kinetically. 
Later during activation, when factor-DNA interactions reach equilibrium, transcription 
levels off. The conclusion, which indicates that formation of stable protein-DNA complex 
requires sustained high level of transcription factors, is also in agreement with the 
interpretation for the threshold phenomenon (Fiering et al., 1990) . 
According to our conclusions, it can be argued that mutating one of the binding 
sites should abolish any binding and prevent transcription. But in fact, mutagenesis 
experiments did not give 100% reduction of transcription. This is because first, mutating a 
site is not equivalent to knocking out the activator protein physically. Mutated sites may 
have reduced binding activity when analyzed individually in in vitro assays. In the in vivo 
situation, where all the necessary factors are available upon stimulation, the protein-protein 
interaction may synergize in binding and overcome the low affinity association to the 
mutated site. Beside, there may be multiple sites for one factor, especially in the natural 
gene, and reducing one factor may affect the binding at multiple sites. Mutating one site, 
on the other hand, does not affect the binding to other sites. Second, the high affinity 
binding of factors for mutated sites may not be absolutely required but protein-protein 
interactions including interactions with transcription factors or with general transcription 
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machinery. like the interaction of NF-1eB and TAT A-binding protein may be sufficient 
(Kerr et al .• 1993). Third, studies on MMTV promoter showed that transiently introduced 
template is free of nucleosome and has hormone-independent NFI factor binding. while 
stably integrated MMTV template has phased nuclesomes and requires hormone induction 
to form NFI binding. In both cases, transcription is hormone-dependent, but the stable 
template has 3 to 4-fold greater enhancement by the hormone. This suggests that transient 
template may be derepressed (Archer et al .• 1992). Similarly. transiently transfected IL-2 
templates in mutagenesis assays may have no or improperly phased nucleosome assembly. 
which may change the accessibility of the DNA and the transfected gene may be less 
stringently regulated compared to the endogenous nucleosome-phased IL-2 gene. 
How is the protein-DNA complex assembled? It may take two steps to finish the 
assembly. Since a DNAase I hypersensitive site in this region (--100) is induction-
dependent. the assembly of the protein-DNA complexes may be secondary to the alteration 
of chromatin structure. An inducible. T-cell specific factor may be responsible for such an 
alteration. similar to the role which the glucocorticoid receptor plays in hormone induction 
of the liver-specific TAT gene and the MMTV promoter (Rigaud et al .• 1991; Cordingley et 
al .• 1987). This factor may be among a subset of factors sensitive to cyclosporin A 
inhibition and may bind either to the -300bp or -100 bp DNase I hypersensitive site. Once 
the DNA is accessible. cooperative binding is initiated which can be visualized as stable 
footprints covering almost the entire IL-2 promoter. Such cooperativity could increase the 
binding affinity 3 to 6 orders of magnitude in certain cases (Xia et al .• 1991). These two 
steps are sequential events in the activation process. 
Different types of IL-2 non-expression can be enforced by different mechanisms. 
As for non-T cells. like muscle cells or fibroblasts. the inaccessibility of DNA to nuclease 
indicates a closed chromatin structure at the IL-2 locus. In addition to the deficiency of 
inducible transcription factors, the chromatin inaccessibility also acounts for the IL-2 gene 
repression. In resting T cells, which have an activatable chromatin structure characterized 
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by the presence of nuclease hypersensitive sites, the lack of inducible factors to further 
open up the chromatin and initiate cooperative binding may be attributed to their inability to 
express the IL-2 gene. This mechanism may also apply to some T cell related 
hematopoietic cells which also have an activatable chromatin configuration. In activated T 
cells, withdrawing factors during activation by cyclosporin A or forskolin treatment 
destablizes the coordinated binding of all transcription factors along the entire promoter 
region and results in interruption of IL-2 transcription. However, it is not clear whether 
chromatin resumes the resting state. 
The assumption that T-cells committed to make IL-2 may have been imprinted at the 
IL-2locus is not disproven yet. This is because the further upstream 300 bp region is not 
examined and, together with the proximal300 bp, is highly homologous to the human IL-2 
gene and contains an induction-independent DNAase I hypersensitive site specific forT 
cells and some hematopoietic cell lines. It remains possible that T -cell commitment or 
hematopoietic-lineage commitment may be characterized by a distinct pattern of protein-
DNA interactions in this region and at the other two induction-independent hypersensitive 
sites as well. 
Implications of T lineage specification 
IL-2 gene inducibility is known to be specific to CD4+ T cells, but does it correlate 
only with the determination of the CD4+ T lineage or does it correlate with even earlier 
developmental events? Recent progress in understanding the divergence of CD4+ and 
cos+ cells demonstrated that positive selection is not when double positive cells make their 
lineage choices; rather, that decision is made prior to the selection processes (Chan et al., 
1993; David et al., 1993). The functional competency required for either CD4 or CD8 cells 
has been shown to be present in immature CD4-CD8-TCR- cells prior to TCR gene 
rearrangement and prior to the selection process. For example, these imature cells can be 
induced to make T helper-specific genes like the IL-2 gene and T killer-specific genes like 
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perforin (Rothenberg et al., 1993; G. Reynard's unpublished data). It is not known 
whether these cells are either still multi- or hi-potential or whether they have been 
determined to be either CD4 or CDS cells; the distinction requires the identification of 
whether each gene is expressed individually in only a subset of immature cells or if that are 
co-expressed in all cells. Lineage tracing would also answer this question. Several lines of 
evidence, however, may actually indicate that acquisition of IL-2 gene inducibility might 
even occur earlier and that it is possibly maintained in cells which differentiate to the CD4 
lineage but conditionally lost in cells directed towards the CDS lineage. First, both CDS+ 
thymocytes and CDS+ splenic T cells can be induced to make IL-2 under certain conditions 
(McGuire & Rothenberg, 19S7; McGuire et al., 19SS). Second, certain cells in day 14 
fetal thymus and yo T cells in the gut and skin are making IL-2 in vivo, suggesting that 
hematopoietic stem cells from different developmental stages are able to generate IL-2 
producing T cells, and that IL-2 producing cells are not limited to cells derived from stem 
cells that give rise to adult thymic-derived CD4+ afi T cells (Yang-Snyder & Rothenberg, 
1993; Zuiiiga-Pfliicker et al., 1993). Third, some B cell lines orB lymphomas can also be 
induced to make IL-2 (Arnigorena et al .• 1992; Bonnerot et al .• 1992). Splenic B cells 
from transgenic mice bearing 3x(NF-AT sites)-TK promoter-SV 40 large T antigen 
construct also make T antigen, although with kinetically delayed expression compared to 
splenic T cells (Verweij et al., 1990). Some T-lineage specific transcription factors for 
activating the expression ofTCR genes are also present in pre-B cells and mature B cells, 
more interestingly, some even express in cells beyond the prothymocytes stage (Clevers et 
al., 1993; and later discussion). These data may suggest that IL-2 gene inducibility occurs 
earlier before the divergence ofT and B lymphocytes. Fourth, chromatin structure analysis 
revealed that the three DNase I hypersensitive sites observed in resting T cells are also 
present in two related hematopoietic cell lines, but not in two non-hematopoietic cell lines, 
including an epithelial Hela cell line (Siebenlist et al., 19S6). Although the presence of 
nuclease-sensitive sites may indicate the potential to make IL-2, it has not been shown that 
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non-lymphoid hematopoietic cells can make IL-2. Thus, based on these observations it can 
be speculated that the IL-2 gene may be methylated and has a repressed chromatin 
structure. Generation of hematopoietic stem cells from blood island, fetal liver, and adult 
bone marrow might be accompanied by demethylation and changes in chromatin structure 
of the IL-2locus. Differentiation of hematopoietic cells to non-lymphoid cells might be 
accompanied by maintaining or losing nuclease-sensitive sites. Finally, differentiation to 
lymphoid cells might be accompanied by acquisition of lymphoid cell-specific transcription 
factors which enable them to make IL-2. However, further differentiation to B cells, CDS+ 
T cells, and to T helper type 2 cells probably down-regulates these factors, as has been 
shown for the regulation of cortical cells, which make them less competent than T helper 
type 1 cells. The latter point is supported by the observation that exogenously introduced 
IL-2 promoter-CAT gene constructs cannot be activated in a series of cell lines representing 
B-cells, pre-mast cells, macrophages, Th2 type helper cells, thymoma cells, and CTLs 
(Novak et al., 1990). It is also supported by the fact that increasing certain transcriptional 
activators by over expressing eiF-4E in Th2 cells can activate the IL-2 gene (Barve et al., 
1994). 
What are the transcription factors that potentiate IL-2 gene inducibility? One 
candidate is NF-AT, which has been shown to beaT-cell specific transcription factor by in 
vitro gel shift studies and by transgenic studies which showed aT-cell restricted expression 
pattern of a reporter gene driven by a heterologous promoter plus a multimerized NF-AT 
site (Verweij et al., 1990). NF-AT is composed of two components; one is Ca2+ signalling 
sensitive cytoplasmic protein, the other is a PKC sensitive general transcription factor AP-1 
(Flanagan et al., 1991; Jain et al., 1992). The lack of this cytoplasmic NF-AT could block 
IL-2 gene activation as shown in this study and other studies (Flanagan et al., 1991), it is 
very important to fmd out whether this factor is developmentally regulated and whether it is 
the factor which endows lymphoid or T lymphoid cells with the competence to make IL-2. 
The second candidate is AP-1. It is not simply because it is the nuclear component of 
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NF-AT, but also because it is co-regulated with NF-AT in cortical thymocytes. Since AP-I 
is a general transcription factor and regulates multiple genes, it is difficult to envision it as a 
regulator involving T cell differentiation and mediating ll..,-2 gene activtion. However, we 
showed that the inducible transcription of three fos genes is reduced in cortical thymocytes, 
and the AP-I factor formed in these cells would only be Jun-Jun intrafamily dimers which 
have greatly reduced DNA binding affinity and may have reduced transcriptional activity. 
A similar up and down regulation of AP-I has been reported during meyloid and 
granulocyte lineage differentiation (Mollinedo et al., 1993). The B cell developmental 
defect in c-fos knockout animals is another example of how this seemingly general 
transcription factor can actually fme tune lineage differentiation (Okada et al., 1994). This 
regulation of transcription factor level is mediated by developmental signals. Signals 
mediated by receptors other than the TCR have been shown to regulate c-fos and c-jun 
expression. For example, signals transmitted through the IL-2 receptor induce c-myc, 
c-fos, and c-jun transcription, and IL-2 receptor r chain has been implicated for this 
function (Asao et al., 1993). Since the r chain is down-regulated during the transition to 
cortical cell type, there might be a connection between r chain expression and c-fos 
expression. It is highly possible that both tissue or lineage specific factors and general 
transcription factors may function in cooperation to control differentiation processes. The 
NF-AT and AP-I are more likely involved in not only the acquisition and maintenance of 
the competence to make IL-2, but they may also take part in the lineage commitment 
process. 
Recently, a number ofT-cell specific or lymphocyte specific transcription factors 
were discovered which may also correlate with or contribute to early T -cell commitment 
and IL-2 gene activation. Among these factors are a group of minor groove binding 
proteins which are difficult to visualize by the DMS in vivo footprinting technique used in 
our assays. These factors were discovered during an attempt to identify TCRa and CD3-E 
gene trans-acting factors. Three T-cell specific transcription factors (TCF-1, LEF-1, and 
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Sox-4) were cloned; all of them contained a motif for high mobility group protein (HMG) 
and are required for enhancer activity in CD3 and CD4 gene expression (reviewed by 
Clevers et al., 1993). The HMG proteins are a family of proteins containing a region of 
homology to HMG-1 proteins, and can be categorized as either those that recognize DNA 
in a relatively non-specific fashion, like HMG I(Y), or those that display high sequence 
specificity like TCF-1/LEF-1 and Sox-4, etc (Laudet et al., 1993; Bustin et al., 1990). The 
former has been implicated in the transcription of lymphotoxin genes and the IFN-13 gene 
(Fashena et al., 1991; Thanos & Maniatis, 1992). T cell factor 1 (TCF-1) and lymphoid 
enhancer-binding factor 1 (LEF-1) do not have any transactivation activity by themselves, 
but Sox-4 can activate a reporter gene driven by concatamerized Sox-4 sites (van de 
Wetering et al., 1993). However, LEF-1 has been shown to bend DNA and facilitate 
assembly of functional nucleoprotein structures in a LEF-1 and a bacterial integration host 
factor bend-swap experiment (Giese et al., 1992). It is likely that TCF-1 and LEF-1 may 
function as architectural proteins which bend DNA and facilitate the interaction of proteins 
bound at the distant 5' and 3' sites in the enhancer. Sequence inspection reveals that the 
IL-2 promoter region contains many AT-rich islands and two perfect TCF-1/LEF-1 sites 
are at -130 bp and -95 bp respectively. The site (AACAAAG) at -130 is immediately 
downstream of the NF-AT site, while the -95 site (CTITGAA) is immediately upstream of 
the Oct/OAP40 site. More interestingly, no DNA occupancy or any known binding sites 
was identified between -130 to -95 bp, and the in vivo footprinting results suggest a lack of 
protein-DNA interaction in this segment in the major groove. It is likely that in addition to 
increasing the affinity of NF-ATd and Oct/OAP40 bindings, these minor groove binding 
proteins may also participate in IL-2 gene regulation by inducing a bending in the region 
and bringing the proteins bound upstream or downstream of the HMG region closer and 
facilitating protein-protein interactions. Similar to TCF-1/LEF-1, HMG-I and HMG-Y 
have been demonstrated to be required for IFN-13 gene regulation. Although like 
TCF-1/LEF-1 they do not have trans-activation activity, they are able to bind to the minor 
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grooves which fully or partially overlap the NF-KB and A1F-2 sites in the IFN-f3 promoter 
and can increase their DNA binding activities by 30 and 4 fold respectively. It has also 
been shown that there is a direct physical association between HMG-I(Y) and NF-KB or 
ATF-2 (Thanos and Maniatis, 1992; Duet al., 1993). Therefore, it can be hypothesized 
that upon stimulation the HMG-domain-containing T cell specific factors will initiate and 
stabilize the protein-DNA interaction at the IL-2 promoter/enhancer by cooperatively 
interacting with their adjacent factors like NF-AT and Oct/OAP40. Such increased binding 
affinity of these transcription factors is crucial for the IL-2 promoter, since the binding sites 
are not canonical and have relatively low affinity. One experiment showed that conversion 
of NF-lCB, AP-I, and Oct sites to canonical sites resulted in an increase of IL-2 enhancer 
constitutive and inducible activity in both T cells and non-T cells (Hentsch et al., 1992). 
Non-T cells do not have TCF-1, LEF-1, or Sox-4 and therefore could not increase the 
binding affinities of other inducible trans-acting factors and also could not induce bending 
of the DNA to facilitate protein-protein interaction. There has not been any evidence which 
shows that these minor groove binding proteins are involved in IL-2 gene regulation. 
However, the presence of the consensus sites in the promoter and their similar cell-
specificity make it possible that these factors may direct early lymphoid and T lineage 
differentiation; and one of their target genes would be IL-2. 
In short, current studies suggest that activation or repression of transcription factors 
involved in T -cell specific gene regulation may also control lineage specification. A 
number ofT -cell specific transcription factors have been found by studying the regulation 
ofT-cell specific genes (Reviewed by Clevers et al., 1993). As I was writing this up, the 
murine form of cytoplasmic NF-AT was reported to be cloned (McCaffrey et al., 1993). It 
seems that now is a good time to test whether any of these factors or sets of factors, in 
addition to regulating any cell-specific gene expression, can actually initiate T-lineage 
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